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Abstract 
One of the hallmarks of successful immunotherapy is the generation of high avidity 
cytotoxic T cells which can recognise and respond to very low concentration of antigens. 
This sensitivity of T cells is usually determined by peptide titration ELISpot assays. 
Even though these assays are generally useful, they are laborious and sample 
demanding. The assays become even more difficult if the peptide(s) accountable for the 
generation of vaccine specific responses are unknown such as whole protein or cell 
vaccines. Therefore, there is a need to identify markers which can quickly and reliably 
identify a high avidity T cell response in cancer vaccination settings.  
To achieve this goal, this study utilised a C57Bl/6J mouse model which could 
efficiently generate high and low avidity T cell responses, when immunisation was 
undertaken with two form of vaccines to deliver the target antigens. The antigenic 
epitopes used for this study were derived from TRP-2 ‘self’ and ovalbumin (OVA) 
‘foreign’ antigens. Immunisation of animals with these antigens in a DNA vaccine 
format induces a high avidity T cell response, in contrast to the response when these are 
administered in the peptide vaccine format. However, both the immunisations produced 
same number of peptide specific CD8+  T cells, which was assessed my multimer 
staining. When these cells were subjected to in vitro stimulations with the target 
peptides, the functionality of the low avidity T cells was restored whereas the high 
avidity T cells failed to respond to lower peptide concentrations. This showed the 
plasticity of antigen specific T cells and their ability to modulate their functionality 
according to the stimulation they have received. 
In order to identify markers that are associated with the high avidity T cell responses in 
vivo, antigen specific CD8+ T cells were isolated from high and low avidity groups 
using MHC multimer sorting.  A global transcriptional profiling was conducted on the 
mRNA isolated from these cells. Analysis of expression data identified several 
differentially expressed genes between the groups. Six differentially expressed genes 
(Granzyme A, Granzyme B, FAS Apoptotic Inhibitory Molecule, Telomerase RNA 
Component, CD5 Antigen-Like, Spi-C Transcription Factor) were further selected and 
confirmed using qRT PCR. Expression of three genes were correlated with the 
microarray gene expression data. Among these, two genes (Granzyme A & B) were 
further confirmed at the protein level using flow cytometry. Further to this, studies of 
gene expression activation kinetics of TCR signalling using pentamer sorted cells with 
anti-CD3/CD28 monoclonal antibody coated microbeads, revealed that ImmunoBody® 
derived high avidity T cells are more signal competent with rapid up-regulation of genes 
involving in T cell receptor signalling pathway.  
Proteomic characterisation of MHC multimer sorted cells using LC-MS profiling 
identified several proteins uniquely associated with Peptide or ImmunoBody® pentamer 
positive T cells. Many of these proteins were associated with important T cell functional 
properties. Further confirmation of these markers and their role in T cell avidity is 
required, however these studies were limited by the lack of availability of proteins from 
the low number of peptide-specific cells and antibodies. 
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Chapter 1  
General Introduction 
1.1 The Immune system  
Multicellular organisms, particularly higher order vertebrates, live in a place where they 
encounter various environmental and pathogenic hazards. Their normal tissue 
homeostasis is constantly challenged by invading pathogenic microorganisms and their 
own cellular malfunctions. Adaptability of these organisms to maintain their natural 
homeostasis against alterations in their natural physical habitat, changes in their normal 
physiological status are remarkable. This remarkable adaptability is attained from their 
normal physical adjustments to the changing environmental conditions and also with 
their advanced immune system evolved over millions of years. The vertebrate immune 
system coexisted with them during their evolution as a higher tissue grade organism, so 
it has learned, adapted and evolved with them to meet their needs and deeds over the 
time. Present day, the immune system of vertebrates is by far the best defence system 
allowing adjustments to any perturbations in their natural tissue homeostasis (Taniguchi 
et al., 2009; Barreiro & Quintana-Murci, 2010) and endows them with ultimate survival 
advantage. 
The realisation that the immune system has the ability to detect dangerous substances 
dates back to the fifteenth century, in the fight against deadly small pox disease and the 
subsequent use of ‘variolation’ (Kindt et al., 2007). This was followed by Edward 
Jenner’s use of ‘cow pox fluid’ which induced a protective immunity against smallpox 
in humans (Smith, 2011). However, it was Louis Pasteur who conducted the first 
systematic study in chickens and sheep using cholera and anthrax bacteria to elucidate 
the body’s ability to develop a protective immunity with the use of external agents 
(Pasteur, 1881, 2002 [republished]). Jenner coined the term ‘vaccine’ derived from the 
Latin word ‘vacca’ meaning cow. However, Pasteur is widely accepted as the ‘father of 
immunology’ due to his systematic study which led to the birth of modern immunology 
as a systematic discipline (Smith, 2012). Since then the causative components 
(antibodies first, then the T cells) which endow immunity have been identified and the 
types of immune cells ‘fully’ classified. Today, there is an active area of research aimed 
at entirely understanding the ‘sub-subsets’ of immune cells and effector molecules 
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which organise the highly coordinated entity of the ‘immune system’ in a faultless 
manner.  
Studies conducted in the last century have classified the mammalian immune system 
into two key categories based on the nature of the immune mechanisms and cells 
involved - “innate” and “adaptive” immunity ( Kindt et al., 2007). The innate immune 
system is widely considered to be the first line of defence against pathogenic organisms, 
whereas the adaptive immunity is acquired and evolved during the course of one’s own 
life time. The cells and organisation of these two arms of basic immune system are 
different; however they are interdependent with many signals and functions overlapping 
between them. The immune system is not exclusively restricted to the eradication of 
pathogens; it is also capable of the identification and elimination of malignant 
transformations within the body. Therefore it is important to understand tumour 
immunity in the context of basic characteristic of these two immune arms, their 
interdependence and shortfalls. 
1.1.1 Innate immunity 
The innate immunity is considered to be the most primitive type of defence mechanism 
with its different layers of first line of immune barriers (Beutler, 2004). The footprints 
of innate immunity can be traced back to the very early days of evolution up to 
invertebrate organisms (Boehm, 2012) and even in plants with their pathogen related 
(PR) proteins (Zvereva and Pooggin, 2012).  The basis of the innate immunity starts 
with the physical barriers which block the entry of any invading organism into the body 
such as skin and mucous membrane. These physical barriers are usually sufficient 
enough to protect against the hazardous extrinsic factors such as bacteria and fungi 
(Gallo and Nizet, 2009). However, there are many occasions when these primary 
barriers are broken or compromised and the internal spaces of the body are then exposed 
to the outer environment. Once this has happened, other components, predominantly 
innate immune cells, will come into play as the next layer of immune defence (Gallo 
and Nizet, 2009). 
1.1.1.1 Cells of the innate immune system 
All the cells of the innate immune system originate from myeloid precursor cells of the 
bone marrow (Figure.1.1). These cells are broadly divided into two major classes as 
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mononuclear phagocytes (dendritic cells, mast cells and macrophages), and 
polymorpho nuclear phagocytes (neutrophils, basophils, eosinophils) depending on the 
shape of their nucleus. Blood monocytes and macrophages are the key cells with a 
ubiquitous distribution throughout the body to facilitate the instantaneous detection of 
 
 
 
 
Figure 1.1: Schematic representation of haematopoiesis by which different cells of innate and 
adaptive immune system is generated in the bone marrow. The left panel shows myelopoiesis in 
which the cells of the innate immune system are formed and the right panel shows 
lymphopoiesis where the cells of adaptive immune lineage is generated. 
Fig 1.1. Schematic representation of haematopoiesis by which different cells of
innate and adaptive immune system is generated in the bone marrow. Both
lineages come from the haematopoietic stem cells which are capable of self-
renewal. The left panel shows myelopoisesis in which the cells of the innate
immune system are formed and the right panel shows lymphopoiesis where the
cells of adaptive immune lineage are generated.
  
4 
 
 
danger signals anywhere in the body. Macrophages are produced in the bone marrow as 
immature monocytes and circulate in the blood to become mature monocytes. Once they 
arrive in the tissue environment they become mature macrophages (Sica and Mantovani, 
2012). Depending on the tissue or anatomic site in which they reside, macrophages can 
acquire different morphologic shapes (e.g. Histiocyte and Kuppffer cells in the liver, 
microglial cells in central nervous system). The main role of macrophages is the 
management of cellular homeostasis by the detection of danger signals and elimination 
of them by phagocytises (Biswas et al., 2012).  
Macrophages also play an important role in the recruitment of the entire army of 
immune effector cells of innate and adaptive immunity by secreting chemoattractant 
when a danger signal is detected. The minority population of mononuclear phagocytes 
are dendritic cells which were first noticed by Paul Langerhans (1868) and later brought 
into the limelight by Steinman and Cohn in 1973. Unlike many other innate cells, 
dendritic cells can originate from both myeloid and lymphoid progenitors of the 
haematopoietic system in the bone marrow. They are also distributed in the skin, kidney, 
liver, connective tissues, internal lining of the body and many other organs (Sato & 
Fujita, 2007).    
Among the polymorphonuclear phagocytes, neutrophils are considered to be the key 
cell type in fighting against infection (Simons, 2010). They are produced in the bone 
marrow and are capable of migrating into tissues with the capacity to perform 
phagocytic function. Eosinophil’s and basophils mainly fight against parasitic infection 
and allergic responses, respectively, with the latter being non-phagocytic (Kindt et al., 
2007).  
1.1.1.2 Defence coordination by innate immune cells 
One of the hallmarks of innate immunity is the lack of specificity and immunologic 
memory, mainly due to the lack of specialised receptors such as T cell receptors (TCR) 
and B cell receptors (BCR). Even though no antigen specific receptors are available on 
innate cells, almost all of them have a highly conserved and versatile ‘generic’ family of 
receptors that are known as toll like receptors (TLR) (Pradere et al., 2013), or pattern 
recognition receptors (PRR) (Wolska et al., 2009; Seya et al., 2010). PRRs are capable 
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of detecting invading micro-organisms and the pathogens by scanning for danger 
molecules broadly known as pathogen-associated molecular patterns (PAMPs) (Akira & 
Hemmi, 2003) expressed by pathogenic organisms or dying self-cells with damage 
associate molecular patterns (DAMPs) (Krysko et al., 2012; Ahrens et al., 2012). 
The cells of the innate immune system continually keep normal cells, tissues and their 
microenvironment under their watchful surveillance, for the maintenance of tissue 
homeostasis, and to keep them from diseases. Any perturbations in tissue or cellular 
homeostasis trigger macrophages and mast cells to secrete cytokines, and other chemo-
attractant molecules which enhance the infiltration of further leukocytes to the damaged 
or malignantly transformed tissue. Neutrophils are the first innate cell to reach the site 
of such changes. They mainly use TLR2/TLR4 for the detection of a multitude of 
bacterial lipoproteins and keep the pathogen in check by phagocytic clearance, however 
the use of these receptors by neutrophils for the detection of cancer cells also has also 
been reported (Klink et al., 2012). Subsequently, dendritic cells take up the antigens and 
migrate to the nearest lymphoid organs and present them to the adaptive immune system 
thereby acting as an interface between innate and adaptive immunity. (DeVisser et al., 
2006). Macrophages also have elevated levels of MHC class II expression (Baumgart et 
al., 1998; Xaus et al., 2000) and can therefore also act as a primary bridge between the 
innate and adaptive immune system, mainly by communicating with helper T cells (TH 
cells). 
An outlier in the classic innate cell lineage (myeloid) are the natural killer cells (NK 
cells), capable of secreting two well-known immune modulatory cytokines tumour 
necrosis factor (TNF-∞) and interferon-γ (IFN-γ). They are also capable of secreting a 
variety of chemokines such as Macrophage Inflammatory Protein-1α & β (MIP-1∞ and 
MIP-1β) and RANTES [Regulated on Activation, Normal T Cell Expressed and 
Secreted] (Fauriat et al., 2010; Roda et al., 2006). NK cells expresses a variety of non 
TLR receptors (activation & inhibitory) for detecting danger signal and can discriminate 
between self and non self (Jaeger and Vivier, 2012). Recent studies revealed that they 
are capable of developing antigen specific immunologic memory which was previously 
thought to be an exclusive property of B and T lymphocytes (Sun et al., 2011; 2012). 
This has resulted in a paradox for the classical definition of innate and adaptive immune 
system. 
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1.1.1.3 Innate immunity and its significance in cancer  
All the cells of the innate immune system are capable of recognising and interacting 
with malignant cells (Liu and Zeng, 2012). Among the innate cells, NK cells have 
attracted much attention recently because of their capacity to detect tumour cells in an 
MHC independent manner (Le Maux Chansac et al., 2005). This has generated a 
renewed interest in NK cells, since most tumours down regulate MHC molecules as an 
immune escape mechanism (Maeurer et al., 1996) and thereby become invisible to 
MHC dependent T cell adaptive immunity. NK cells can therefore provide protection in 
such instances where cellular immunity fails (Stojanovic and Cerwenka, 2011). The 
receptors and the mechanism of NK cell detection are now an area of intense study and 
their clinical utility has been demonstrated in in vitro model systems using antibody 
mediated NK receptor blocking. Huge strides in NK cell biology is evident from the 
work done by Ahn et al., (2013) via expanding cytotoxic NK cells in a GMP setting 
which makes them suitable for adoptive transfer into cancer patients and this work has 
now progressed the use of NK cells as a cellular therapeutic strategy nearer to the clinic. 
Manipulation of NK killing efficiency was also achieved by classical non vaccine 
approaches in patients. This includes delivery of mild physiological stress, such as 
thermal and oxidative stress to the tumours to up-regulate natural NK cells ligands on 
their surface and thereby increase their susceptibility to NK cell lysis (Dayanc, et al., 
2013; Hedlund et al., 2011). These approaches are gaining momentum as an alternative 
method for tumour control in a less invasive therapeutic approach.  
Another key cell type in the tumour microenvironment is the macrophages, which have 
both pro and anti-tumour capabilities (Bingle et al., 2002).  However, some 
macrophages are found to be more tumourigenic than tumour suppressive by promoting 
angiogenesis and metastasis (Laoui et al., 2011). In many cases, detection of tumour 
associated macrophages can be a poor prognosis factor for patients with head and neck 
cancers, lymphoma and gastric cancer (Cai et al., 2012).  However, in certain cancers 
such as colorectal cancer, macrophage infiltration has been directly correlated with good 
clinical outcome (Forssell et al., 2007), indicating that the prognostic value of these 
cells within the tumour. 
Neutrophils have not been well studied in the context of tumour progression, possibly 
due to their short lived nature. However, studies have emerged recently highlighting 
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that the presence of neutrophils in tumours has been associated with poor prognostic 
factor (Jensen et al., 2009) including high tumour growth, metastasis and tumour 
immunoediting (Gregory and Houghton, 2011).  Even though the innate immune system 
has a significant role in the detection of cancers and also alerts the adaptive immune 
system in a generic way through inflammatory cytokines and in more specialised way 
through the antigen processing and presentation pathways, it is the adaptive immune 
system which holds the most clinical promise, if any, in cancer immunotherapy settings. 
These achievements can be mainly attributed to the discovery of tumour antigens, 
monoclonal antibodies and antigen specific vaccine in prophylactic and therapeutic 
settings.  
1.1.2 The adaptive immune system 
Adaptive immunity is characterised by its receptor specificity (antigen specificity), its 
ability to memorise a previous antigenic encounter (antigenic memory) and the capacity 
to discriminate self and non self. Another important feature of the adaptive immunity is 
the need for antigen presenting cells (APCs) processing and presenting antigens in 
combination with specialised molecules known as major histocompatibility complexes 
(MHCs) (Janeway et al., 2001). Above all, the most striking feature of the adaptive 
immunity is its ability to generate vast receptor diversity in their antigen recognising 
receptors (B cell receptors on B cells and T cell receptors on T cells). This is believed to 
be an advanced evolutionary genetic feature in terms of its genetic complexity (Haynes 
and Wu, 2004) which will be discussed in the following sections.  
1.1.2.1 B and T lymphocytes  
B and T lymphocytes are generated from committed B or T cell progenitors in the bone 
marrow via a process of haematopoiesis (Figure.1.1) (Pieper et al., 2013; Koch and 
Radtke, 2011). Even though these cells derive from a common progenitor they are 
functionally different in terms of their antigen clearance and their receptor organisations. 
In B cells, the final effector functions are executed by a secreted receptors, commonly 
known as secreted antibodies; whereas in T cells, the receptors are always bound to the 
cells and the effector function (antigen clearance) is directly mediated by T cells 
themselves, hence T cell immunity is widely known as ‘cellular immunity’.  When the 
B cells encounter a foreign antigen they differentiate into effector cells and memory 
cells. The effector cells are also known as plasma cells and they produce millions of 
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copies of antibodies of the same specificity of the antigen against which they have been 
primed. The detailed development of B cell lineage and antibody generation is well 
reviewed in Pieper et al., 2013.  
The T cells which matured in the thymus can also be broadly classified into two classes 
of T cells, The cytotoxic T cells (TC) and the helper T cells (TH) depending on the 
membrane glycoprotein found on their surfaces known as cluster of differentiation 
antigens (CD antigens).  TCs express a glycoprotein known as CD8 (Cluster of 
differentiation 8) and TH express a different glycoprotein known as CD4 (Cluster of 
differentiation 4). The functional roles of these cells are also different in cellular 
immunity, although in many occasions they are highly interconnected and 
interdependent.   
1.1.2.2 Evolution of a complex ‘anticipatory’ receptor repertoire in adaptive  
 immunity  
The diversity of antigenic receptors, memory and 'self - non-self' discrimination are 
considered to be the hallmark of a highly evolved evolutionary feature in adaptive 
immunity. While innate immunity depends on the TLR, NLR (node like receptors) and 
scavenger receptors for pathogen recognition, the origins of these sophisticated receptor 
mechanisms of adaptive immunity can be traced back to 500 million years ago. The 
rudimentary adaptive receptor mechanisms are believed to be existed in the jawless fish 
where they used them as a primitive form of ‘generic’ receptors in their lymphocytes, 
generally known as variable lymphocyte receptors (VLRs). VLRs are generated with 
simple recombinational events, which is not as extensive as any recombinational events 
seen in the higher order vertebrates today (Cooper and Alder, 2006). VLRs are leucine 
rich repeats (LRRs), capable of offering a moderately wider range of protection to those 
organisms (Cooper and Alder, 2006). The studies conducted on these receptors 
suggested that many convergent evolutionary factors were responsible for the 
generation of TCR and BCR diversity in higher order organisms (Pancer et al., 2004). 
The origin and evolution of present day BCR and TCR repertoire diversity can also be 
linked to the identification of two key genes which are conserved throughout the animal 
kingdom, (which has a defined adaptive immune system) known as recombination 
activation gene 1 & 2 (RAG-1 and 2) (McBlane, 1995). Although there is no evidence 
to suggests the existence of these two genes in animals which lack an adaptive immune 
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system, studies conducted in sea urchins identified two closely related genes known as 
spRAG1L and spRAG2L, suggesting that these genes might have existed much before 
the evolution of modern adaptive immune system in some other form and functionality 
(Fugmann et al., 2006). Mutations in  RAG-1 and 2 genes abolishes the entire adaptive 
immune system and patients with these mutations die due to a complete immune 
deficiency, thereby further emphasising the role of these genes (Asai et al., 2011) for 
maintaining a healthy adaptive immune system. 
In humans and higher order mammals the TCR and BCR diversity is generated through 
a process known as V(D)J somatic recombination (Lieber, 1992). This process mainly 
involves the genes of immunoglobulin family known as variable (V), diversity (D) and 
joining (J) genes. The recombinational diversity of B cells is generated in the bone 
marrow and for T cells this occurs in the thymus (Boehm and Bleul, 2007). This 
recombinational event can generate a theoretical diversity of ~1011 antibody receptors 
(Janeway et al., 2001) and more than 1011 - 1015 TCRs in both mouse and humans 
(Sewell, 2012; Robins et al., 2009). Some experimental observations have reported the 
existence of more than the above estimates (Robins et al., 2010). The recombinational 
events are facilitated by conserved heptamer sequences known as recombinational 
signal sequences (RSS) flanking the V and J genes mediated by RAG-1 and RAG-2 
enzymes (Grawunder and Lieber, 1997; Swanson et al., 2009). This complexity and 
diversity of the adaptive immune system is considered to be a highly advanced feature 
in humans and other higher order vertebrates which complement the primitive innate 
TLR and VRR receptors and thereby offers immune protection which is adapted to a 
complex and challenging environmental niche.   
1.1.2.3 Peripheral fine tuning of B and T cell diversity 
The estimated number of receptors (BCR and TCR) which exists in the adaptive 
immune system is vast. The previous section discussed the ways in which the 
structurally similar immunoglobulin gene family can generate such a huge diversity by 
somatic recombination (V (D) J recombination). In B cells, these diversities can be 
further enhanced several fold by two other classic processes known as somatic hyper 
mutations and class switching (Muramatsu et al., 2000). The V(D)J recombination 
generate the primary antigen independent repertoire for B cells and in the periphery 
these B cells can undergo an error prone DNA mismatch repair mechanism catalysed by 
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the enzyme activation induced DNA deaminase for site directed mutations in the 
antigen binding region of the antibody. This will further increase the affinity of 
antibodies against the antigens present on the invading pathogens or malignant tissues 
(Griffiths et al., 1984). This process of fine tuning the affinity of antibodies is known as 
affinity maturation. A second mechanism of further diversification of the antibody 
repertoire is class switching which help to produce different classes of antibody isotypes 
with the same specificity (Wysocki et al., 1992).  
T cell repertoire diversity can also be generated by the same primary mechanism of V 
(D) J recombination of immunoglobulin genes. However, there is no evidence of 
somatic hypermutations or class switching of TCR in the periphery after thymic 
selection. T cells recognise short peptide fragments presented on the surface of MHC 
molecules through their complementary determining region (CDR) which has a high 
similarity to the antibody fab fragment (Bentley and Mariuzza, 1996). The binding 
diversity of the TCR repertoire is also generated by CDR regions (Janeway et al., 2001).  
These CDRs detect the top portion of MHC molecule and the peptide which sits in its 
groove. The T cell diversity is mainly attributed to two categories: structural diversity 
and functional diversity (Mahajan et al., 2005). The generation of the TCR structural 
diversity has been discussed in the above section, whereas the functional diversification 
mainly occurs as a consequence of the antigenic stimuli and the cytokines to which they 
have been exposed to (Buchholz et al., 2012). In short, a T cell which has a set number 
and type of αβ receptors can perform different effector functions depending on the 
nurturing they have received during their time in the central and peripheral organs. The 
detailed mechanisms for the generation of T cell lineages and thymic selection are 
discussed in Chapter 2. 
As discussed earlier, the theoretical estimation of the TCR diversity after V (D) J 
recombination is in the region of >1011 - 1015 different specificities (Sewell, 2012; 
Robins et al., 2009). Now the question is whether the theoretical estimate is in line with 
the actual receptor diversity in the body? No conclusive studies have fully estimated this 
diversity; however it is possible that using next generation deep sequencing, one day the 
complete TCR CDR diversity will be assessed.  
The TCR is only one component in the functionality of T cells. The abundance of co-
receptor molecules and adhesion molecules also contribute towards the fine tuning of 
  
11 
 
the repertoire within the body during the course of antigen exposure (Chen and Flies, 
2013). The allelic polymorphisms found in the MHC molecules also influence the 
preferential expansion or deletion of certain T cell populations (Walser-Kuntz et al., 
1995). Unlike antibody diversification, which is mediated by the affinity of antigens, the 
T cell populations undergo a different mode of functional diversification which is 
known as avidity maturation (von Essen et al., 2012) (discussed in chapter 2). This 
process of avidity maturation will mainly diversify the functionality of T cells by 
keeping all other factors identical for a given population of antigen specific T cell 
(Slifka and Whitton, 2001). In other words, a T cell population having the same TCR 
will have diverse proliferative, cytokine and chemokine secretion capability.  How this 
status of functional diversity is achieved is a poorly understood and the genetic and 
epigenetic factors governing these processes are yet to be dissected.  
TCR receptor is an ‘anticipatory receptor’ with an assumption that the diversity 
established in the above mentioned processes are good enough to cover all antigenic 
peptides generated during one’s life time (Lo and Allen, 2013). Studies have argued that 
the maximum available TCR diversity is not sufficient to offer protection against all the 
possible antigenic peptide fragments produced within the body if it operates in a strict 
key and lock mechanism (Wooldridge et al., 2011). So a degree of cross-reactivity 
(termed as TCR promiscuity) in the T cell repertoire adds flexibility to T cells for 
recognising not exactly but similar epitopes (Wooldridge et al., 2011). The idea of TCR 
promiscuity is not firmly established yet, but ample evidence is available for the 
existence of vast cross reactivity in studies conducted with T cell clones in the 
laboratory. The extent of this cross reactivity in the living organisms has to be 
established before promiscuity can be considered as an additional mechanism for TCR 
diversification. For the purpose of this thesis the main literature discussion will be 
limited to T cells. However, the similarities and contrasts between these two arms of the 
immune system will be mentioned as and when a cross comparison is required. 
1.1.2.4 Mechanism of T cell mediated immunity   
T cell immunity is mediated by two structurally and functionally different sets of T 
lymphocytes known as CD8+ and CD4+ T lymphocytes (Janeway et al., 2001; Kindt et 
al., 2007). The T cell pool which is present in the periphery after positive thymic 
selection comprises ‘naïve T cells’ which are always patrolling through the circulatory 
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and lymphatic system of the body (Kindt et al., 2007). A class of myeloid lineage cells 
known as dendritic cells take up antigen from the infected site, and present it to the T 
cell pool after undergoing antigen processing pathways in the secondary lymphoid 
organs (Kindt et al., 2007). This action by dendritic cells is still believed to be the 
central link of T cell mediated immunity and due to the nature of their antigen 
processing machinery and their ability to stimulate T cells, they often portrayed as 
professional antigen presenting cells along with macrophages and B cells. (Sprent, 
1995). Once the selection of a suitable receptor bearing T cell is established from the 
available naïve pool, they expand clonally and produce large numbers of the effector 
populations with other co-stimulatory signals received from the dendritic cells. During 
clonal expansion both CD4+ and CD8+ T cells can develop into an effector population 
(capable of implementing the effector functions immediately), or as a memory 
population (which is known as central T cell memory or TCM) (Zhang and Bevan, 
2011). The effector cells rapidly mobilise towards the region of infection and clear the 
antigen immediately by their cytotoxic molecules such as granzymes and perforins 
(Janeway et al., 2001). These effector cells can be further developed into an effector 
memory population (TEM) after pathogen clearance (Williams and Bevan, 2007). All 
these cells can be differentiated by the presence of different markers on their surface 
(Table 1.1). 
Table: 1.1: Phenotypic differentiation of different functional classes of T cells based on the 
expression pattern of surface and effector molecules. 
 
 
  
 
 
 
 
In T cells, functional diversity is more prevalent in CD4+ T cells. Depending on the 
functional cytokine profile, CD4+ T cells (helper T cells) are divided in to either TH1 or 
 Marker Naïve Effector TCM TEM 
CD45RO + +++ + +++ 
CD45RA +++ - ++ + 
CCR7 +++ - +++ +/- 
CD62L +++ - +++ +/- 
CD95 +/- +++ +/- ++ 
GranzymeB - +++ - +/- 
CD25 - + - - 
CD28 ++ - +++ + 
CD127 ++ - ++ + 
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TH2 subtypes (Mosmann et al., 2009). The TH1 group mainly secrete pro-inflammatory 
cytokines such as interferon- γ (IFN-γ), IL-2, and TNF-α. TH2 cells mainly secrete IL-4, 
5, 6, 10, and 13 are mainly involved in non-inflammatory mediated response (Yamane 
and Paul, 2013). There are further subdivisions depending on their functional profile as 
measured by cytokine signature.  This polarisation is mainly shaped by the cytokine 
milieu and the transcription factors (Zygmunt, Veldhoen, 2011) in the region of antigen 
exposure which is summarised in Figure 1.2. TH-1 is involved in the cell mediated 
immunity and TH-2 is associated with humoral immunity. 
  
 
 
 
 
 
 
 
 
 
 
 
 
The direct cytotoxicity of T cells is mainly carried out by antigen activated CD8+ T cells, 
and is mediated by two major pathways (Janeway et al., 2001; Kindt et al., 2007). 
Granzyme and perforin mediated (Ca2+ dependent) apoptosis, and FASL and FAS 
mediated apoptosis (Ca2+ independent). Once the TCR of an effector cell is engaged 
with the cognate antigen presented on a MHC class I molecule on the infected cell, it 
activates the granzyme perforin synthesis pathway and results in the secretion of 
cytotoxic molecules towards the target cells. As the name indicates perforins are 
capable of making numerous perforations on the surface of the plasma membrane which 
Figure.1.2: Functional diversity of T cells up on antigen stimulation. CD4+ cells can 
be differentiated into different functional phenotypes depending on the upregulation 
of transcription factors. Exposure of a naïve T cells to antigen presenting cell results 
in the generation of CTLs  that are capable of performing cytotoxicity function  
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results in an easy access route for the granzymes, a serine protease into the cytoplasm of 
the target cells. (Figure 1.3) 
 
 
 
 
 
 
 
 
 
 
1.1.2.5 Antigen processing and presentation a key factor in T cell mediated 
immunity 
Recognition of peptide antigens mounted on a special molecule known as MHC is a 
prerequisite for T cell mediated immunity (Janeway et al., 2001). There are two major 
classes of MHC present in human and they are referred to as MHC class I and II (or 
human leukocyte antigen, HLA). The MHC class I molecule is a heterodimer made up 
of a glycoprotein heavy chain and a protein light chain expressed on almost all the 
nucleated cells with varying levels of expression (Blum et al., 2013). MHC class II is 
only present on professional antigen presenting cells such as macrophages, dendritic 
cells and B cells. MHC class I is mainly involved in the processing and presentation of 
endogenous antigens and MHC class II is mainly involved in the clearing up of 
extracellular pathogens. So for that matter both of the molecules employed different 
antigen processing pathways known as endogenous pathways for MHC class I 
molecules and exogenous pathways for MHC class II molecules (Blum et al., 2013; 
Basler et al., 2013). Class I and Class II protein chains are synthesised in the cytoplasm 
and transferred into the rough endoplasmic reticulum (RER) for further folding and 
Figure.1.3: Mechanism of CTL mediated cytotoxicity: recognition of a 
cognate antigen by a CTL leads to the activation and release of effector 
molecules. Two mechanisms of cytotoxicity is known so far, first one is 
perforin and granzyme mediated and second is FASL and FAS mediated. 
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antigen loading (Janeway et al., 2001). MHC class I and II pathways are explained in 
Figure 1.4.  
Even though the term endogenous processing and presentation (also known as direct 
presentation) are applied to indicate the processing of the endogenously derived 
antigens in all the MHC expressing cells, sometimes some of the APCs are capable of 
feeding the peptides derived from exogenous pathways into the class I pathway (cross 
presentation) (Nierkens et al., 2013). Cross presentation is more prevalent in the 
dendritic cells and this is of importance in tumour immunology in which dead and 
inflamed tumour tissues can be mopped up by scavenging dendritic cells, processed and 
presented to the class I pathway where they potentially trigger both CD8+ and CD4+ arm 
of the immune system for a better tumour immune surveillance (Brusic et al., 2012; 
Engelhardt et al., 2012). Even though this is reported in many cases, the precise 
mechanism of how cross presentation is happening in what otherwise would be a 
normal exogenous pathway, still remained to be fully elucidated. The class II pathway is 
mainly driven by TLR mediated detection and phagocytosis of the exogenous antigens 
(mostly bacteria and viruses) by macrophages, dendritic cells and B cells (Blanchet and 
Piguet, 2010). The successful response depends on how early these danger signals 
(PAMPs and DAMPs) have been picked up by these cells (Kaisho and Akira, 2006).    
It is noteworthy that the loading of the peptides onto the MHC molecules has slightly 
different mechanisms. In the endogenous pathway, antigen loading is carried out by the 
involvement of TAP and associated molecular chaperones, commonly referred to as 
peptide loading complexes, whereas in the exogenous pathway, antigen loading is 
carried outside of rough endoplasmic reticulum (RER) (Leone et al., 2013; Hulpke and 
Tampé, 2013). There is a difference in the peptide binding cleft of both the molecules, 
in MHC class I, both the sides are closed and it is open for MHC class II molecules. The 
length of the peptide fragment which can be comfortably loaded on to these two 
molecules is also different, with a peptide of 8-10 amino acid for MHC class I with 
anchor residues present at both the ends and 13-18 amino acids for MHC class II with 
anchor residues distributed possibly throughout the length (Hulpke and Tampé, 2013; 
van Bleek and Nathenson,  
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Figure 1.4: The classical antigen processing and presentation pathway. Left panel (endogenous 
MHC class I pathway). 1, 2 Antigens for this pathway are either endogenously produced a 
product of DNA transcriptional or mRNA translational error happened in the normal cellular 
process, or originate from a translated protein product of a viral nucleic acid. 3, 4, 5 the 
damaged or foreign proteins are immediately tagged by ubiquitin and enter through the 
proteosomal machinery. 6 The peptide fragments coming out of the proteosomal machinery is 
then transported in to the rough endoplasmic reticulum with the help of a protein known as 
transporter associated with antigen processing (TAP). 7. The antigen is now loaded on to a fully 
folded MHC class I molecule with the help of molecular chaperones calnexin, calreticulin and 
tapasin. 8, 9 once the peptide is loaded on to the MHC molecule the molecular chaperones 
dissociates and the peptide MHC complexes leave the RER and transported on to the surface 
through the golgi complex. Right panel (exogenous MHC class II pathway). A, B Exogenous 
danger signal is detected by the TLR molecules on its surface and subsequently engulfed by 
phagocytosis (phagosomes). C. The phagosomes are combined with the lysosome compartment 
and form the phagolysosomes. D. class II MHC synthesis takes place in a similar fashion as 
Class I synthesis but are synthesised with an additional invariant chain. This invariant chain 
prevents unanticipated binding of pepides at very early stages of MHC II formation. E,F,G. The 
MHC class II depart the RER and pass through the golgi endosome and finally fuse with 
phagolysosome. As the acidic environment increased in the endosomal compartment the 
invariant chain is gradually disintegrated to leave only a small fragment in the peptide binding 
groove known as CLIP (class II associated invariant chain peptide). Finally CLIP is replaced by 
foreign peptide fragment and move towards the membrane. H. MHC class II is presented on the 
surface of a professional antigen presenting cell with antigenic peptide mounted on it for CD4+ 
recognition and expansion. 
Fig. 1.4. The classical antigen processing and presentation pathway
Left panel (endogenous MHC class I pathway).
, 2 Antigens for this pathway is endogenously produced either a product of DNA
tr nscri tional or mRNA translational error h ppened in the normal cellular process, or
coming from a translated protein product of a viral nucleic acid. 3, 4, 5 the damaged or
foreign proteins are immediately tagged by ubiquitin and enter through the proteosomal
machinery. 6 The peptide fragments coming out of the proteosomal machinery is then
transported in to the rough endoplasmic reticulum with the help of a protein known as
transporter associated with antigen processing (TAP). 7. The antigen is now loaded on to
a fully folded MHC class I molecule with the help of molecular chaperones calnexin,
calreticulin and tapasin. 8, 9 once the peptide is loaded on to the MHC molecule the
molecular chaperones dissociates and the peptide MHC complexes leave the RER and
transported on to the surface through the golgi complex
Right panel (exogenous MHC class II pathway).
A , B Exogenous danger signal is detected by the TLR molecules on its surface and
subsequently engulfed by phagocytosis (Phagosomes). C. The phagosomes are combined
with the lysosome compartment and form the phagolysosomes. D. class II MHC synthesis
takes place in a similar fashion as Class I synthesis but synthesis with an additional
invariant chain. This invariant chain prevents unanticipated binding of pepides at ery early
tages of MHC II formati n. E, F, G. Th MHC class II depart the RER and pass through
the golgi endosome and finally fu e with phagolys som . A the aci ic environment
increased in the endosomal compart the invariant chain is gradually disintegra e a d
leaving only a small fragment in the peptide binding groove known as CLIP (class II
associated invariant chain peptide). Finally CLIP is replaced by foreign peptide fragment
and move towards the membrane. H. MHC class II is presented on the surface of a
professional antigen presenting cell with antigenic peptide mounted on it for CD4+
recognition and expansion.
  
17 
 
1993; Rothbard and Gefter, 1991). The deficiency of this antigen processing machinery 
is a common immune escape mechanism in evading tumour tissue, which will be 
discussed in the later sections. 
1.2 Cancer                                                                     
Cancer accounts for 13% (7.3 million) of all deaths worldwide in 2008 and it is 
projected to rise to over 13.1 million by 2030 (WHO, 2013). As with many other 
developed countries, cancer incidence in the United Kingdom is also on the rise with 
521 cases for every 100,000 people (Cancer Research UK, original estimates based on 
2010 data and reviewed on December 2012). Cancer can be defined as the anomalous 
growth of cells developing into a population of cells which can proliferate indefinitely, 
invade surrounding tissues and spread (metastasise) to distant sites through the blood 
and the lymphatic system (Ruddon, 2006). Most of cancers originate from single 
somatic cell and which has acquired many accumulated genetic and epigenetic changes. 
These changes alter the balance of cellular proliferation and cell death (Ruddon, 2006) 
and thereby become tumourigenic. Interestingly cancers also contain multiple cell types 
such as fibroblasts, epithelial cells, cells of innate and adaptive immune system, cells of 
blood and lymphatic vasculature and mesenchymal cells.  This intricate system of cells 
collectively acts as major cellular supportive machinery and a unique microenvironment 
for the growth of cancers (de Visser et al., 2006; Hanahan and Weinberg, 2011). 
Because of this self-contained tissue organisation and the many other immune escape 
mechanisms that have been developed by the tumours, it is highly difficult to kill every 
single cancer cell. So for that very reason, attempts to develop very effective cancer 
vaccines to eradicate cancer still remain a daunting task. However, the broadening of 
our basic understanding in cancer biology and its interactions with the immune 
compartment of the body is having a positive impact on the future therapeutic or 
prophylactic cancer vaccination strategies. The therapies for cancer treatment has been 
broadly divided into conventional and immunotherapeutics.  
1.2.1 Conventional therapies for cancer management 
Conventional therapy including surgery, radiotherapy, chemotherapy and hormone 
treatment represents the mainstay of efficient cancer ‘management’ in clinical settings 
(Macmillan Cancer Support 2013, “Cancer treatment” [online]). The term 
Antigen presenting cell 
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‘management’ is used here on purpose, since none of the above treatment modalities 
guarantee complete cure of cancer and the disease can reoccur later on in life.  
1.2.1.1 Surgery 
The single most important cancer management in patients and its origins trace back to 
2000 BC where the ancient Hindus were known to remove abnormal growth of the body 
(Encyclopædia Britannica 2013, “history of medicine” [Online]). With the latest 
advancement in surgical procedures it is now possible to precisely locate and remove a 
tumour with utmost precision. Surgical procedures can be performed with neoadjuvant 
(Yoshioka et al., 2013) or adjuvant settings (Kruse et al., 2013); in the former the 
chemotherapeutic agents is given to the patients prior to the surgery to shrink or reduce 
the tumours and in the latter the same agents are given after the surgical removal of the 
cancerous tissue to prevent the re-emergence of cancer cells post-surgery (Redden and 
Fuhrman, 2013; Kruse et al., 2013). Minimal invasive surgery is a common 
methodology now, where the surgeon uses minor incision in the body to reach the 
malignant tissues and precisely remove the cancer tissues without destroying much of 
its normal surrounding tissues. This methodology is highly supported by the advances in 
cancer imaging and computer modelling (Bharathan et al., 2013; Lamadé et al., 2002) 
to precisely help surgeons to define positive margins around the tumour and use a 
robotic guided mechanical arm (Bharathan et al., 2013) to reach and excise the tumours 
with accuracy (Venkat and Guerrero, 2013; Randall and Gilbert, 2013). Surgical 
procedures can be performed in various situations such as preventive, diagnostic, 
staging, curative and palliative depending on the patient clinical status (Meijers-
Heijboer et al., 2003, Khankan, and Al-Muaikeel, 2012). Three major surgical 
procedures used for the management of the most common cancers are lumpectomy and 
mastectomy in breast cancer and radical prostatectomy in prostate cancer patients 
(Karam, 2013; Healy and Gomella, 2013).   
1.2.1.2 Chemotherapy 
 Chemotherapy is the second most important conventional anti-cancer therapy which 
can be used either on its own or in conjunction with any other conventional therapies.  
The term chemotherapeutic agents is broadly used to refer to the substances which can 
interfere with the growth of cancer cells (Skeel, 2007; Cancer Research UK 2013, 
"Chemotherapy and cancer" [online]). The specificity of the chemotherapeutic drug is 
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mainly is confined to their ability to target rapidly dividing cells, and this often causes 
deleterious side effects in the patients (Skeel, 2007). Haematopoietic cells and hair 
follicles also divide rapidly and are therefore also affected by this treatment, thereby 
resulting in the loss of hair and decreased production of immune cells in the patients. 
Chemotherapeutic agents are classified into several categories depending on their 
chemical properties and mechanism of action, for example alkylating agents (covalently 
binds to DNA and leads to the apoptosis of the cells), anti-metabolites (nucleic acid 
base analogues which resemble nucleosides or bases are incorporated into the DNA 
strand during the DNA synthesis), microtubule inhibitors (disrupt the assembly and 
disassembly of the microtubule formation during cell cycle and hence prevent mitosis), 
topoisomerase inhibitors (inhibit the DNA topoisomerase activity and disrupt the 
transcription and translational machinery) and other agents (mainly antibiotics having a 
variety of inhibitory properties in cancer cells) (Skeel, 2007). Chemotherapy also can be 
used as an adjuvant setting in many cancers in conjunction with other conventional 
treatment modalities. Major FDA approved chemotherapeutic drugs used in the 
treatment of cancers are epirubicin (breast cancer), methotrexate (melanoma, breast, 
head and neck, or lung cancer), docetaxel (breast, prostate and non-small cell lung 
cancers) cyclophosphamide (leukaemia, lymphoma, lung and breast cancer), mitomycin 
(stomach, breast, oesophagus and bladder cancers), doxorubicin (various), plaxitaxel 
(ovarian, breast, non-small cell lung cancer), mitoxantrone (breast, prostate, myeloid 
leukaemia and non-Hodgkin lymphoma) (Macmillan Cancer Support 2013, “Individual 
chemotherapy drugs” [Online]). 
1.2.1.3 Radiation 
 Another important conventional therapeutic strategy involves the use of strong, 
deleterious ionising radiation (mainly photons) to target neoplastic cells (Greco and 
Zelefsky, 2000). Ionising radiations carefully delivered to the tumour mass can cause 
two types of DNA damages. Single and double stranded breaks can be induced either 
directly by ionising the DNA bases or indirectly by creating free radicals that are 
capable of DNA damage. Several different types of conventional radiotherapy are 
applied: conventional external beam radiations (Halperin, and Burger, 1985), 3-
dimensional conformal radiation therapy (Creak et al., 2013), intensity-modulated 
radiation therapy (Poon et al., 2013) and brachytherapy (Park et al., 2013).  
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1.2.1.4 Hormone therapy 
The last conventional cancer treatment is hormone therapy. Some cancers such as 
prostate, ovarian and breast are dependent on hormones for their rapid growth (Jordan 
and Furr, 2002). Two of the hormones which have a profound effect on tumour growth 
are oestrogen and testosterone in breast and prostate cancer respectively (Jordan and 
Furr, 2002). Hormone treatments for these cancers are generally focussed on shutting 
down the hormone production or blocking the hormone receptors in the tumour. The 
most widely used hormonal drugs are tamoxifen, zoladex and faslodex in breast cancer 
(Breast Cancer Care 2013, “Hormone therapy” [online]) and the major hormone 
therapeutics for prostate cancer are leuprorelin, zoladex, histerillin (leutinising hormone 
releasing hormone agonist), flutamide, bicalutamide (anti-androgenic) (Cancer Research 
UK 2012, “Hormone therapy for prostate cancer” [Online]).  
1.2.2 The origin and evolution of T cell based immunotherapy 
The idea that the immune system is able to fight cancerous cells was first proposed 
around two centuries ago. The very first recorded observation probably dated back to 
the 1850’s, where German doctors noticed the rapid shrinkage of streptococcal infected 
tumours. This was followed by William Coley’s (1862–1936) famous cancer vaccine 
nicknamed ‘Coley’s toxin’, which used a crude preparation of Streptococcus pyogenes 
to treat cancer patients on a large scale. At the beginning of 20th century, Nobel laureate 
Elie Metchnikoff and Paul Ehrlich first suggested that the immune system suppresses 
the growth of tumours (Blair & Cook, 2008), however it took more than 50 years before 
this was fully acknowledged after the pioneering concept of ‘Immunosurveillance’ was 
proposed by Burnett (Burnet, 1970). Frank Macfarlane Burnet (1899–1985) was 
instrumental in putting the idea of the immune system’s capacity to fight against cancer 
on a firm ground during the 1970’s. Burnet proposed the vital role of lymphocytes in 
the detection and rejection of transformed malignant cell in human body. However, this 
was later abandoned as a consequence of experiments conducted in athymic nude mice, 
which showed similar disease incidence in comparison to the wild type animals and 
suggested that T cells did not have any effect on tumour control (Stutman 1979; Parish, 
2003). The real breakthrough came in the 1980s with the observations that some auto-
reactive T cells could be demonstrated to escape thymic selection (Sakai et al., 1979) 
and could be recruited later to combat the transformed cells. This led to the dawn of a 
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new era of T cell based immunotherapy (Topalian and Rosenberg, 1990) which was 
further fuelled by the identification of tumour associated antigens (TAAs). The first 
proof of an effective use of T cell based immunotherapy was reported by van Pel & 
Boon (1982) who used MAGE-1 and demonstrated that T cells located in the periphery 
are capable of recognising specific proteins expressed on the tumour cells. This opened 
up novel strategies for targeting specific tumour antigens with T cell mediated 
immunity induced by vaccination. The important scientists and the landmark 
discoveries which put immunology in the limelight for fighting cancer are given in 
Figure 1.5   
 
 
 
 
 
 
 
 
 
 
Figure 1.5: The key milestones in the origin and evolution of T cell based cancer 
immunotherapy over past 200 years 
1.2.3 Tumour antigens as a target for T cell based immunotherapy 
1.2.3.1 Tumour associated antigens (TAAs) 
The formulation of a vaccine which would stimulate the adaptive immune system to 
control tumour growth is the holy grail of tumour immunologists. The first proof of an 
effective use of T cell based immunotherapy was reported by van Pel & Boon (1982) 
with MAGE-1 - they demonstrated that T cells which are capable of recognising 
specific proteins expressed on the tumour cells (tumour associated antigens, TAAs) can 
be observed in the periphery. This opened up a novel strategy for targeting specific 
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tumour antigens with T cell mediated immunity induced by vaccination. One of the 
problems using these TAAs as an effective target for immunotherapy is their specificity, 
since most of them are self-proteins and constitutively expressed in almost every cell. 
As a consequence, the effector cells (T cells) do not recognise them very well because 
of the phenomenon known as immunological tolerance, which will be discussed later in 
more details. In short, cancer is a disease which arises from self-mutated cells and in the 
majority of cases the biochemical alterations in cancer cells are subtle when compared 
to their normal healthy counterparts. So the successful immune reaction should be 
capable of recognising these subtle alterations as an altered self and the molecular 
changes as lethal changes prior to mounting a successful immune response. From a 
cancer vaccination point of view, it is essential to identify these altered proteins or 
antigens before devising potential therapeutic strategies. A comprehensive account of 
major approaches used for the identification of human tumour antigens was reviewed in 
Li, et al., 2005; Mathieu, et al., 2009, Coulie, et al., 2014.   
1.2.3.2 Classes of tumour associated antigens (TAAs) 
Based on the expression status and their function, TAAs are classified into different 
categories. The first one is “mutated antigens”,- these antigens originate from mutations 
occurring during tumour development, so have huge limitations. Each of these 
mutations is patient or tumour specific so large-scale patient specific mutation screening 
is required prior to device any immunotherapy interventions. The second class of TAA 
are “shared tumour antigens”, which are specifically expressed in different kind of 
tumours and not expressed in the normal tissues. An example includes the cancer testis 
antigens (CT antigens) which expression is restricted to cancer tissue, placental 
trophoblast and testicular tissue. Since placental trophoblast and testicular tissues do not 
express MHC class I antigens they are immunoprivileged and hence immune to T cell 
mediated immunity. The third group of TAA includes “differentiation antigens” which 
are expressed in the cancer tissue as well as the corresponding normal tissues. 
Tyrosinase is an example of a differentiation antigen since it is present in normal 
melanocytes and melanoma. One of the potential limitations of this type of antigens is 
autoimmunity. The final group of TAAs are “overexpressed antigens” which have a 
normal expression in normal tissues, but are overexpressed in malignant tissues. Well 
studied examples of all these tumour classes are given in Table 1.2. 
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   Table: 1.2. Examples of Tumour associate antigens identified in different classes 
Gene  Tumour HLA Peptide Reference 
1. Mutated antigens    
BCR-ABL chronic myeloid leukaemia A2 SSKALQRPV* Yotnda et al., 1998 
beta-catenin Melanoma A24 SYLDSGIHF* Robbins et al., 1996 
FLT3-ITD acute myelogenous 
leukaemia 
A1 YVDFREYEYY* Graf et al., 2007 
N-ras Melanoma A1 ILDTAGREEY* Linard et al., 2002 
2. Shared tumour specific antigens    
LAGE-1 Shared A2 MLMAQEALAFL Aarnoudse et al., 1999 
MAGE-A1 Shared A2 KVLEYVIKV Ottaviani et al., 2005 
NY-ESO-1  Shared B7 APRGPHGGAASGL Ebert et al., 2009 
SAGE Shared A24 LYATVIHDI Miyahara et al., 2005 
3. Differentiation antigen    
gp100  Melanoma A2 KTWGQYWQV Bakker et al., 1995 
Kallikrein 4 prostate cancer DP4 SVSESDTIRSISIAS Hural et al., 2002 
PAP prostate cancer A2 FLFLLFFWL Olson et al., 2010 
TRP-2 Melanoma A2 SVYDFFVWL Kawakami et al., 1998 
4. Overexpressed antigens    
HER-2 / neu ubiquitous (low level) A2 KIFGSLAFL Fisk et al., 1995 
alpha-fetoprotein Liver A2 FMNKFIYEI Pichard et al., 2008 
p53 ubiquitous (low level) A2 RMPEAAPPV Barfoed et al., 2000 
survivin Ubiquitous A2 ELTLGEFLKL Schmidt et al., 2003 
Telomerase testis, thymus, lymph  A2 RLVDDFLLV Minev et al, 2000 
* Red coloured letters indicates the mutations 
Although all the antigens mentioned in the Table 1.2 have been shown to be able to 
generate immune responses in patients, the efficacy of most of these vaccines remains 
limited. The primary reason for this is the tolerogenic properties that are exerted by 
tumour cells (Caspi, 2008). In other words, immunotherapy and autoimmunity share a 
common conceptual ground in the recognition of their target molecules. By using 
immunotherapy we are altering the fine balance of self-tolerance of T cells and this may 
lead to catastrophic outcomes such as spontaneous auto-immunity while on treatment. 
In order to completely understand the fine balance between the auto-immunity and 
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cancer immunotherapy, one must understand how these cells are generated and educated 
in the thymus - this is discussed in Section 2.1. 
1.2.4 Cancer Immunotherapy 
Immunotherapy is a treatment modality which fine tunes our own immune system to 
recognise and eliminate cancer cells. In the past few decades progress in the field of 
cancer immunotherapy has led to the production and use of promising therapeutic 
vaccines such as rituximab (Marcus & Hagenbeek, 2007) in non-Hodgkin’s lymphoma 
and trastuzumab (Hudis, 2007) in breast cancer. However, T cell based therapy has still 
not achieved its final goal of effective protection for various reasons such as its high 
similarity to the natural protein within the body, other immune mechanisms operating in 
the tumour microenvironment etc. Nonetheless, different tumour associated antigens 
have been identified in various cancers and these could effectively trigger cytotoxic T 
lymphocyte (CTL) responses in cancer patients (Dougan & Dranoff, 2009). The broad 
overview of the immune system fighting cancer is depicted in Figure 1.6. The inward 
investigation into the unsatisfactory performances of many vaccines despite their ability 
to generate good T cell responses led to the resurgence of other areas of tumour biology, 
including the study of the tumour microenvironment (TME), immune suppression and 
tumour immune escape mechanisms. Studies conducted by various groups have 
identified a range of causative components and they are of profound importance to 
tumour vaccination strategies, as a better understanding of these will help to increase 
vaccine efficacy. Therefore, it is essential to mention the suppression mechanism as a 
part of this literature review in order to fully understand the current status of T cell 
mediated immune therapy.  
 1.2.4.1 The three E’s of immunosurveillance, the central theme of cancer 
immunotherapy 
A recent revisiting of the concept of cancer immunosurveillance (Zitvogel, et al., 2006) 
has led to a better understanding that the immune system can recognise mutated pre-
cancerous cells and ‘eliminate’ them before the tumour becomes a clinically detectable 
condition. However, a tumour might bypass these mechanisms by selecting less 
immunogenic variants of the mutant cells (immunoselection) or by active suppression of 
the immune system (immunosubversion). Therefore, it is essential to “boost” the 
immune system with combinatorial vaccination strategies along with the currently 
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available immunotherapeutic approaches. According to the recent immunoediting 
hypothesis of Spiotto et al. 
 
 Figure 1.6: A simplified view of the immune system combating a tumour. The most effective 
way of killing the tumour is CD8+ (CTLs) mediated killing. Interferon- γ secreting CD4+ helper 
cells also recruit NK cells, granulocytes and macrophages towards the tumour environment and 
these cells interact with the tumour stroma and interfere with the angiogenesis processes. CD4+ 
cells are also critical for the maintenance of memory CD8+ cells, so at the time of reoccurrences 
of the tumour these cells can be sensitised to re-emerging tumours much more quickly, this is 
known as TH1 response. In the TH2 response antibodies are produced against the tumour 
antigens and give a much needed humoral immunity support for combating the tumour. 
Fig .1.6. A simplified view of the immune system combating a tumour. The
most effective way of killing the tumour is CD8+ (CTLs) mediated killing.
Interferon- γ secreating CD4+ helper cells also recruit NK cells granulocytes and
macrophages towards the tumour environment and these cells interact with the
tumour stroma and interfere with the angiogenesis processes. CD4+ cells are
also critical for the aintenance of emory CD8+ cells, so at the time of
reoccurances of the tumour these cells can sensitise faster against the
reemerging tumors, this is known as TH1 response. In the TH2 response
antibodies are produc against the t mour antigens and give a much needed
humoral immunity support for combating the tumour.
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(2004) a perfect balance exists between the immune system and tumour progression, but 
when that balance is perturbed the immune system can no longer defend itself from 
tumourigenesis. The strategies employed by the tumour also facilitate the process of 
keeping the immune system at bay (Figure 1.7.). So the three E’s: elimination, 
equilibrium and escape are commonly known as the mechanisms involved in the 
process of tumourigenesis.  
 
 
 
 
 
Figure 1.7: There are three separate phases in the crosstalk between tumour progression and 
immune system defence. In the first phase, the immune system recognises and destroys cancer 
cells, this leads to a state of equilibrium between the tumour cells and immune cells. During this 
phase, tumours select less immunogenic variants of the cancer cells and ultimately break the 
equilibrium and leads to clinically apparent cancers. The yellowish green pyramid indicates 
tumour progression and the red inverted pyramid represents immune system progression. 
(Figure adapted from Zitvogel et al, 2006) 
Fig.1.7.There are three separate phases in the crosstalk between tumour
progression and immune system defence. In the first phase the immune system
recognise and destroy cancer cells, which leads to a state of equilibrium
between the tumour cells and immune cells. During this phase, tumours select
less immunogenic variants of the cancer cells and ultimately break the
equilibrium and leads to clinically apparent cancers. The yellow pyramid
indicates tumour progression and the red inverted pyramid represents immune
system progression.
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1.2.4.2 Tumour escapes mechanisms and immune suppression  
The renaissance of Burnet’s theory of immunosurveillance in the past few decades has 
been mainly fuelled by the observations made in patients and laboratory animals, that an 
immune system can check the growth of an ‘immunogenic’ tumour. The term 
‘immunogenic’ is not always associated with tumours because of the selection of non-
immunogenic variants of tumour cells as discussed above. However, the failure of many 
clinical trials involving cancer immunotherapy created a re-examination of mechanisms 
under which tumour specific CTLs execute their effector functions and the factors 
which prevent it. Over the past decades many tumour derived factors have been 
identified and they have been broadly classified as tumour micro environment (the 
collective tumour ecosystem) and tumour cells (at the cellular level).  
1.2.4.2.1 The ‘tumour microenvironment’ and immune suppression 
Among many factors identified, the immune suppressive environment that the tumour is 
creating, during the process of tumour evolution, has been identified as the single major 
contributing factor for the failures of immunotherapy (Becker et al., 2013). As 
discussed in the previous section, a tumour is a self-contained system of organisation 
including cancerous cells, noncancerous stromal cells and most of the immune cells 
within the tumour environment. This unique ecosystem of cells capable of producing 
various secretory and cell surface signalling molecules and ligands has been identified 
to have both pro and anti-tumour characteristics. A classic example of such a molecule 
is TGF-β, which exhibits both tumour suppressive and tumour promoting activity 
(Smith et al., 2012; Bachman & Park, 2005). Studies have shown that overexpression of 
TGF-β leads to increased invasiveness and metastasis by promoting epithelial to 
mesenchymal transition (EMT) in primary tumour (Miyazono, 2009) which has been 
attributed to the influence of TGF-β in a SMAD mediation transcriptional regulation in 
cancer cells (Valcourt et al., 2005). Up regulation of TGF-β has also been reported to 
cause chemoresistance in colon cancer (Brunen et al., 2013) and also to be negatively 
influence the immune cells by inhibiting the differentiation of Th1 and Th17 responses 
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by dendritic cells (Min et al., 2012), as well as directly inhibiting cellular cytotoxicity 
by affecting the expression of cytolytic factors such as granzyme A & B, perforin, Fas 
ligand and interferon-γ (Thomas, & Massagué, 2005). TGF-β production can also be 
increased by the production of IL-13 by NKT cells (Terabe et al., 2003) which in turn 
can inhibit CTLs. These molecules can also prevent the maturation of dendritic cells and 
thereby prevent the complete activation of CTLs which may potentially become 
tolerogenic (Torres-Aguilar et al., 2010). Targeting TGF-β and its upstream molecules 
has been found to be a useful clinical strategy for regaining the immune surveillance 
mechanisms (Fichtner-Feigl, 2008; Takaku et al., 2010).  
Another important potent immune suppression molecule which is produced by tumour 
tissue is IL-10 (de Vries, 1995). IL-10 can down regulate the expression of MHC and 
other costimulatory molecules on the antigen presenting cells (Halak et al., 1999; Joss et 
al., 2000; Liu et al., 2013) and also directly check the proliferation of T cells. However, 
a recent study in murine models has shown an increased activation and expansion of 
tumour residing CD8+ T cells in an IL-10 expressing tumour microenvironment 
suggesting the potential proinflammatory role of IL-10 in tumour microenvironment 
(Emmerich et al., 2012). Prostaglandin E2 is a small molecule secreted by the tumour 
cells which has an effect on a wide variety of immune cells. It inhibits the cytotoxic 
activity of NK cells (Goto et al., 1983), the function of granulocytes (Ballinger et al., 
2006) and the phagocytic capacity of macrophages (Aronoff et al., 2004). Another 
immunomodulatory molecule present in the tumour microenvironment is Indoleamine 2, 
3-dioxygenase (IDO), a product of tryptophan catabolism. This molecule is expressed 
by dendritic cells and also by tumour cells (Munn et al., 2004). Over-expression of IDO 
in various cancers has been correlated with poor prognostics (Smith et al., 2012). 
Other substances produced in the microenvironment include galectin-1, gangliosides 
(Deng et al., 2000), CCL22 and arginase (Rabinovich et al., 2007). Galactin, a 
proteoglycan produced by many tumour tissues and stroma is positively correlated with 
tumour progressions and is now considered as an ideal target for cancer therapy 
(Laderach et al., 2013). It is also believed that galactin inhibits of CTL function in the 
tumour by promoting apoptosis in those cells (Perillo et al., 1995). CCL22 and CCL17 
are two chemoattractants produced by tumours and other myeloid cells in the 
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microenvironment which are playing a key role in the trafficking of regulatory T cells 
into the tumours (Peng et al., 2012; Rawal et al., 2013).  
‘Immune cells’ which are supposed to be the master controllers of the tumour growth 
can sometimes act as a tumour promoter (Schreiber, 2011). Two important classes of 
immune suppressive cells present in the tumour microenvironment are regulatory T 
(Treg) cells and myeloid derived suppressor cells (MDSCs). MDSCs (Young et al., 
1987) are cells of myeloid origin, characterised CD11b+Gr1+ phenotype in mice, Lin-
HLA-DR-CD33+ or CD11b+CD14-CD33+ phenotype in humans (Gabrilovich and  
Nagaraj, 2009). They develop during myelopoiesis in the bone marrow and 
subsequently migrate to different peripheral organs for immune surveillance. In cancer 
patients, these cells also migrate to the tumour site. In the peripheral lymphoid organ 
these cells present the tumour antigens to the effector T cells, however they can produce 
large quantities of reactive oxygen species (Kusmartsev et al., 2004), nitrogen species 
(Lu and Gabrilovich, 2012) and nitrites such as peroxynitrite (Gabrilovich and  Nagaraj, 
2009). Interaction of MDSCs with T cells leads to unresponsiveness of T cells (Nagaraj 
et al., 2008). MDSCs are highly plastic and respond to various stimuli which they 
receive from the tumour microenvironment. Once they enter the tumour, the tumour 
microenvironment prevents them from maturing and they become immunosuppressive 
and are broadly known as tumour-associated macrophages (TAMs) (Gabrilovich and 
Nagaraj, 2009).  
TAMs can secrete a myriad of immunosuppressive cytokines such as IL-10, IL-1, IL-6, 
and TGF-β which are known to have various CTL suppressive activity (Gabrilovich and 
Nagaraj, 2009; Sica and Mantovani, 2012). One of the well-studied immune 
suppression mechanisms is metabolic depletion of L-arginine, an essential amino acid 
present in the tumour microenvironment. TAM produces enzyme arginase in large 
quantities which catabolise the L-arginine in the tumour microenvironment leading to 
an increased depletion of this essential amino acid required for optimal T cell 
proliferation (Munder, 2009). Another mechanism of tumour suppression by MDSCs is 
the generation of reactive oxygen species within the tumour microenvironment. They 
can also secrete VEGF and matrix metalloproteinases (MMP) which help tissue repair 
and angiogenesis, and promote tumour growth (Gabrilovich and Nagaraj, 2009). These 
cells can adapt to their environment and are very plastic, for this reason it is believed 
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that many subsets of TAMs are present within the tumour microenvironment, with 
different roles as tumour suppressors or promoters.  
Regulatory T cells (Treg) are CD4+ cells which constitutively express high levels of 
CD25 on the cell surface molecule and the forkhead box P3 (FoxP3) transcription factor. 
This population of cells is naturally present in the periphery of normal individuals, but 
their prevalence is increased in the blood of patients with cancer and also in their 
tumours. The primary role of these cells is in the maintenance of peripheral immune 
tolerance and the prevention of autoimmunity in healthy individuals (Goodman et al., 
2012). There are many ways that a Treg cell can be recruited or expanded in tumours. 
The first mechanism involves the trafficking of naturally occurring peripheral Treg cells 
into the tumour. This is driven by CCL17 and CCL22 produced by the tumour and 
which are ligands for CCR4 and CCR8 receptors present on the Treg cells (Mizukami et 
al., 2008). The presence of immature antigen presenting cells such as MDSCs 
(especially the M-2 polarised) can trigger the recruitment and expansion of Treg cells in 
the tumour microenvironment (Biswas and Mantovani, 2010). Several other factors 
such as the presence of TGF-β (Huber et al., 2004) and IDO (Curti et al., 2007) 
produced by the tumour cells or the TAMs have been reported to play a favourable role 
in the Treg cell expansion, especially in the induced Treg cell compartment (Huber et al., 
2009). The presence of these cells in the tumour microenvironment has been reported to 
be associated with poor prognosis in patients with prostate (Flammiger, 2013), breast 
(Decker, 2012) and many other cancers. Immune suppressive mechanisms in the tumour 
microenvironment are depicted in Figure 1.8.   
1.2.4.2.2 Prevention of tumour killing at the ‘point of contact’ 
Cytotoxic T cells (CTLs) are capable of mounting an efficient anti-tumour effect by 
direct killing of antigen bearing tumour cells. Even if the tumour microenvironment is 
favourable for the infiltration, expansion and killing by CTLs, the tumour can directly 
impair their functionality at the ‘point of contact’ by carefully orchestrating the 
expression of inhibitory signals and apoptotic molecules on their surface. This 
represents another defence mechanism which the tumour can use to evade attack by 
adaptive immunity (Kerkar and Restifo, 2012; Rabinovich et al., 2007). 
MHC down regulation and the defects in antigen processing and presentation pathways 
are the primary mechanism of immune evasion (Seliger et al., 1998; 2000). MHC down 
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regulation results in the avoidance of CTL detection by the tumours since this process 
demands the mounting of antigenic epitopes on the surface of appropriate MHC class I 
molecules. Some of the defects in MHC molecule expression are reversible with 
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Figure 1.8: Tumour and tumour microenvironment mediated immune evasion is a hallmark of 
immune resistant tumours. '+' signs indicate a positive influence and '-' sign indicate a negative 
influence on the target. The substances secreted by the tumour such as IL-10, TGF-β, galectin, 
ganglioside, PGE2, has a direct negative effect on CTLs, whereas the secretion of VEGF, IL-10 
and TGF-β will prevent the maturation of tumour infiltrated dendritic cells which in turn trigger 
their immune suppressive activity on CTLs by upregulating STAT3, IDO, arginase and SOCS1. 
Another class of dendritic cells known as plasmacytoid dendritic cells (pDC) can secrete IDO 
which leads to the degradation of tryptophan an essential amino acid, for T cell proliferation. 
Other immune cells such as Treg cells and IL-13 secreting NKT cells also have an immune 
suppressive activity by directly inhibiting the proliferation of CTLs. 
 
 
 
 
Fig.1.8. tumour and TME mediated immune evasion is a hall mark of immune
resistant tumours. + signs indicate a positive influence and - sign indicate a negative
influence on the target. The substances secreted by the tumour such as IL-10, TGF-β,
Galectin, ganglioside, PGE2, has a direct negative effect on CTLs. Whereas the
secretion of VGEF, IL-10 & TGF-β will prevent the maturation of tumour infiltrated
dendritic cells which intern trigger their immune suppressive activity on CTLs by
upregulating STAT3, IDO, Arginase and SOCS1. Another class of DC k own as
plasmo ytoid DC (pDC) can secrete IDO whi h leads to the trypto han degradation an
essenti l aminoacid for T cell proliferation. Oth r immune cells such as Treg & IL-13
secreting NKT cells also have a immune suppressive activity by ditectly inhibiting the
proliferation of CTLs.
  
33 
 
interferon-γ or TNF-α treatment since they are mainly originating from epigenetic 
regulation. However, some of these changes are permanent and irreversible such as the 
mutations or deletions in the β-2 macroglobulin encoding genes (Restifo et al., 1996).  
Another potential escape mechanism involves defects in antigen processing machinery, 
mainly including the defects in transporter associated with antigen processing (TAP), a 
crucial element in the transport of antigenic peptides coming out of the proteosomal 
complex into the endoplasmic reticulum (Leone et al., 2013). Mutations in the TAP 
genes have also been reported to be a major cause of defective antigen presentation in 
many tumours (Seliger et al., 2000), resulting in the failure to mount antigenic peptides 
onto the surface of tumour cells and thereby rendering them invisible to the immune 
system.  
The immune synapse is where T cells make their decision to kill a cell (Franciszkiewicz 
et al., 2013; González et al., 2013). MHC molecule-TCR interactions trigger many 
proximal signalling events which are discussed in Chapter 3. These proximal signalling 
events are supported with many other signals coming from co-receptor ligand 
interactions in the synaptic complex interface. Tumours can preferentially manipulate 
these signals for their advantage in order to evade immune attack (Peggs et al., 2008; 
Pardoll, 2012). Three main classes of negative signals can be generated at this contact 
point: negative co-inhibitory signals, apoptotic signals and down regulation of proximal 
signal components in the CTLs (Figure 1.9). The role of these receptors in immune 
escape is discussed in Chapter 2.    
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Figure 1.9: Checkpoints of CTL inhibition at the point of contact. CTLA-4 is an inhibitory 
receptor present on T cell which has a high homology to another stimulatory receptor CD28 on 
T cells. Ligands of both the receptors are CD80 and CD86 on the tumour surface. If the 
expression of CTLA is higher in T cells, they can bind to the CD80 and CD86 ligands on 
tumour cells much faster than the stimulatory receptor CD28. This results in the non-
functionality of T cells. Similarly, PD-1 present on the T cell which binds to its corresponding 
ligand PDL1 also leads to inhibition of T cell activation. Major apoptotic signals are generated 
in T cells via receptors present in the T cell surface such as TRAIL, RACS1 and FAS and also 
via the by-product of tryptophan catabolism known as kynurenines. The down regulation of 
proximal signal molecules such as LCK, Fyn, CD3 and Shp1 primarily results in the weakened 
TCR signalling and leads to the incomplete activation of T cells.  
(Figure adapted from Rabinovich et al., 2007)   
Fig.1.9. Checkpoint of CTL inhibitions at the point of contact. CTLA-4 molecules
present on the tumour surface having high similarity to CD28 a surface molecule
present on the T cells which binds to CD80 and 86 on the tumour surface and
sending costimulatory signal for T cell activation and expansion. CTLA can also
bind to the CD80 and 86 molecule because of its high structural similarity and
generate an inhibitory signal for T cell. Similarly PD-1 present on the T cell binds
to its corresponding ligand PDL1 also leads to inhibition of T cell activatio . Major
apoptot c signals are generating in T cells through three re eptors present in the T
cell surface such as TRAIL, RACS1 & FAS and also through the by-product of
tryptophan catabolism known as kynurenines. The down regulation of proximal
signal molecules such as LCK, Fyn, CD3 & Shp1 are mainly resulting in the
weekend TCR signalling and leads to the incomplete activation of T cells
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1.2.5 Cancer vaccines 
Surgery, chemotherapy and radiotherapy are still the mainstays of cancer treatment, 
however these treatments do not always get rid of the cancer completely and even when 
they do, the disease can come back after many years. Therefore, using vaccination to 
stimulate one’s own immune system for detecting and eliminating cancer cells is an 
attractive additional strategy to cancer treatment. One potential benefit of 
immunotherapy compared to traditional treatment options is the detection and 
elimination of residual cancer cells and the development of immunologic memory in 
cancer patients. These would then keep a constant vigil on cells which may relapse 
during life by gaining cancerous properties. So, in a broader definition, cancer vaccines 
are substances which can either direct or restore the immune system to specifically 
detect and eliminate pre-malignant and malignant cells and tissues within the body. The 
cancer vaccination strategies can be prophylactic (protective) or therapeutic (treatment) 
(Emens, 2008; Frazer et al., 2007). 
1.2.5.1 Prophylactic cancer vaccination strategies 
Two of the recently FDA-approved prophylactic vaccines for the prevention of cervical 
cancer in women and head and neck cancer in men have recently been launched after 
the successful use of hepatitis B virus (HBV) vaccine in humans to prevent HBV 
induced liver cancers in 1981. Gardisil® and Cervarix® are the two recently approved 
prophylactic vaccines for human papilloma virus (HPV) developed by Merck and Glaxo 
SmithKline respectively (Lowy & Schiller, 2006; Schmiedeskamp & Kockler, 2006). 
Gardisil is a mixture of four proteins specific for HPV strains 6, 11, 16 & 18 and acts as 
a virus like particle (VLP); and also known as quadrivalent vaccine because of the four 
antigens; (Siddiqui & Perry, 2006). This vaccine has been administered in both males 
and females between the age of 9 and 26, and in men they proved to be combat genital 
warts, another papilloma induced condition. Cervarix® is a bivalent vaccine and only 
contains antigens from two of the most dangerous strains of HPV 16 and 18 (accounts 
for 70% of cervical cancers) (Schmiedeskamp & Kockler, 2006). It is approved to be 
given to females aged between 9-25 years. 
Apart from the above preventative vaccines approved by the FDA, and the much earlier 
approved HEPB vaccine (which is mainly against viral induced tumours), prophylactic 
vaccines against non-virally induced tumour have not yet materialised. It is also worth 
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noting that some microbes have been shown to be a contributing factor in kaposi 
sarcoma (hepatitis virus), adult T cell leukaemia (human T cell lymphotrophic virus 
type-1), stomach cancer (Helicobactor pylori) and bladder cancer (schistosomes). 
1.2.5.2 Therapeutic cancer vaccination strategies 
Therapeutic vaccinations on the other hand are used in cancer treatment to eradicate an 
already established tumour. Some are focused on shrinking an established tumour prior 
to surgery, delaying the tumour progression, preventing tumour relapse and eradicating 
tumour spread and metastasis. Unlike the above mentioned prophylactic vaccines or any 
of the conventionally available microbial vaccines, the development of therapeutic 
cancer vaccines is difficult. The main reason for this is that cancer, which is derived 
from self, has accumulated many genetic alterations over many years, to which the 
immune system has been rendered tolerant. Self-tumour antigens are highly tolerated by 
T cells because of their high similarity to their normal counterpart (immune tolerance 
and thymic selection of T cell repertoire is discussed in Chapter 2).  
So for the above reasons, therapeutic vaccination in cancer patients is at least 
theoretically a double edged knife. Ideally stimulation of T cells with any of the vaccine 
should lead to the breaking of tolerance and result in the eradication of the tumour by 
mounting potential anti-tumour immunity. On the other hand, serious autoimmune 
reactions are also a real possibility, depending on the expression profile of the target 
antigen and the potency of the immunity generated. The vaccination strategies can be 
divided into two main categories, passive therapy and vaccine mediated active 
immunotherapy.  
1.2.5.3 Adoptive therapy 
Adoptive immunotherapy is a modality by which tumour antigen/tumour reactive 
specific cytotoxic T cells are isolated and expanded ex vivo and transferred back into the 
patients. Early studies of adoptive transfer focused on the isolation of tumour infiltrating 
lymphocytes from the surgically removed tumour from patients and their subsequent 
expansion before transferring back into the patients (Rosenberg et al., 1994). The 
success of such studies was, however, limited and short-lived. With the identification of 
tumour derived suppression mechanisms and the immune suppresser cells it is now 
possible to possible to revisit adaptive transfer and improve the efficacy and outcome. 
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One of the potential problems of using adoptively transferred T cells to treat an already 
established tumour is their capacity to infiltrate (Bordon, 2012). This can be due to the 
poor or damaged vasculature of the tumour due to the harsh hypoxic environment 
generated by hypoxia inducible factors (HIF) in the tumour microenvironment. 
Treatment with blood vessel remodelling agents can improve the tumour vasculature 
and thereby the capacity of adoptively transferred T cells (ACT) to infiltrate the 
tumours (Bordon, 2012). Studies conducted in pancreatic neuroendocrine tumours have 
shown that that the presence of interferon-γ in the tumour microenvironment can abolish 
the tumour vasculature and a low dose of tumour necrosis factor-α (TNF-α) can 
improve vessel perfusion and thereby increase tumour infiltration of ACT and tumour 
control (Johansson et al., 2012). Apart from this physical barriers, tumour residing 
suppressive cells such as Treg cells and MDSCs can also influence the effect of 
adoptively transferred T cells. The presence of Treg cells in the tumour vicinity has 
been reported to be a limiting factor for a positive clinical efficacy of ACT (Viguier et 
al., 2004) and selective depletion of Treg cells in the tumour has been shown to increase 
T cell mediated immunity in pre-clinical models (Marabelle et al., 2013). Similar to 
Treg cells, MDSCs also have a negative influence of ACTs, and the depletion of these 
cells prior to ACT has also demonstrated to result in a positive therapeutic outcome in 
pre-clinical models (Kodumudi et al., 2012).  
 With the development of genetic engineering and the ability to manipulate T cells in 
the laboratory, many groups have started to create antigen-specific T cells with high 
affinity T cell receptors widely known as chimeric antigen receptor T cells (CARs) 
(Turtle et al., 2012). The utility of this technique has been demonstrated using a mutated 
peptide of p53 (Cohen et al., 2005) and NY-ESO-1 (Li et al., 2005). The clinical 
usefulness of these CARs was first demonstrated in patients with metastatic melanoma 
with significant tumour reduction (Morgan et al., 2006). Another strategy which uses 
antibodies fused to CD3ζ chain of TCR to mimic the TCR stimulation, and avoid the 
need for MHC dependent detection of tumour antigens are novel and promising 
(Chmielewski et al., 2013). The drawback of these adoptive transfer treatments is their 
cost and the expertise needed for the identification and expansion of antigen-specific T 
cells. Adding to that paradigm, the treatment has to be patient specific and hence it is 
not always going to be a treatment of choice in the first instance. However, CARs can 
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overcome the limitation of treating the ‘self-derived’ tumours by using predefined high 
avidity ones against the self-antigens without the limitation of tolerance.  
1.2.5.4 Active immunotherapy 
Active immunotherapy is the manipulation of the patient's own immune system using 
immunostimulatory agents such as peptides, activated dendritic cells, whole tumour 
cells and DNA vector vaccines. The advantage of active immune therapy is its low 
toxicity. In many cases, vaccines are well tolerated in treated patients and will generate 
immunologic memory (Dillman et al., 2007; Winter et al., 2011). A comprehensive 
current status of all the four major active immune treatment strategies is discussed 
below with relevant examples.   
1.2.5.4.1 Peptide and protein vaccines 
The identification of tumour antigens and their ability to trigger antitumor immunity 
generated a new interest in the use of these antigens for mounting immune responses in 
cancer patients in the past few decades. This approaches often resulted in clinical 
efficacy in various cancer types (Yamshchikov et al., 2001). Various vaccination 
strategies have been used within this strategy, the most studied of which is the use of 
short sequences (nonamer, octamer or decamer) for the generation of a CD8+ T cell 
response or the use of larger fragments (13-18 amino acid long) for the generation of 
CD4+ T cell response. The use of long peptides over shorter peptides is justified by 
studies that have shown that vaccine strategies including the long peptides generated 
stronger responses than the shorter ones (Bijker et al., 2007). In many occasions, the 
whole protein can be used as an immunogen, thereby allowing the patient to process and 
presenting all the possible antigenic peptides derived from those proteins. However, 
Melief's group also showed that that long peptide rather than the entire HPV protein 
generated stronger immune response (Rosalia et al., 2013). The selection of these 
peptides is usually carried out by the help of bioinformatics tools which predict the 
binding affinity of the peptide for an MHC.  
Numerous vaccine trials have been completed with tumour antigens and still many more 
are ongoing (Schlom, 2012; Yamada et al., 2012). Traditionally, peptide vaccines are 
injected with different immune modulatory adjuvants such as incomplete or complete 
Freund’s adjuvants (IFA/CFA) in many preclinical studies. These adjuvants in vaccine 
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formulations act as depot for the antigenic peptide preventing them from immediate 
diffusion. Now the critical question is “why these vaccines have not showing good 
clinical efficacy?” In melanoma, peptide vaccines have been tried and tested many 
times, however the clinical efficacy of these vaccines has not been promising (Stewart 
& Rosenberg, 2000; Kirkwood et al., 2009). That question has been answered by a 
seminal paper published in Nature Medicine by Hailemichael et al., (2013). Their 
studies demonstrated that vaccine generated T cells can remain localised at the site of 
injection in a gp100 melanoma tumour model which used incomplete Freund's adjuvant. 
They also observed a gradual FASL and IFN-γ mediated apoptosis. So the failure rate of 
the majority of peptide vaccine trials might be attributed to the use of adjuvants.  
The first generation peptide vaccines exclusively targeted CD8+ T cell responses and for 
that reason many of the vaccine trials used short peptides. Recently, studies have been 
conducted using long peptide vaccines which harbour multiple CD8+ T cell and CD4+ T 
cell epitopes, and these proved to be more efficient in the generation of durable anti-
tumour response (Melief and van der Burg, 2008). These observations correlated with 
the previous findings using a long ovalbumin peptide sequence (Bijker et al., 2007). 
Authors attributed this observation primarily to the processing and presentation of long 
peptide prior to the presentation. Diversifying the adjuvants has also proved to increase 
the efficacy of peptide vaccine, as in the case of TLR agonists like CPG motif (Nava-
Parada et al., 2007) and Poly IC (van Duikeren et al., 2012). The advantage of using 
whole tumour antigen vaccines rather than long or short peptide vaccines is the ability 
to generate a broader spectrum of immune response. However, it is difficult to measure 
the response after therapy since there is no prior knowledge about the responsible 
peptide. In the case of using natural peptides for the immunisation, one potential 
problem is their poor immunogenicity.  
Different research groups have modified the peptide sequence to enhance the binding 
affinity to the MHC or to the TCR and found this to be an efficient strategy (Valmori et 
al., 1998). Some of the vaccines in this category, such as an altered gp100 with 
Montanide ISA 51 have shown positive clinical outcomes in phase III trials in 
melanoma patients (Schwartzentruber et al., 2011). With the knowledge of large 
number of tumour antigens and their characterised epitopes, it is possible to combine 
multiple epitopes in a single vaccine provided they are all stable in the mixture. Such 
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approaches have been carried out in a clinical trial for melanoma in which multiple 
peptides (up to 12 peptides) were mixed in the same emulsion and injected into the 
patients with the aim of increasing the breadth of immune reaction. The studies were 
compared against a peptide mixture of just four and found that there is no significant 
drop in the overall antigen specific response when more peptides were used for the 
immunisation (Rosenberg   et al., 2006). This study discarded the assumption that 
peptide competition towards the MHC molecule at the site of vaccine injection might 
reduce the overall immunogenicity of each peptide. These observations are crucial for 
the development of future multi-epitope vaccines, particularly in the case of tumours. 
The reason for this is mainly attributed towards the tumour escape mechanisms 
employed by the tumour which selectively down regulate the antigen targeted by the 
immune system. So, multi epitope peptide vaccines may hold the future for peptide 
based vaccine therapy in cancers.  
The failures of using single epitope vaccines might be due to several factors other than 
the overall immunogenicity of the peptide used for the treatment. The short peptide 
vaccines (8AA length) do not require any antigen processing for presentation and for 
that reason they can bind directly to the available MHC molecules at the site of vaccine 
administration. The non-professional cells such as fibroblasts also express MHC 
molecules resulting in the antigen presentation to T cells without sufficient 
costimulatory signals, thereby leading to tolerance induction (Rosenberg   et al., 2006). 
The stability of the injected peptides within the body is another concern with large 
quantities of peptidases present in the serum which would degrade the peptides before 
they can reach the secondary lymphoid organs for antigen presentation (Slingluff, 2011). 
The final drawback of peptide and protein vaccines might be the affinity of the antigenic 
peptide. If the peptide does not have sufficient affinity, then it can be displaced from the 
MHC binding groove by a higher binder which would result in the poor presentation of 
the antigen (Slingluff, 2011).  
The above discussed points highlight the fact that, despite their limitations, peptide 
vaccines are still a favourite vaccine modality for the treatment of the cancer patient 
with visible positive clinical outcomes. However, careful design of vaccine formulation 
and the administration procedures can further improve the efficacy of these vaccines. 
This is also applied to long synthetic and multi-epitope vaccines where more relevant 
  
41 
 
clinical and preclinical studies are needed as a rationale for pushing peptide and protein 
based vaccines to the next level of clinical efficacy.  
1.2.5.4.2 Whole cell and dendritic cell vaccines 
The use of whole cancer cells to trigger immunity against the cancer has been in 
practice since the very beginning of cancer immunotherapy (Hanna & Peters, 1978). 
The vaccination has potential advantage over other vaccines in that the immune 
response is much broader and eliminates the possibility of tumour antigen escape 
variants. Mainly two types of whole cell vaccines are in use. The first one is called the 
autologous whole cell vaccine, derived from the cancer cell removed from the patients 
own tumour. The second type is the allogeneic whole cell vaccine where the vaccine 
consists of an irradiated cells derived from different patients and cancer cell lines (de 
Gruijl et al., 2008). Once the source is identified the cells are irradiated and 
administered into the patient with appropriate immunostimulatory agents. The former 
therapy is highly patient specific and it requires the isolation of cancer cells from the 
patient tumour. Allogeneic therapy is hence more amenable in a hospital setting if the 
logistics are constrained. Attention must be given to the immune rejection (anti HLA) 
reactions due to the tissue mismatch by using allogeneic cells in a HLA mismatched 
patient. However, not many studies have suggested that this is a potential problem 
(Nemunaitis et al., 2006). 
 There are numerous strategies employed to increase the immunogenicity of cells 
nowadays, these includes co-injection of GM-CSF, IL2, IL6, TNF-α and IFN-γ as 
immune-stimulatory agents. The cells can be transfected with a cytokine plasmid which 
continues to induce the secretion of cytokines, even after irradiation has been tested 
using a whole cell vaccine (Olivares et al., 2011). Most of the tumours were found to 
produce TGF-β and therefore whole cell vaccines combined with antisense RNA for 
TGF-β are promising by blocking the production of TGF-β, a potent inhibitor of tumour 
immunity (Olivares et al., 2011; Fakhrai et al., 2006). The utility of whole cell tumour 
vaccines have been demonstrated in various cancers including hormone-resistant 
prostate cancer (Michael et al, 2005), pancreatic cancer (Laheru et al., 2013) and 
melanoma (Mackiewicz et al., 2012). Another study which used well known prostate 
cancer cell lines (LNCaP, PC-3) transduced with GM-CSF (known as ‘GVAX’) in 
human patients has showed positive survival over a period of 26 months (Small et al., 
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2007). When these cells injected in to the patients the dendritic cells recognise these 
dying cell and taken them in for processing and presentation. The GM-CSF produced by 
the cells helps to recruit and mature dendritic cells.   
Another therapeutic opportunity exploited by many cancer vaccination trials involves 
dendritic cells (Schuler, 2010). These are professional antigen presenting cells and the 
background information on these cells is given in section 1.1.1.3. They originate from 
the hematopoietic stem cells as CD34+ cells, or monocytes can also be converted into 
mature dendritic cells depending up on the cytokine stimulus they received. Because of 
their strong antigen processing and presentation capacity they are considered to be 
potent cell for the stimulation of cellular immunity. In cancer immunotherapy, dendritic 
cells have been used extensively for the same purpose and dendritic cells based vaccines 
have demonstrated their potential in many clinical settings.  
The primary objective of any dendritic cells vaccine strategy is to load the cells with 
sufficient amount of tumour associated antigens (TAAs). There are several strategies 
that have been employed since their introduction in cancer immunotherapy. There are 
two main protocols usually followed for the antigen loading into the dendritic cells. The 
first approach is to target the dendritic cells in vivo using specific DNA vectors or 
molecules to deliver in to TAAs. Secondly, dendritic cells precursors are isolated from 
patients’ blood and induced to differentiate in to dendritic cells in vitro prior to loading 
the antigens and transfer them back into the body after their maturation. Initial studies 
involving ex vivo manipulation of dendritic cells for therapeutic purposes were limited 
to the use of CD34+ haematopoiesis precursors and were limited by the availability of 
sufficient number of dendritic cells for antigen loading. Evolution of dendritic cell 
vaccination and the search for abundantly available dendritic cells leads to the use of 
CD14+ monocytes to generate dendritic cells from the peripheral blood, and this 
methodology is become widely accepted method for current dendritic cell vaccination 
strategies.  GM-CSF and IL-4 are the most widely used cytokine for the generation of 
the immature DCs from blood isolated CD14+ monocytes, however other cytokines such 
as IFN-α, TNF-α and IL15 have also been used.  
The derivation of immature dendritic cells from the monocytes is the initial step of 
dendritic cell based therapy, complete maturation of the dendritic cells in the presence 
of suitable agents is crucial, since incomplete maturation of the dendritic cells leads to 
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the poor expression of the costimulatory molecules which would results in the induction 
of T cell tolerance and anergy in CTLs instead of stimulation and activation.  
Inflammatory cytokines such as TNF-α PGE2, R848, IL-1β and IL-6 in current 
immunotherapeutic settings are the best candidates for the maturation of the dendritic 
cells ex vivo. (Tuyaerts et al., 2007; Skalova et al., 2010). The use of TLR agonists such 
as Poly-I:C (Polyinosine-polycytidylic acid) or LPS (Lipopolysaccharide) can enhance 
dendritic cell maturation significantly (Tuyaerts et al., 2007). However, studies have 
indicated that the use of TLR agonists for dendritic cell maturation has a negative 
influence on the mobility of mature dendritic cells.  
The antigen loading of the dendritic cells can be performed with various methods such 
as transducing the immature dendritic cells with mRNA or DNA derived from 
allogeneic or autologous tumour cells or tissues (Cao et al., 2013; Chen et al., 2013).  
The antigen loading can be performed with irradiated dying tumour cells, defined 
peptides (Oshita, 2012) or whole protein lysates. The use of whole protein lysates 
(Lasky et al., 2013), cells or mRNA is more efficient, since they harbour a wide 
antigenic repository for the dendritic cells to process and present to the T cells 
(Bringmann et al., 2010). The major breakthrough of dendritic cell derived vaccine 
came with the first FDA-approved prostate cancer vaccine Sipuleucel-T. This offers a 
low (4 months compared to placebo), but significant survival advantage to the patients 
with metastatic hormone-resistant prostate cancer (Gould, 2006; Higano et al., 2009, 
2010; Schellhammer et al., 2013). The vaccine uses autologous dendritic cells and 
needs leukapheresis of the patients for the loading of antigen to the dendritic cells.  
1.2.5.4.3 DNA Vaccine 
DNA vaccines are an attractive delivery system for TAAs into the cancer patient. The 
main advantages of this type of vaccine are the flexibility it offers to tailor the vaccine 
according to the theoretical and conceptual requirement of the researcher. In general, the 
vaccines are constructed into a bacterial or viral expression vector backbone with 
sufficient expression of control element such as optimal eukaryotic promoters and 
polyadenylation signals (Ghanem et al., 2013). Since it is tailor made, many 
costimulatory molecules of the adaptive and cellular immunity can also be co-expressed 
in this backbone in order to facilitate a better immune response (Lan et al., 2013). The 
vaccine delivery has been traditionally carried out with either electroporation or gene 
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gun mediated route and subsequent incorporation of these vaccines into the skin 
dendritic cells and also to the normal muscle cells (myocytes) (Rice et al., 2008).  The 
dendritic cells incorporated vaccine translates the tumour antigens and subsequently 
enters into the class I or class II pathway for its presentation. Another mechanism is 
cross presentation which is elicited by non- dendritic cells at the vaccine sites. Antigens 
required for the cross presentation were either produced and secreted from the myocytes 
if the vaccine design intends to do so, or derived from the dying or dead cells at the 
vaccination sites. This unique ability of direct and cross presentations with constant 
supply of the antigens may be an important parameter for the increased immunogenicity 
of the DNA vaccines in cancer therapy settings (Rice et al., 2008). The clinical utility of 
DNA vaccines for various cancers has been demonstrated in pre-clinical models and 
also in  Phase I and II clinical trials (Mincheff et al., 2000; Rosenberg et al., 2003; 
Tagawa et al., 2003; ; Triozzi et al., 2005 ; Wolchok et al., 2007; Chudley et al., 2012).  
An example of DNA based vaccine used for immunotherapy is against melanoma 
known as ImmunoBody®, by Scancell Ltd. a UK based company. This is capable of 
generating consistent high avidity T cell responses in cancer patients (Pudney et al., 
2010). This study utilises this vaccine as a model system for generating high avidity T 
cells and hence the details are discussed in the Chapter 2. Some of the representative 
examples of the above discussed vaccine strategies are given in the Table 1.3.  
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* Renal cell carcinoma, † Dendritic cell, ‡ Monoclonal antibody,  
1.2.5.5 The quantity and quality of T cell responses 
To study T cell functionality it is important to understand its properties at the 
immunological, transcriptional and protein level. Not much work has been carried out 
on the characterisation of high avidity T cells at the molecular level. Here we 
summarise the techniques available for the characterisation of these cells. The earlier 
assays used for the functional studies of T cells and estimating the overall response to 
immunotherapy included delayed type hypersensitivity (DTH) in vitro proliferation 
assays for CD4+ cells and in vitro cytolytic assays for CD8+ cells, or measuring the 
humoral responses by enzyme linked immunosorbant assays (ELISA). These assays 
Vaccine Type Cancer  Stage/clinical 
trial 
Reference 
Rituximab MAb‡ Lymphoma FDA  Anderson et al., 1997 
Tositumomab MAb Lymphoma FDA  Vose et al., 2000 
Alemtuzumab MAb Leukaemia FDA  Lemery et al., 2010 
Gemtuzumab MAb Leukaemia FDA  Bross et al., 2001 
Trastuzumab MAb Breast FDA Traynor, 2013 
Cetuximab MAb Colorectal FDA  Vincenzi et al., 2010 
Bavacizumab MAb Colorectal, 
Lung 
FDA  Cohen et al., 2007 
Gardasil (HPV)  Prophylactic Cervical FDA  Ghazal-Aswad, 2008 
Cervarix (HPV) Prophylactic Cervical FDA  Schmiedeskamp et al., 2006 
Imiquimod Adjuvant Baselcell  FDA  Tinelli et al., 2012 
Sipuleucel-T Therapeutic (DC †) Prostate FDA  Gould, 2006 
IFN-α Cytokine Melanoma, 
RCC* 
FDA  Tarhini et al., 2012 
IL-2 Cytokine Melanoma, 
RCC* 
FDA  Dillman et al., 2012 
TNF-α Cytokine Melanoma FDA  Lejeune et al., 1994 
DCVax Dendritic cell Brain  Phase III Fishman 2009 
Rindopepimut Peptide Brain  Phase III          Babu & Adamson, 2012 
GV-1001 Peptide  Lung Phase III Nava-Parada et al., 2007 
PROSTAVAC DNA Prostate Phase III DiPaola et al., 2006 
Trovax DNA Renal Phase III Harrop et al. , 2011 
SCIB1 DNA Melanoma Phase I & II Pudney et al., 2010 
Table: 1.3. Representative example of immunotherapeutic drugs used in cancer 
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have limitations such as low sensitivity and the need for in vitro manipulations which 
makes them inferior to the modern techniques. Modern T cell studies are broadly 
classified into two types, structural based assays and functional based assays.  
1.2.5.6 Structure based assays 
 1.2.5.6.1 MHC Multimeric complexes: Multimeric complexes used for the 
identification of peptide-specific T cells were first devised by Altman et al., in 1996. 
Like antigen antibody specificity, the principle of this method is also based on the 
affinity of the T cell receptor towards its cognate antigenic peptide presented on MHC 
molecules. The construction of these multimeric (dimer, tetramer, pentamer and 
dextramer are most widely used classes of MHC multimers) complexes involves the use 
of Class I or Class II MHC monomers joined together by fluorescent conjugated avidin. 
The peptide of interest can be used for tracking peptide-specific CD4+ or CD8+ cells 
after immunisation using flow cytometry (Wooldridge et al., 2009). This can also be 
used for the isolation of those cells for further in vitro studies or biochemical and 
molecular characterisations (Duplan, et al., 2007; Callan, et al., 1998).     
1.2.5.6.2 Real time quantitative PCR: Unlike conventional PCR which depends on 
gel-based techniques for product detection, real time PCR combines the target 
amplification and product detection into a single step (Higuchi et al., 1993; Heid et al., 
1996). This real time detection is achieved mainly because of the development of 
different fluorescent dyes (SYBR Green®, BEBO®) which can be used to relate the 
increase in product accumulation and fluorescent intensity quantitatively. Quantification 
is mainly done by the measurement of ‘Ct values’, which is the number of cycles 
required for the fluorescence values of each sample to rise above the background 
fluorescence (Wong and Medrano, 2005). The relationship between copy number and 
Ct value is inversely proportional, i.e. high initial template copies results in more 
products accumulation and therefore more fluorescence resulting in a lower Ct value. 
In an immune response, if the hypervariable complementary determining region (CDR) 
of the T cell is known, then real time PCR can be used for the quantitative measurement 
of that T cell specificity using clone specific primers that flanks the unique CDR 
(Ochsenreither et al., 2008;  Seo et al., 2001).   
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1.2.5.7 Functional based assays 
 1.2.5.7.1 Real time quantitative PCR: Antigen specific immune responses can be 
measured by studying the antigen driven gene expression of cytokines such as 
interferon-γ (INF-γ), granulocyte macrophage colony stimulating factor (GM-CSF), 
tumour necrosis factor-α (TNF-α) and interleukin-2 (IL-2). This approach provides a 
clear picture of antigen specific functional property of the T cells when used with 
appropriate controls.   
1.2.5.7.2 Flow cytometry cytokine analysis: Possibly, the most widely used technique 
to isolate cells is fluorescent activated cell sorting. It is possible to analyse or sort cells 
occurring at low frequency (Russell, et al., 2013; Ho et al., 2013). Sorting of cells are 
based up on the labelling with antibodies conjugated with fluorophores having different 
spectral characteristics (Bendall et al., 2012; Chattopadhyay and Roederer, 2012). The 
fluorescent signal can be obtained using a flow cytometer instrument if the antibody 
binds to the specific cellular markers. fluorescent activated cell sorting is widely used 
for the analysis of antigen-specific T cells. T cells subjects to a brief in vitro stimulation 
of 10-12 h with the desired antigenic peptide with protein transport blocking reagents 
such as brefeldin A or monensin. This helps in the retention of any cytokines produced 
upon antigen stimulation within the cells. The cells are then fixed and permeabilised 
using different reagents to detect the cytokine produced. Antibodies against the 
corresponding cytokines can be used by a process commonly referred as intra cellular 
cytokine staining (ICS).  One drawback of this technique is that the permeabilisation 
kills the cells (Yee and Greenberg, 2002). A modified version of this analysis known as 
Cytokine Capture Analysis (CCA) capture the secreted cytokines immediately using an 
antibody bound to the CD45 receptor of the T cells (Becker, et al., 2001; Campbell et 
al., 2011). The advantage of flow cytometry over ELISpot  assays are the opportunities 
to include multiparameter analysis using different surface phenotypic markers for the 
complete characterisation. 
  1.2.5.7.3 Enzyme Linked Immuno SPOT (ELISpot). This is most widely used 
functional assay for following the functionality and responsiveness of the T cells 
(Camisaschi et al., 2013; Diaz et al., 2013). Isolated splenocytes or peripheral blood 
mononuclear cells (PBMCs) are stimulated in an ELISpot plate which contains a 
membranous surface pre-coated with an antibody against the desired cytokine. Cells are 
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stimulated for 24-48 h at which time, captured cytokine is detected using a detection 
antibody which is labelled with chromogenic substances. The resultant spots are then 
counted on an automated plate reader based on its intensity. The number of spots is then 
expressed as the spots per total number of T cells that were put on the plate, thereby 
providing quantitative estimates of the T cell functionality. This assay is very useful to 
catch anergic cells when combined with structural assays such as multimer staining.   
 
1.3 Aim  
The main aim of this study is to identify biomarkers which would allow the detection of 
high avidity T lymphocytes in the blood or tissue of cancer patients after 
immunotherapy, irrespective of the peptides used for the immunisation. Recent studies 
using functional and structural assays on CTLs revealed that a highly diverse 
functionality of T cells exists with same specificity. The molecular mechanisms 
revealing this functional heterogeneity are not well studied. There are arguments that T 
cell functionality is decided during the early encounter of a naive T cell with an antigen 
presenting cell. The kinetics and the duration of signals received during that first 
encounter prior to clonal proliferation decide the function of the T cell (Sykulev, 2010). 
The large scale study of these peptide-specific cells are now feasible with the high 
through put platform such as high density cDNA Microarrays and LC-MALDI based 
mass spectrometry (liquid chromatography-matrix assisted laser desorption ionisation).  
To achieve this main objective the entire project is subdivided in sections  
• Establishment of two mouse model systems for studying the generation of high 
and low avidity CTL responses using immunologic methods.  
• Isolation of pentamer positive CD8+ T lymphocytes from high and low avidity 
mouse models. 
• Generate a peptide mass fingerprint (PMF) for high and low avidity T 
lymphocytes and identify molecular biomarkers associated with high avidity T 
cell responses.  
• Creation of complete transcription profiles for high and low avidity T 
lymphocytes using cDNA microarrays/quantitative real time PCR.  
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• Deciphering the genetic and protein interaction networks operating in high and 
low avidity T cells.  
• Confirm and validate the markers and the pathways in a second mouse model and 
then in human immunotherapy settings.  
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Chapter 2.  
Immunological characterisation of high and low avidity T 
cells 
2.1 Introduction 
Identification and characterisation of tumour associated antigens (TAAs) and its ability 
to generate potent anti-tumour immunity has presented tumour immunologists with a 
new opportunity to design and develop an effective vaccine against cancer. Although 
vaccination strategies have been shown to be capable of stimulating the adaptive arm of 
immune system, especially cellular immunity, in experimental settings, many clinical 
trials remained unsuccessful (Kudrin and Hanna, 2012). In the majority of the cases, the 
responses have been detected in the patients on the basis of detecting of antigen-specific 
CTLs or increased tumour infiltrations of lymphocytes (TILs) (Gajewski, 2007). This 
poor clinical efficacy, in the context of generating antigen-specific T cell responses has 
perplexed many in the field and a myriad of limiting factors which check the 
functionality of the effector cells have now been identified (Gajewski, 2007; Abastado, 
2012; Bellone and Calcinotto, 2013). This includes several escape mechanisms and 
immune suppression mechanisms operating within the tumour microenvironment or by 
immune cells such as Treg cells and macrophages. Targeting these limiting factors of 
vaccine efficacy is therefore an active area of research at the present (Sounni and Noel, 
2013; Samples et al., 2013).  
Although monoclonal antibodies against major tumour antigens have been effective in 
the delivery of cytotoxic payloads and triggering humoral immunity (Sliwkowski and 
Mellman, 2013) in patients, T cell based vaccine therapy has been more attractive to the 
tumour immunologists for two reasons. First, the majority of the identified tumour 
antigens are intracellular proteins that are either produced as a consequence of 
erroneous molecular events in the tumour cells, as a consequence of which they are 
often presented to immune system via an MHC class I or II MHC molecule (Borghaei et 
al., 2009). Secondly, the capacity of cellular immunity to establish immunologic 
memory can provide an additional level of long-term protection to patients, post 
treatment (Caserta et al., 2012). 
The different vaccination strategies discussed in the Chapter 1 are capable of generating 
different types of T cell responses. Peptide vaccines or epitope defined multivalent 
  
51 
 
vaccines are capable of generating a more defined T cell antigen specific repertoire and 
it is relatively easy to measure the efficacy of the vaccine by different immune 
monitoring techniques such as ELISpot® or multimer staining. On the other hand, whole 
cell and protein vaccines generate a highly polyclonal T cell response against different 
antigenic targets that are available in the whole cell preparations or the number of 
antigenic peptide derived from a single whole protein (Keenan and Jaffee, 2012; 
Kageyama et al., 2013). If this is the case, then immune monitoring is highly difficult 
mainly because of the lack of information about the responsible peptide(s). 
Apart from the immune suppression exerted on vaccine generated T cells, another major 
limiting factor is the quality of the effector cells (Viganò et al., 2012). The number of 
tumour-antigen specific CTLs is not necessarily a good indication of a quality response, 
rather it is the ability of these cells to execute the effector function in a fool proof way. 
This efficiency can be measured ex vivo by its ability to secrete effector cytokines in a 
peptide-specific manner. This ex vivo data can be used as a surrogate marker for 
predicting the in vivo vaccine efficacy in clinical trials (Malyguine et al., 2012; 
Malyguine2007; Ogi and Aruga, 2013).  
T cell avidity and functional avidity are two major indicators of vaccine efficacy. 
Avidity is the overall binding strength of the T cells to the target antigen and functional 
avidity is the ability of vaccine generated T cells to respond against its cognate antigen 
in a dose dependent manner. The detailed discussions of these topics are given in the 
later sections of this chapter. In short, a general consensus among tumour and viral 
immunologists is that a clinically beneficial vaccine response is one which is capable of 
generating a high functional avidity T cell response (Viganò et al., 2012; Mothe et al., 
2012).  
Unlike foreign antigen based vaccinations, tumour vaccinations are mainly depending 
on the self-antigenic targets. This is an additional challenge because of the fact that the 
vaccines are attempting to target a T cell repertoire which is highly tolerant to the self-
proteins. Therefore, it is ideal at this point to understand the generation of T cells within 
the body, careful thymic selections which avoid the high avidity self-reactive T cells 
and their tolerance mechanisms. This is particularly important because understanding 
these mechanisms are crucial for appreciating the availability of the total T cell 
repertoire in the periphery for vaccine targeting.  
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2.1.1 Ontogeny of T lymphocytes: careful nurturing of T cells in the thymus  
The life cycle of a T cell is a journey of careful differentiation, specificity development 
and a period of intense education, where it learns to recognise self from non-self. For 
any immunologist, it is important to understand elements of this selection process which 
take place in the thymus. During this process of thymic selection some autoreactive T 
cell clones can escape the negative selection and escape into the periphery (Mohan et al., 
2010, Enouz et al., 2012). The possible mechanisms for generation of these cells are 
discussed in the later sections of this chapter.  
The remarkable ability of T cells to discriminate self and non-self is not an acquired 
character in their late stages of development. The trustworthy T cell repertoire is 
carefully monitored in the thymus before they are released in to the peripheral organs 
for immune surveillance. Each T cell originates from haematopoietic stem cells in the 
bone marrow, as committed progenitors known as thymic seeding progenitors (TSP) 
(Vicente et al., 2010). These TSPs then move in to the thymus through blood vessels, 
and known as early thymocytes. At this stage they lack the expression of CD4, CD8 or 
T cell receptor molecules on their surface and are known as double negatives (DN). 
This DN population can further be divided into four subcategories by the presence of 
other cell surface markers: DN1 (CD44+CD25-), DN2 (CD44+CD25+), DN3 (CD44-
CD25+) and DN4 (CD44-CD25-) (Vicente et al., 2010). At late DN stages (DN3 and 
DN4) the emergence of T cell receptor - CD3 complex [α/β, γ/δ] takes place and is 
characterised by the expression of a non-rearranged Tα and a rearranged Tβ chain. In 
the next step, the rearrangement of the Tα chain also completes and the cells enter into 
the double positive (DP) stage of their thymic lifecycle expressing αβ TCR, CD8 and 
CD4 molecules on their surface (Haars et al., 1986). 
This is followed by the development of CD8+ and CD4+ single positive T cells by the 
interaction of double positive T cells with MHC class 1 or 2 molecules present on the 
cortical epithelial cells of the thymus which are loaded with self-peptides (Anderson et 
al., 2009). DPs binding to  MHC class 1 molecules become CD8+ single positive (SP) 
and conversely those which binds to MHC class II become CD4+ single positive (SP) T 
cells. Major signalling pathways such as Notch (Carlin et al., 2012) and hedgehog 
(Rowbotham et al, 2008) play an important role in the above differentiation and lineage 
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commitments in the thymus. The detailed development of T cell ontogeny is depicted in 
Figure 2.1 
 
 
 
 
Figure 2.1: Thymic maturation of a T cell: Journey of a T cell start from the haematopoietic 
stem cells (HSC) in bone marrow. HSC’s are quickly converted to thymic seeding progenitors 
(TSP) before entering in to the thymus. Subsequently these cells were passed through cortex of 
the thymus. At this point they have the potential to differentiate in to dendritic cells (DCs), 
natural killer cells (NK cells) or macrophages (Mϕ). However, tight regulation of NOTCH 
signalling pathways prevent these cells from entering in to that alternative differentiation and 
remain stick to the T cell differentiation root. TCRγδ and TCRβ rearrangement starts at the late 
double negative 2 (DN2) stage and ends in subcapsular zone of the cortex at the double negative 
3 (DN3) stage. Two different lineages of T cells (γδ and αβ) formed at this point of late DN3. At 
early double negative 4 (DN4) stage, cells committed to follow the αβ lineage double positives 
(DP) move in to the cortex region of thymus. Most of the TCR gene rearrangements take place 
at this region. The cells subsequently enter into the medulla of the thymus and undergo negative 
and positive selection before entering into the periphery. The cellular phenotypic markers at 
each development stage is also given under each stages. 
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Fig 2.1. Thymic maturation of a T cell: Journey of a T cell start from the
haematopoietic stem cells (HSC) in bone marrow. The HSC’s quickly converted to
thymic seeding progenitors (TSP) before entering in to the the thymus. Subsequently
these cells were passed through cortex of the thymus. At this point they have the
potential to differentiate in to dendritic cells (DC), Natural killer cells (NK cells) or
Macrophages (Mφ). However tight regulation of NOTCH signalling pathways
prevent this cells to enter in to that alternative differentiation and remain stick to the
T cell differentiation root. TCRγδ and TCRβ rearrangement start at late double
negat ve 2 (DN2) and ends in subcapsular zone of the cortex t double negative 3
(DN3) stage. Two different lineages of T cells (γδ and αβ) formed at this point of late
DN3. At early double negative 4 (DN4) stage the cells commits to follow αβ lineage
double positives (DP) move in to the cortex region of thymus. Most of the TCR gene
rearrangement take place at this region. The cells susequently enter in to the medulla
of thymus and undergo negative and positive selection before entering in to the
p riphery. The cellular phenotypic mark rs at each development stage is also given
under each stages.
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The ability of T cells to discriminate between ‘self’ (one’s own proteins) and non-self 
(foreign antigen) has also been decided at this point of T cell development (Starr et al., 
2003; Pardoll, 2001). This is discussed in the next sections.         
2.1.2 Positive and negative selection (Thymic selection) 
One hallmark of T cells is their receptor specificity towards foreign antigens and their 
MHC restricted recognition, combined with the ability to be tolerant of self-proteins and 
peptides. This ability of a T cell to discriminate between ‘self’ and ‘non-self’ is acquired 
during their thymic maturation processes (figure 2.1). In late foetal development 
approximately 10-100 thymic seeding progenitors enter the thymus through a guarded 
access point (Foss et al., 2001; Shortman, 1990). These cells then undergo 20-25 
divisions during their stay as double negatives (Shortman, 1990; Kyewski & Klein, 
2006). Once their lineages are committed, there is an extensive rearrangement of TCRα 
gene locus until each T cells reaches the region of positive selection in the thymus 
(Klein et al., 2009). Positive selection is required by the T cell in order to rescue 
themselves from apoptosis which is induced by the interaction of T cells with the 
peptide MHC complexes in the medullary region of the thymus (Kisielow & Miazek, 
1995). These cells now develop the MHC restriction of their TCRs and also up regulate 
RAG genes for active recombination of TCR locus and Bcl- XL (Ioannidis et al., 2001) 
for anti-apoptotic characters. Several studies suggest that the journey of a T cell on its 
late double positive stages to reach the medulla is dependent on its optimal survival 
capability which is invariably determined by TCR engagement and the quality of ligand 
and type of presentation (Wilkinson et al., 1995; Yasutomo et al., 2000). Once the T 
cell reaches the medulla it has a fully developed TCR and other functional co-receptors 
(Anderson et al., 2013). There are two models widely available for describing thymic 
selection as “qualitative” and “quantitative”. In the “qualitative” model the assumption 
is that the nature and type of peptide generate qualitatively different signals for the 
survival or death of the T cells (Jameson, 1995). The “avidity” or “quantitative” models 
suggest that the strength of interaction between the MHC and TCR complexes (P-MHC) 
determines the outcome of the T cell fate and this strength of interactions are often 
decided by the nature of peptide. If the strength of the interaction is too strong, the 
interacting T cells die off by a process referred as “clonal deletion” (death by excessive 
signals). Weak binding leads to death by ‘neglect’ (death by lack of signals) (Figure. 
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2.2). T cells which receive the optimum levels of binding strength and signal will 
proliferate and proceed to the periphery.  This process of thymic selection of T cells 
equips T lymphocytes to recognise ‘self’ from ‘non-self’ (foreign) peptides.   
 
       
 
 
 
 
 
 
 
 
Figure 2.2: The quantitative (affinity or avidity) model of positive selection. For a T cell to be 
positively selected the strength of interaction (affinity) is crucial. If the affinity of P-MHC 
complexes is below a certain threshold, the T cells die by a process called “death by neglect”. If 
the affinity is too high clonal deletion will occur by a process called serial triggering (super 
optimal signals). A T cell which receives the optimal signal by the P-MHC complexes at a 
suitable threshold only will survive by positive selection and enter the periphery. 
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Fig 2.2 The quantitative (Affinity or avidity) model of positive selection. For a
T cell to be positively selected the strength of interaction (Affinity) is crucial. If
the affinity of P-MHC complexes is below a certain threshold, the T cells die by
a process called “death by neglect”. If the affinity is too high clonal deletion
will ccur by a process called serial triggering (super optimal signals). A T cell
which receives the optimal signal by the P-MHC compl xes at a suitable
threshold only will survive by positive selection and enter the periphery.
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2.1.3 Impact of thymic selection on cancer immunotherapy  
The selective deletion of self reactive T cells in the thymus predominantly resulting in 
the generation of a T cell repertoire which are low avidity in their response against self 
antigens.  During the thymic selection 95% of all T cells entering the thymic medulla 
perishes due to negative selection, the other 5% are released into the periphery and the 
majority of them do not complete maturation as a consequence of peripheral tolerance 
mechanisms (Huesmann et al., 1991). However, thymic selection is not always fool 
proof, T cells with specificity towards the self-antigens can also escape from thymic 
selection by various other mechanisms and are reviewed in the literature (Ignatowicz et 
al., 1996; van Meerwijk J.P.M, et al., 1996, Enouz et al, 2012).  
 
 
 
Figure 2.3: The mechanism of generation of low avidity T cells in the thymus. T cells 
having a moderate affinity/avidity against the self-antigens are only selected towards the 
periphery. They include the T cells with low number of TCR on its surface, thus having 
low avidity, T cells with multispecific TCR and the T cells having a certain degree of 
low affinity towards the self-antigens. These cells can be effectively used in cancer 
immunotherapy using suitable vaccination strategies against TAAs. (Adapted from 
Visser et al., 2003) 
 
Fig 2.3 Mechanism of generation of low avidity T cells in the thymus. T cells
having a moderate affinity to the self antigens only selected for the periphery. A
repetore of low avidity T cells always escape from the thymic selection and end up
in the periphery. They include the T cells with low number of TCR on its surface, T
cells with multispecific TCR and the T cells having a certain degree of low affinity
towards the self antigens. These cells can be effectively used as a tool in cancer
immunotherapy using suitable vaccination strategies
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For tumour immunotherapeutic settings, the available pool of responding CD8+ T cells 
are predominantly low avidity T cells having low to moderate affinity towards self-
antigens known as naïve population. As discussed earlier the naïve population has a 
high degree tolerance towards the self antigens, therefore one obvious question is, “are 
CD8+ T cells exposed to all the tissue restricted antigens in the body?”  if not, the 
chances of highly reactive tumour specific high avidity T cells will be in the body. 
Studies suggested that cortical thymic epithelial cells and the medullary thymic 
epithelial cells express mostly all the tissue restricted antigens (TRA) in the thymus by a 
process referred to as, promiscuous, or ectopic gene expression controlled by 
autoimmune regulator genes (AIRE) (Anderson et al., 2002; Gardner et al., 2009). 
Therefore, the majority of the CD8+ cells get a chance to be exposed to TRA at least 
once, before leaving the thymus (Derbinski et al., 2001; Kyewski and Klein, 2006) and 
it is therefore reasonable to assume that all or most of the high avidity self reactive T 
cells are completely eliminated.  
However, T cells having low or moderate affinity towards the self antigens escaped in 
the thymic selection will be still in the periphery. This has been a paradoxical situation 
for immunologists for many years that the cells escaped from the central tolerance live 
happily in the periphery without causing significant auto-immune disease (Ian & Heath, 
2008). How are the cells, having a moderate affinity towards the self-antigens, tolerated 
in the periphery? Two main mechanisms are operating; one is the “avoidance of self-
antigens” by physically separating them into the immunologically privileged regions so 
that T cells never see them in their life cycle (Streilein et al., 1997).  
A second way of tolerance is by the “anergic mechanisms” in which T cells remains 
functionally at a nonresponsive stage even when exposed to the self-antigens (Yuuki et 
al., 1990). Tolerogenic dendritic cells (Ma et al., 2013) and regulatory T cells (Tregs) 
(CD4+CD25high Foxp3+) are also known to induce peripheral tolerance (Schmidt et al., 
2012). This dangerous balancing act of cellular immunity could be disrupted when 
suitable conditions arises which break the tolerance mechanisms (Illés et al., 2005) and 
mount destructive autoimmunity such as the one observed in neonatal insulin-dependent 
diabetes (Radu et al., 1999). While this is a danger in terms of autoimmunity, it can be 
used as a tool in cancer immunotherapy by carefully selecting the antigens to 
specifically target the tumour and mobilising self reactive T cells into the tumour sites 
(Eggermont et al., 2013) for better therapeutic killing of the malignant cells providing 
  
58 
 
the tumour expresses self tumour antigens. Breaking the avidity barriers of these cells 
should be carefully monitored, otherwise side-effects such as vitiligo (depigmentation 
of the skin) can be triggered. Vitiligo mainly observed as a treatment side effect in 
melanoma patients, when treated with immunotherapy against the most common 
melanoma specific antigens such as gp100, MART1, TRP1 (tyrosinase-related protein 
1) and TRP2 (Alonso-Castro et al., 2013; Byrne & Turk, 2012). The reasons for this 
phenomenon are that targeted antigens are involved in the normal melanin synthesis and 
the immune-mediated loss of these melanin pigment producing cells, in extreme cases, 
loses of retinal pigments (Caspi, 2008). However, given the choices available for the 
melanoma patients, the benefits of T cell based therapies outweigh the side effects in the 
majority of cases. So in summary loopholes in thymic selection result in the release of 
low to moderate avidity T cells into the periphery which can be used to target the 
malignant tissues by immunotherapeutic intervention, providing the targeted antigen is 
not expressed by vital organs. Moreover the success of any cancer vaccination strategies 
depends on the naïve T cell precursor frequency against the target antigen and also 
vaccine’s ability to recruit and expand those existing specificities (Jenkins and Moon., 
2012).  
2.1.4 T cell affinity, avidity and functional avidity 
2.1.4.1 TCR Affinity 
 The terminology affinity, avidity and functional avidity are highly interconnected and 
often confusing in the field of immunology (Viganò et al., 2012). T cell affinity is the 
first level of interaction where a single TCR interacts with only one MHC molecule. 
The strength of this monomeric interaction between a TCR and pMHC is referred to as 
T cell affinity (Kindt et al., 2007). Unlike T cells, in B cells, the antibodies are 
generated and the affinity is fine-tuned by somatic hyper-mutations (SHM) in the 
variable region of antigen binding sites. Even though both BCR and TCR gene 
rearrangements shared a high degree of similarity, the lack of SHM in T cells leads to 
generation of TCR with fixed affinity for the rest of their life cycle. The measurement of 
affinity is usually carried out by measuring the dissociation constant (kD) of soluble 
TCR- pMHC complexes using Surface Plasmon Resonance (SPR) or by measuring the 
half-life (t1/2) of TCR- pMHC interactions. (Margulies et al., 1996).  
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2.1.4.2 TCR Avidity  
Avidity or structural avidity is the cumulative strength creating from the overall 
interactions happening at the binding site, which is the collective strength of all the 
TCRs and other co-receptor molecules involved in the synaptic complex formation (van 
den Boorn et al., 2006). The best way to measure the TCR structural avidity is using 
multimer staining (MHC tetramers, pentamers or dextramers) and the use of multimer 
dissociation assay (measuring the dissociation rate of TCR bound multimers) using flow 
cytometry analysis. These analysis has been usually performed using multimer decay 
assays (Wooldridge et al., 2009), in which the multimers bound to its cognate TCR in 
the sample and then measure the dissociation of these bound multimers over the time. If 
the binding strength is high (higher avidity), then the dissociation over the time is slow 
and vice versa for low binding strength interactions.  
2.1.4.3 T cell Functional Avidity (TFA) 
 While two of the above discussed factors are related to the structural property of TCR 
and other contributing molecules during the T cell antigen presenting cell interaction, 
the term “functional avidity” refers to the measure of functional sensitivity of T cells 
towards its cognate antigen (Viganò et al., 2012; von Essen et al., 2012; Amoah et al., 
2012), in other words it is the biological readout of T cell functionality.  The detailed 
review of functional avidity is discussed in the following section. 
Affinity and structural avidity are two important parameters contributing towards the 
functionality of T cells, however in many cases high frequency high affinity T cell 
response might not indicate a successful immune reaction because of its poor correlation 
between T cell responses and clinical outcome (Jonuleit et al., 2001; Anichini et al., 
1999; Lee et al., 1999). Apart from structural affinity and avidity, a more reliable way 
to assess the quality of the immune response is the T cell functional avidity (TFA). TFA 
is defined as the measure of the functional response of T cell to activation by an 
antigenic peptide presented on a MHC molecule, usually measured by T cell activation 
by the target cell using techniques such as cytokine release assays (peptide titration 
ELISpot assays, intracellular cytokine staining) or cytolytic (chromium release) 
(Pudney et al., 2010; McKee et al., 2005) target cell killing assays using a titrated 
concentration of peptide pulsed on a TAP (cells having defective antigen processing 
machinery) deficient antigen presenting cell (Luft et al., 2001). The effector biological 
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function is measured as the concentration required for 50% maximum effector function 
(EC50) of T cells by plotting a sigmoidal graph with logM concentration of the peptides 
(Figure 2.4). 
High T cell avidity is the ability of T cell to recognise and respond to low levels of the 
antigen concentration (hence having low EC50) and the opposite is for the low avidity 
(High EC50) T cells (McKee et al., 2005). In many clinical settings this functional 
measurements of T cells have been positively correlated with tumour recognition and 
therapeutic efficiency making it an effective indicator for successful immunotherapy 
(McMahn & Slansky, 2007; McKee et al., 2005).  
There are many contributing factors for functional avidity of T cells other than TCR 
affinity and avidity such as T cell receptor (TCR) expression levels, expression of co-
stimulatory molecules, cellular microenvironment (McMahn & Slansky, 2007; Viganò 
et al., 2012; von Essen et al., 2012) and the signal modulation in T cells during their 
encounter with an antigen presenting cell (Sharma & Alexander-Miller, 2011).  
Depending on the functional profile (antigen requirement for optimal activation) T cell 
population can be roughly classified in to high avidity (required < 1 nM peptide), 
medium (required < 1-100 nM peptide) or low avidity (required >100 nM peptide) T 
cells (Snyder et al., 2003).   
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Figure 2.4: Representation of high and low avidity T cell responses, x-axis represent antigen 
concentration and y-axis represent percentage of T cell activity. High avidity T cell response 
(Red line) requires very low amounts of target antigen to generate visible populations of effector 
T cells. These cells recognise the typically low concentration of peptide present on the tumour 
surface and effectively check the tumour growth. In contrary, low avidity T cells required (blue 
line) very high concentration of antigenic peptides for its optimal activation; hence these cells 
were only activated when the tumour expressed very high level of tumour associated antigens. 
 
2.1.5 Factors influencing T cell functional avidity 
The first reported evidence of differences in functional avidity was depicted in the 
memory (antigen experienced) and naïve (antigen inexperienced) T cells (Byrne, 1988). 
This followed by subsequent studies also have demonstrated that the T cells can 
dramatically improve their functionality following an antigen exposure despite the fact 
that these cells are not capable of modifying their TCR by any type of somatic mutation 
in their antigen recognition motifs (Pihlgren et al., 1996). Several arguments are in 
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Fig 2.4 Representation of high and low avidity T cell responses. High avidity T
cell response (Red line) required very low amount of target antigen to generate
visible population of effector T cells, these cells recognise the typically low
concentration of peptide present on the tumour surface and effectively check the
tumour growth. In contrary Low avidity T cells required (blue line) very high
concentration of antig nic peptides for its optimal activation; hence these cells
were only activated when the tumour expressed very high level of tumour
associated antigens.
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place for explaining the increase in functional avidity, like existence of different TCR 
clonotypes having various affinities in the T cell repertoire or T cell having a fixed 
affinity can be converted into low and high avidity based on the stimulus they received 
in their clonal evolution. Most predominant support for the first argument came from 
the studies of a diabetes murine model (Han et al., 2005), where they showed that the 
very low frequency existence of high avidity T cell at the beginning of the disease and 
when the disease progressed there is a correlated increase in the high avidity T cell 
population. For the support of second argument Alexander-miller and colleagues have 
showed that a single T cell clone can be functionally tuned into high and low avidity 
phenotypes by subjecting them into two extreme concentrations of peptide stimulations 
(Kroger & Alexander-miller, 2007). Their studies showed that the clones expanded in 
the presence of high concentration of antigenic peptide subsequently required high 
concentration of peptide for its optimal activation and vice versa for the clones 
expanded with the low concentration of the peptides. Both of these studies are 
counterintuitive in term of understanding the exact mechanism behind the shaping of 
functional profile of T cell repertoire.    
Studies of T cell avidity in tumour antigens were first reported in murine melanoma 
model system (Zeh et al., 1999), where they demonstrated the efficiency of high avidity 
T cells raised against low levels of tumour antigenic peptide TRP-2 for the elimination 
of lung metastases compared with low avidity T cells. The utility of high avidity 
response has been effectively reported in many other preclinical and clinical settings as 
well (Janicki et al., 2008; Aranda et al., 2011; Rezvani et al., 2011). Adoptive transfer 
studies in a breast cancer model of NT2.5 tumours with high and low avidity HER2/neu 
420-429 specific T cells have demonstrated that high avidity T cells were effectively 
capable of controlling the tumour growth after depleting the CD25+ T regulatory cells 
using cyclophosphamide and antibodies (Weiss et al., 2012) and pointed towards the 
potential problem of T cell functionality repression in the tumour environment. A recent 
study by Zhu et al., (2013) which adoptively transferred high and low avidity TRP-2 
specific T cell in a C57Bl6 mice bearing B16 melanoma tumour reported a more 
pronounced infiltration of high avidity T cells into the tumour in comparison to the low 
avidity counterparts. The high avidity T cells delayed the tumour growth initially, but 
were then suppressed in the tumour microenvironment. PD-1 blockade in the tumour 
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and the depletion of tumour associated dendritic cells quickly restored their 
functionality, highlighting the importance of susceptibility of these cells towards the 
tolerisation which is exerted by the tumour and can be reversed with targeting 
suppressive cells and the molecules within the tumour microenvironment.   
The area of functional avidity is still controversial; the problem is mainly because all 
the three factors: affinity, structural avidity and functional avidity are highly 
interconnected and so it is very difficult to draw a clear line between them to define the 
functionality of T cells. Hence, it is highly important not to define functional avidity 
without considering the TCR peptide-MHC affinity and structural avidity. Factors that 
can influence avidity and thereby the property of functional avidity are discussed in the 
following sections.  
2.1.5.1 TCR affinity is the single most influencing factor of T cell functionality? 
Affinity is the first parameter to be fine-tuned in order to get a high functional avidity T 
cell. If pMHC complexes are naturally high in their affinity, low affinity TCRs will 
recognise them and mount T cell mediated immune response. Conversely, if the pMHC 
complexes are of very low affinity then they require very high affinity T cell receptors 
(Stone et al., 2009). There are many independent models available to explain the 
optimum TCR affinity (Figure.2.5), of which the two most important are the kinetic 
proof reading (KFR) model and serial triggering (ST) model. KFR model (McMahan & 
Slanskya, 2007) proposes that a TCR peptide MHC interaction should be in place right 
from the beginning to the end of the signalling process, whereas the ST model proposes 
that the pMHC complexes engaged with multiple TCRs for giving a sustained signal 
throughout the process of T cell activation. Studies with high affinity T cells in vitro 
(Corse, 2010; McMahan, 2006) found a good correlation between CTL activation and 
affinity in the laboratory. However, these correlations were not able to be reproduced in 
the in vivo models, in which the maximum response was obtained from the intermediate 
affinity peptide, not from the high affinity peptide. These studies suggested that even 
though affinity is a determining factor for the stimulation of the T cells, it is not the only 
a single factor which determines the functionality in the living system.  
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Figure 2.5: Three possible interactions of TCR and pMHC complex and their outcome as 
described by affinity model. Right hand side of the interaction is antigen presenting cell (APC) 
and the left side illustrate T cell and the possible outcome of each interactions. Despite of many 
existing theories about TCR Peptide-MHC, all the models are however suggesting three 
important aspect as illustrated in the figure. High affinity interactions will leads to 
overstimulation of T cells, results in functionally incapacitating the cells or ultimate deletion. 
Moderate affinity will be optimum for the best survival chance and the proliferation of T cells. 
Weak affinity leads to sub optimal stimulation and results in non-proliferation of the target cell. 
Adapted from McMahan & Slansky 2007 
 
Moreover, the affinity determinations were routinely undertaken with soluble single 
TCRs which might not be an accurate representation of the multimeric interactions 
which occur in the antigen presenting cell. Furthermore, the T cell is highly dynamic 
and is also in a different spatial plane (Nel, 2002). Now the question is ‘is the affinity 
the single most influencing factor?’, perhaps not. Studies using the viral models have 
Fig 2.1.5 Three possible interactions of TCR and pMHC complex and their
outcome as described by affinity models suggest that high affinity interactions
are necessary for better activation of the T cells. All the models are however
suggesting that high affinity interactions will leads to overstimulation of the
cells, results in functionally incapacitating the cells or ultimate deletion.
Moderate affinity will be optimum for the best survival chance and the
proliferation of T cells. Weak affinity leads to sub optimal stimulation and
results in non-pro iferation of the target cell.
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reported that T cells are capable of modifying their functional avidity several folds 
without selecting for high affinity receptors (Slifka & Whitton et al., 2001). 
2.1.5.2 Effect of co stimulatory and inhibitory molecules 
The second important parameter which affects the T cell functional avidity is the co-
receptor distribution and abundance on T cells. Of many co-receptors, CD8 is the most 
important one, which is a  glycoprotein receptor present on cytotoxic T cells adjacent to 
the TCR-CD3 complex (Cole and Gao, 2004). (The detailed signalling mechanism from 
CD8 co-receptor is illustrated in Chapter 3). A slightly different role for this molecule in 
TCR signalling cascades has been observed in many studies that have compared naïve 
and primed T cells. CD8 molecules help to stabilise the interaction of TCR-pMHC at 
the synaptic complex formation and hence it play an important role in the stabilisation 
of the interactions. The critical role of CD8 in modulating the functionality in relation to 
TCR affinity was first demonstrated by Holler & Kranz (2003). In their study they have 
used engineered TCR (αβ) receptors with varying degrees of TCR affinity, as measured 
by the dissociation constant (kD). These cells are engineered with or without CD8 
molecule to assess the role of this molecule in conjunction with TCR of varying affinity. 
Their study concluded that the receptors having higher affinity can stimulate with or 
without CD8, whereas the low affinity TCRs always required CD8 interaction. This 
observation is critical in terms of CTL based tumour immunology, as T cell repertoire in 
the periphery typically exhibits low affinity towards majority of all the tumour antigens 
due to their self-nature. These studies are further backed up by the data obtained from 
multimer staining of T cells (Choi et al., 2003). Choi et al used an MHC molecule of 
mutated CD8 binding region to make the tetramers and found that the clones which are 
having the high affinity towards the cognate antigen will only bind to the tetramers and 
thereby readily identify the higher avidity T cells.  
Another important co-receptor which might play an important role in functional avidity 
is CD28. The utility of CD28 in synaptic complex formation and TCR signal 
modulations has been well documented in the literature (Huang et al., 2002; Yokosuka 
et al., 2008; Acuto & Michel, 2003). Like CD8, CD28 is a glycoprotein receptor on T 
lymphocytes and it binds with the ligands present on the antigen presenting cells known 
as CD80 (B7.1) and CD86 (B7.2) to generate the second important signal (Signal 2) 
which is required for T cell activation. Previous studies of these molecules on naïve and 
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primed T cells (Manickasingham et al., 1998) have demonstrated that CD28 has 
different roles in these cell types. The involvements of other stimulatory molecules such 
as CD45 and CD81 in the functionality of T cells have been reported previously 
(Watson & Lee, 2004; Sagi et al., 2012) 
In contrary to stimulatory molecules, inhibitory molecules have a negative influence on 
the activation and proliferation of T lymphocytes. Three major inhibitory receptors of T 
cells are well characterised till today viz CTLA 4 (cytotoxic T lymphocyte antigen 4) 
PD-1 (programmed death 1 receptor) and BTLA (B and T cell attenuator). CTLA is a 
molecule expressed by T cell which binds to the CD80 and CD86 ligands present on the 
antigen presenting cells with higher affinity than their conventional receptor CD28 
(activation receptor), and which results in the loss or reduced transmission of signal 2 
required for the T cell activation (Korman et al., 2006). PD-1 is also expressed on T 
cells with its ligands (PDL-1 and PDL-2) expressed in many other normal organs 
(Riella et al., 2012). Expression of this ligand in normal organs was believed to be a 
mechanism of tolerance against self-reacting T cells (Hutchinson, 2012). In tumour 
immunology, PD-1 is the number one inhibitory signal which is expressed by the 
tumour and this will neutralise the potential cytotoxic activity of tumour infiltrating T 
cells (TILs) (Nirschl & Drake, 2013). The third member of inhibitory molecule is 
BTLA, and this is found to be upregulated in many T and B cells and its expression is 
used to regulate tolerance (Liu et al, 2009) by dampening the strength of the signals that 
are received by activated cells. Therefore, blocking of the expression of BTLA can 
resurrect the functionality of otherwise attenuated in these cells naturally (Pasero & 
Olive, 2013). 
2.1.5.3 Other influencing factors 
As has been discussed in the above sections, the temporal and spatial expression of 
activation and inhibitory receptors along with the affinity are not the only factors that 
govern the functional outcome of T cells. Physical role of cytoskeletal rearrangement 
and the distribution of lipid raft micro clusters are another possible area to be 
investigated since they are the two important parameters which determine the effective 
formation of a synaptic complex (Piragyte & Jun, 2012; Moran & Miceli, 1998). The 
involvement of these parameters are reviewed in Jenkins and Griffiths, 2010. 
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2.1.6 Immunologic memory, CTL phenotypic orientations implications in cancer 
immunotherapy 
The ability of immune system to establish immunologic memory (B and T cell memory) 
is the hall mark of adaptive immunity. For T cell based tumour immunology it is having 
far more reaching implications in terms of preventing tumour reappearance after 
therapeutic interventions. In a broad definition, T cell memory is the ability of T 
lymphocytes to memorise the previous encounter of an antigen by keeping a long 
lasting pool of phenotypically and functionally distinct population of cell, capable of 
detecting subsequent repeated infection or malignancy in the future. For prophylactic 
vaccination settings memory is well studied and it is widely considered to be a key 
feature for keeping viral and bacterial pathogens in check during the rest of the life time 
in vaccinated individuals.  
The process of establishing this immunologic memory starts at the very beginning of 
antigen exposure of naïve T cell population to the antigenic stimulus in the lymphoid 
organs. Naïve populations are expanded by receiving the appropriate antigenic and co-
receptor stimulus and execute their effector functions which ultimately leads to the 
pathogen clearance. Ninety percent of the antigen specific effector CTLs then perishes 
(Gourley et al., 2004) and the rest become memory T cell populations. Based on the 
expression of cell surface markers and secreted cytokine and other effector molecules, 
the memory population is further classified in to T central memory (Tcm) and effector 
memory (Tem) phenotypes (Zanetti et al., 2010), with the former located primarily in 
the lymphoid organs and the latter in the peripheral tissues (Gourley et al., 2004 ). It is 
widely understood that the changes in the gene expression patterns, transcription factors 
and epigenetic regulations control the process of converting the naïve and effector cells 
into memory phenotypes and keeps them in the body for longer time (Weng et al., 
2012). Predominantly, our understanding of memory differentiation has been derived 
from viral models. Studies of mouse models and chronic human viral infections have 
revealed the nature and establishment of the memory phenotype (Seder and Ahmed, 
2003). In a basic model derived from the viral model, the memory is established in three 
phases. The clonal expansion of viral specific T cells takes off during the first wave of 
infection and reaches a peak of expansion in a few days. This population will decline 
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upon the viral clearance subsequently and the remaining population is converted in to 
the memory phenotype (Appay et al., 2002). 
 As discussed earlier the magnitude and the nature of T cell immune response against 
the TAAs are slightly different due to their self-nature and hence it is crucial to 
understand the mechanism and the kinetics of memory establishment in major cancer 
vaccine trials (Seder and Ahmed, 2003).  It is also noteworthy that most of the cancer 
vaccination strategies are in the therapeutic settings (i.e. vaccinating the patients already 
having the disease), hence antigen-specific T cells are presented with dual challenges of 
encountering a self-antigenic protein and immune suppression. However, most of the 
preclinical cancer trials have been conducted in mouse models and in this respect it is 
important to understand the phenotypic changes happening in these settings in terms of 
prolonged exposure of T cells to the antigenic stimulus.  Cancer vaccination strategies 
used for the stimulation of T cell immunity are highly heterogeneous with regards to the 
various vaccine modalities such as whole cell, protein, peptide, DNA and dendritic cells 
(Ref. Chapter 1). These different vaccines are known to have different capacities to 
stimulate T cells at a different rate. The rate of expansion might have a consequence in 
the subsequent establishment of memory phenotypes (Seder and Ahmed, 2003). 
However, no studies were reported in the literature to study the effect of various vaccine 
strategies on the shaping of immunologic memory.  However, many studies have agreed 
upon the fact that Tcm is more protective than Tem in patients undergoing a recall 
response with the same antigen (Goldinger et al, 2012; Klebanoff et al., 2005). 
 2.1.7 Aim of this study 
It is widely accepted that the generation of high functional avidity T cells is an indicator 
of quality immune response. In the viral immunology the selection of the high avidity 
precursor population naturally happens because of the nature of viral antigen (foreign) 
and the high affinity receptors. However, in tumour immunology, because of the self-
nature of the antigenic proteins combined with the tolerance mechanisms discussed 
above will limit the vaccine efficacy by generating inferior quality (low avidity) T cell 
populations. The careful vaccine designs in the recent past have demonstrated the 
generation of high avidity T cells in the patients are plausible. In such a scenario, if the 
antigen responsible for the immune response is known, it is always easy to assess the 
functional avidity by carrying out peptide titration cytokine assays. However, in 
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majority of cases this process is restricted by the limited availability of patient cells for 
conducting large titration assays with sufficient replicates. The situation becomes even 
more problematic when the responsible antigenic peptide is not known, such in whole 
cell and protein vaccines. In this context, we have attempted to characterise a mouse 
melanoma model system which is capable of generating high and low functional avidity 
T cells responding against its cognate antigen with different sensitivities for identifying 
a marker of higher functional avidity. Once, validated in the human vaccination setting, 
these markers will be useful for the identification of a high avidity response in the 
patients without undertaking cumbersome peptide titration assays. The mouse model 
has been previously reported by Metheringham, et al (2009), which reported that 
immunising mice with a DNA vaccine containing a TRP-2 epitope generated a T cell 
response with high avidity characteristics compared to the corresponding peptide 
immunisations. The important advantage of this model is the ability to generate same 
number of peptide specific cells, but only the DNA vaccine immunisation yielded cells 
capable of responding to very low concentration of the antigen in the subsequent 
stimulations (as low as 10-7 M). Therefore,  this is a unique vaccination model to study 
the behaviour of vaccine generated cytotoxic T cells and the molecular mechanisms 
underlying this differences in sensitivity/functional avidity. Immunological 
characterisations attempted in this study aimed to fully characterise and reproduce the 
previous observations made in this model by Metheringham, et al., (2009) with 
additional experiments and markers. The specific aims for this element of the study are 
given below. 
 Assess the generation and frequency of peptide specific cells using multimer 
technology 
 Complete characterisation of a high and low avidity mouse  model using 
functional readouts such as IFN-γ  
 Study the functional changes happening by in vitro stimulations using two 
peptide doses (High and Low) 
 Study the immune phenotype of peptide specific cells using selected cluster of 
differentiation markers 
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2.2 Materials and Methods 
2.2.1 Animal model systems  
The mouse model used for the present study was C57Bl/6 (Charles River, Kent, UK) 
female mouse and melanoma differentiation tumour antigen tyrosinase related protein-2 
(TRP-2). Immunisations were carried out with either a class 1 immunogenic TRP-2 
peptide in conjunction with a class II hepatitis-B (Hep-B) helper epitope known to 
generate low avidity T cell responses or with a DNA based vaccine (ImmunoBody®, 
Scancell Ltd., Nottingham, UK) carrying the corresponding DNA fragment of the above 
mentioned TRP 2 epitope known to generate high avidity T cell responses in the 
C57Bl/6 animals after three round of immunisations. The detailed result of this model 
has been published elsewhere (Metheringham, et al., 2009). In order to cross validate 
the process we have used the same model workflow with a different foreign antigen 
derived from chicken ovalbumin. All the animal work has been undertaken with Home 
Office approval under the project licence number 40/3563.     
2.2.2 Model characterisation 
2.2.2.1 Peptide vaccine and immunisation  
Synthetic HepB/TRP2 peptide TPPAYRPPNAPILAAASVYDFFVWL has been 
synthesised (ALTA biosciences, Birmingham, UK) with minimum purity of 90%. Upon 
arrival peptides were reconstituted in sterile Dimethyl sulfoxide (DMSO) at a stock 
concentration of 10 mg/mL and immediately frozen at -200 C. Similar protocols were 
followed for the synthesis and preparation of ovalbumin epitope SIINFEKL.  Prior to 
each vaccination peptide was prepared in phosphate buffered saline (PBS), emulsified 
with incomplete Freund’s adjuvant (IFA) and administered subcutaneously (SC), on 
either side of the base of the tail at a dose concentration of 25 µg of peptide per animal. 
All the animals used in this study were 7-12 weeks old unless otherwise specified. 
Animals work was performed in a conventional animal facility or in a barrier clean 
environment which is specified wherever necessary in the following chapters. All the 
animals were received two more booster doses after the primary immunisations using 
the same concentration of the peptide or DNA vaccine with seven days intervals 
between them.  
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2.2.2.2 ImmunoBody® DNA Vaccine and Immunisation  
ImmunoBody® DNA vaccine was kindly provided by Prof. Lindy Durrant (Scancell 
Ltd. Nottingham, UK), is a double expression vector (pDCorig), containing a murine 
variable heavy (VH) and kappa (VL) chain in one and a human kappa and heavy IgG1 
constant regions in the second reading frames. Both the frames are under the control of 
separate CMV promoter and ends with Bovine Growth Hormone (BGH) 
polyadenylation signals for maximum stability of mRNAs. Complementary determining 
region (CDR) of the antibody sequences were removed and subsequently replaced with 
unique restriction enzymes containing multiple cloning sites (MCS), which is suitable 
for cloning different Class 1 and class II epitopes. Efficient transcription and translation 
of the antibody chain with inserted antigenic peptide was characterised by 
Metheringham, et al., (2010). The detailed vector map of ImmunoBody® DNA vaccine 
is given in figure 2.6. Prior to immunisation, plasmid DNA (1 μg) was coated onto 1.0 
μm gold particles (BioRad, Hemel Hempstead, UK) as per manufacturer’s instructions. 
These coated DNA bullets were subsequently administered intradermally into the 
shaved abdomen of each mouse by a single shot using a BioRad Helios® gene gun. 
Primary immunised animals were subsequently boosted twice at seven days interval 
with the same DNA dose using the same administration protocol as above. A similar 
protocol was followed for ovalbumin epitope SIINFEKL, where the TRP-2 insert in the 
vector backbone has been replaced with SIINFEKL insert (Figure 2.6.). All the 
ImmunoBody® vaccines were constructed by Scancell Ltd. According to the company 
standard  
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Figure 2.6: Vector map of ImmunoBody® DNA vaccine, this double expression vector 
carrying two open reading frames with an early CMV promoter and a BGA polyadenylation 
signal, the multiple cloning sites available within the two open reading frames allow the 
insertion of antigenic helper/CTL peptide gene sequences. 
 
2.2.3 Isolation of splenocytes and cell counting  
10 days after the last immunisation, all the immunised animals were terminated with 
cervical dislocation and immediately taken into a sterile laminar hood. Spleens and 
lymph nodes (Both axillary and Inguinal) from all the animals were harvested 
immediately using aseptic handling in to a pre-warmed serum free media (RPMI). 
Harvested spleens were placed into a sterile Petri dish containing 10 mL of serum free T 
cell media (RPMI 40 media containing 2mM L–Glutamine, 50 I.U./mL penicillin 
streptomycin and 20mM HEPES buffer). Splenocytes were carefully flushed out using a 
fine needle and with further 10 mL of the same media from both the sides of the spleen. 
The total splenocytes solution was transferred into a fresh universal tube and allowed to 
rest for 2 min. The solution was then carefully transferred into a fresh universal tube 
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leaving the large debris behind. The cells were pelleted by centrifugation in a swinging 
bucket rotor centrifuge at 300g for 10 min at room temperature. The supernatant was 
removed using a sterile aspirator and the cells were re-suspended in 10 mL of complete 
T cell media (10% Heat inactivated (HI) FCS (Lonza), 2mM L-glutamine(Lonza), 50 
I.U./mL penicillin streptomycin (Lonza) and 20mM HEPES buffer(Lonza)) containing 
7x10-5M 2- mercaptoethanol (Sigma Aldridge). 50 µL of cell suspension was mixed 
with 50 µL trypan blue and counted using a disposable haemocytometer (Fast Read 
102®) or a normal laboratory cytometer and the final cell number was adjusted to 5 x 
106  T cell/mL of the media for ELISpot (MABTECH, Sweden) assays.  
2.2.4 Setting up ex vivo ELISpot assay 
TRP-2 Peptide (SVYDFFVWL) dilutions were prepared by freshly diluting the stock 
solution of 10 mg/mL to an initial working solution of 0.1 µg/mL (1x10-1 M) and 
followed by 10 fold dilutions of up to 7 concentrations (1x10-1 -10-7 M). Preparation of 
ELISpot  plates was carried out a day before the assays by wetting the plate with 15 µL 
of 70% ethyl alcohol followed by washing the plates immediately with 170 µL of sterile 
distilled water four times. This plate was then coated with capture antibody (MABTEC 
INF-γ ELISpot kit) and kept in the fridge overnight. Following day the plates were 
washed three times with sterile PBS and blocked with complete T cell media for two 
hours prior to seeding the effector cells on to the plates. After two hours the medium 
was discarded from the plate and 100 µL (5x105 cells) of effector cells were added to 
each well with 100µl of the corresponding peptide dilutions in triplicates. The plates 
were incubated at 370C and 5% CO2 (v/v) for 48 h. On the third day the plates were 
taken out of the incubator and cells were discarded and washed five times with sterile 
PBST (Phosphate Buffer Saline + 0.5% of Tween20). After the final wash100 µL of 
secondary antibody (1:1000 dilutions) was added to each well and incubated for 3 h at 
room temperature. Following the incubation the secondary antibody was discarded and 
washed three times with PBST. Alkaline phosphate conjugate was added to the plates 
and incubated for 90 min in the dark. Plates were washed again with PBST for five 
times and developed by adding 50 µL of development reagent (BioRad AP Substrate kit, 
prepared according to manufacturer’s instruction) and incubated in the dark for 30 - 40 
min. The development reaction was stopped by washing the plates in running tap water. 
The plates were dried at room temperature overnight and imaged in a plate reader 
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(C.T.L Technologies, USA) and the raw data was generated in an automated ELISpot 
counter with quality control performed for each plates. 
2.2.5 Pentamer staining of peptide specific cells 
For detecting the pentamer positive peptide specific cells in both ImmunoBody® and 
peptide immunised animals, class-I PE-2Kb/SVYDFFVWL pentamer (ProImmune) or 
class-I PE-2Kb/SIINFEKL pentamer (ProImmune) were used depending up on the 
antigens used for the immunisation. For the detection of TRP-2 specific CD8+ 
pentamer+ cells from the above immunised animals (1 x 106 total splenocytes prepared 
as in the section 2.2.3) were pelleted down by centrifugation (300 g for 10 min at room 
temperature). Red blood lysis was carried out by resuspending the cells in 5ml of 1X 
red blood lysis buffer (Miltenyi biotech) according to manufacturer’s instructions and 
guidelines. Following red blood lysis, the cells were washed twice in the PBS with 1% 
heat inactivated FCS and the pellet was resuspended in residual wash solution after 
discarding the supernatant. The control unimmunised naïve mice also prepared in the 
same way and one test volume (10 µL) of class I pentamer was added to all the tubes. 
Tubes were incubated at room temperature for 20 min. Antimouse Fluorescein 
isothiocyanate [FITC] labelled CD8 (eBioscience) and antimouse Efluor 450 labelled 
CD3 (eBioscience) were added to each tubes and further incubated in the fridge for 15 
min. Cells were washed with PBS with 1% FCS and resuspended in FACS buffer for 
acquiring the data in a Beckman Coulter Gallios® flow cytometry analyser. The data 
was further analysed using Kaluza® Flow Cytometry Analysis Software (Beckman 
Coulter).  The analysis was performed in both TRP-2 and Ovalbumin model by the 
above mentioned pentamers. The specificity of pentamer binding was also confirmed by 
staining TRP-2 (SVYDFFVWL) high and low avidity TCR transgenic T cell clones 
kindly provided by Arthur Andrew Hurwitz (National Cancer Institute, Frederick, MD, 
USA). (Appendix 7.3) 
2.2.6 Half maximal effective concentration-50 (EC50) calculation 
The peptide concentrations required for 50% maximum activation (Effective 
concentration 50% [EC50]) of high and low avidity T cells was determined by plotting, a 
sigmoidal dose response curve and fitting this using the raw data obtained from peptide 
titration ELISpot assays after removing the background spot values from each 
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concentrations (n=9).  A variable slope model was used for the curve fitting, top and 
bottom constraint were applied as ‘100’ and ‘0’ respectively. All the EC50 calculations 
were done in three independent occasions in triplicates.  
2.2.7 Interferon-γ (IFN- γ) Intracellular cytokine (ICS) staining 
To validate the results obtained from ELISpot assays, an ICS protocol was performed 
on cells obtained from both the immunised animals. 1.5 x106 Total splenocytes obtained 
from ImmunoBody® and peptide immunised animals were seeded on to each well of a 
24 well culture plate with the same decreasing concentration (1x10-1 - 10-7 M) of 
peptides used for the ELISpot assays, leaving one well as control with no peptides. 
Cells were rested for an hour before adding brefeldin-A (5 mg/mL stock) at final 
concentration of 10 μg/mL. Cells were left overnight at 37○C in a 5% (v/v) CO2 
incubator. Next day the cells were harvested in to a 15 mL conical bottom tube and 
washed with PBS + 1% FCS, removed the liquid completely after pelleting the cells by 
centrifugations as described above. Intracellular cytokine staining was performed using 
IntraPrep® (Beckman Coulter) intracellular antigen staining kit as per manufactures 
guidelines. Details on the antibodies and fluorophores that were used in this study are 
given in Table 2.1.   
2.2.8 In vitro stimulation of the splenocytes 
This experiment was designed to investigate the ability of T cells to retain the property 
of functional avidity ex vivo under various experimental conditions, High and low 
avidity CTL’s isolated from both ImmunoBody® and peptide groups were subjected to 
repeated in vitro stimulations using two different doses (100 µg and 10 ng) of TRP-2 
peptide for 7 days. The stimulated cells were analysed by IFN-γ ELISpot assays for its 
functionality.  
2.2.9 Preparation of syngeneic lipopolysaccharide BLAST (LPS blast) 
Lipopolysaccharide is a large molecule containing lipid and carbohydrate molecules 
mainly present in the outer coat of gram negative bacteria is a useful tool in the 
laboratory for the stimulation of immune cells. LPS blasts were prepared on day one of 
the in vitro stimulation protocol as follows. One naïve seven to eight week old C57BL/6 
mice was terminated by cervical dislocation and total splenocytes extracted as described 
earlier. The cells were centrifuged at 300 g for 10 min and resuspended in fresh 
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complete T cell media. Cells were counted and diluted to 1 x 106 cells/mL, LPS and 
dextran sulphate were added to a final concentration of 25 ug/mL and 7 ug/mL of the 
cell suspension respectively and incubated at 37○C for 48 h.     
2.2.10 In vitro stimulation 
On day three, LPS blasts were harvested into a 50 mL tube after visual inspection for 
activation and contamination under the microscope. The cells were irradiated for 8 min 
(6000 Rads) in a GamaCell® Caesium Source. After irradiation cells were washed three 
times with serum free RPMI complete medium and finally resuspended in the same 
medium at 2 x 107cells/mL. Two separate tubes were prepared with the above cell 
number and peptides were added to the tube at high (100 µg/mL) and low (10 ng/mL) 
concentration. Tubes were incubated at 37○C for 75 min in a 5% CO2 incubator with 
cap loosened. While target cells were incubating, spleens were harvested from the 
ImmunoBody® and peptide immunised C57BL/6 mice. Splenocytes were extracted as 
described in section 2.2.3 and counted as described above. These effector cells were 
diluted at 5 x 106 cells/mL in complete CTL media. 1 mL of effecter cells were then 
plated in a 24 well plate from each group. After incubation, peptide pulsed irradiated 
target cells were taken out of the incubator and diluted to 1x106 cell/mL with complete 
CTL media. 1 mL of target cell is carefully pipette out into each well of the effector cell 
and incubated at 37○C for seven days in a 5% v/v CO2 incubator.  
2.2.11 ELIspot assay setting up with in vitro stimulated cells 
On day seven of the first in vitro stimulation, a capture antibody coated ELISpot plate 
was washed four times with sterile PBS and blocked by the addition of 100 µL complete 
T cell media. RMAS cells (antigen processing defective cells) were used as antigen 
presenting cells (target cells) for all the ELISpot assays after in vitro stimulations, these 
cells were cultured in RPMI (5% (v/v) serum + L- Glutamine) at 37○C for 48 h. and 
harvested into a 50 mL falcon tube in a sterile tissue culture hood.  The cells were 
counted and eight aliquots of 5x105 cells were prepared in a 15 mL Falcon tube, the 
cells were pelleted by centrifugation at 300 g for 10 min at room temperature. Six 10 
fold dilutions (-1M to -6M) of TRP 2 (SVYDFFVWL) peptide had been prepared in 
serum free RPMI media. 500 µL of peptide dilutions were added to the RMAS cell 
pellet in a labelled 15 mL tube. To the control tube only 500 µL of serum free RPMI 
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was added. Cells were incubated at 37○C for 75 minutes in a CO2 incubator with cap 
loosened. After the incubation cells were washed with 10 mL of sterile PBS and 
resuspended in complete CTL media. A further 10 fold dilution of the target cells 
(5x104 cells/mL) was prepared with complete CTL media. The effector cells were 
prepared by counting the in vitro stimulated cells from step 2.2.8 and diluting the cells 
to 5 x 105 cells/mL.  Flick off the blocking media from ELISpot plates and 100 µL of 
the effector cells (5x104 cells in total) and 100 µL of target cells (5x103) were pipetted 
into each well of the ELISpot plate. Plates were then incubated at 37○C overnight in a 
CO2 incubator. On the next day cells were discarded and washed the plates with 
PBS+0.5% Tween20 and the plates developed as per the protocol given in section 2.2.4. 
The detailed work flow is illustrated in Figure 2.7. 
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Figure 2.7: Schematic representation of in vitro stimulation of splenocytes using two different 
concentrations of peptides to generate high and low avidity CTL’s. 
 
 
 
ELISPOT 
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2.2.12 Immunophenotyping of high and low avidity T cells using multicolour 
flow cytometry 
In this study, the pentamer positive TRP-2 specific cells were immunoprofiled for 
their markers that were indicative of effector and memory characteristics. Markers 
involved in the functional activation and attenuation status were also present in the 
panel to obtain a comprehensive phenotypic profile of cells that had been generated 
by two immunisations. The markers used for the study were obtained from 
eBioscience and are detailed in the Table: 2.1.  
Table: 2.1 Antibodies and fluorophores used for the immunophenotyping  
Sl.No Marker Fluorophore Made By 
1 CD8 FITC eBioscience 
2 CD3 eFluor450 eBioscience 
3 CD28 PerCP-Cy5.5 eBioscience 
4 CD272(BTLA) APC eBioscience 
5 CD197 (CCR7) Alexa Fluor700 eBioscience 
6 CD62L APC-eFluor780 eBioscience 
7 CD44 PE/Cy7 BioLegend 
8 Mouse IFN-γ APC BioLegend 
9 MHC Pentamer PE ProImmune 
 
The animals were immunised as per the protocol mentioned in the section 2.2.1 
however the immunised animals were left longer than normal (45 days) before 
harvesting spleen and lymph node for further investigation. The splenocytes and 
lymphocytes were prepared as mentioned in section 2.2.3. 1.5 x106 cells from each 
mouse were used for further flow cytometric analysis. Briefly, red blood cell lysis were 
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performed with 1X RBC lysing solution (Miltenyi Biotec GmbH) as per the 
manufacturer’s guidelines and washed twice with PBS containing 1% v/v FCS. 
Subsequently cells were resuspended in 50 μL of PBS containing 1% v/v FCS buffer 
thoroughly. 10 μL of MHC PE conjugated TRP-2 specific pentamer was then added to 
each tubes and incubated at room temperature in the dark for 30 min. After 30 min, all 
other surface antibodies (CD8, CD3, CD28, CD272 (BTLA), CD197 (CCR7), CD62L, 
and CD44) were added as per the recommended concentrations of the manufacturer. 
Tubes were incubated at 4○C for further 15 min and washed with 5 mL of PBS 
containing 1% v/v FCS buffer. Cells were resuspended in flow cytometer buffer before 
subjected to flow cytometric analysis. Naive unimmunised animals were used as a 
control and the data analysis were performed in Kaluza® software (Beckman Coulter).   
 2.2.13 Statistical analysis 
All the data in this study are presented as mean ± standard error of the mean (SEM).  
Pairwise comparisons were performed with non-parametric student t-tests. Multiple 
comparisons were performed using ANOVA and Bonferroni post test. P-value 
significance in the data has been represented by asterisks [p ≤ 0.05 (*), p ≤ 0.01 (**), 
and p ≤ 0.001 (***)].  
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2.3 Results 
2.3.1 Detection of peptide specific CD8+ cells in ImmunoBody® and peptide 
immunised mouse models. 
The rationale of this study is to understand the molecular mechanisms governing the 
generation of high avidity T cells, and the identification of biomarkers that would allow 
us to detect the presence of high avidity T cells in cancer immunotherapeutic 
interventions. In order to achieve the main goal, this study used two mouse models that 
would reproducibly generate high and low avidity T cell responses, so that any markers 
identified will be cross validated in separate models. which use two different antigenic 
epitopes. The advantage of this strategy is that any markers identified can be 
independent of the model or the immunogenic peptide used for the immunisations. In 
most of the T cell targeted vaccination settings, the generation of peptide (antigen) 
specific CD8+ T cells is the key parameter to assess vaccine efficacy. Therefore, present 
study has assessed the number of peptide specific cells in both ImmunoBody® and 
peptide immunised animals to test the capacity of both the vaccines to generate an 
antigen specific response.  
Splenocytes isolated from ImmunoBody® and peptide immunisations were assessed 
using antibody staining and flow cytometry analysis.  The gating strategy used for the 
analysis is given in figure. 2.3.1. In TRP-2 immunised animals, CD8+ pentamer positive 
T cells were detected in the range of 0.35 - 44% of the total CD8+ population, with no 
significant differences noticed between the groups (P ≥ 0.05, n = 8). A similar pattern 
was observed in the ovalbumin group, with the detection of ova specific cells in a range 
of 0.88 - 0.94% of total CD8 with similar number of cells between the DNA and peptide 
vaccine groups (P ≥ 0.05, n = 6). However, ovalbumin immunisation resulted in a 
greater number of peptide specific cells than TRP-2 immunisation, thereby indicating 
that it is more immunogenic among the two model antigens studied. As a staining 
control, a group of un-immunised (naïve) animals were also analysed similarly (Figure 
2.8. B&F). The background staining observed in the control groups was lower than in 
the experimental groups and is represented as a box graph in Figure 2.8.E.    
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A
Figure.2.8: Generation of TRP-2 and Ovalbumin SIINFEKL specific cells in both ImmunoBody® and peptide immunised
animals were studied after three rounds of immunisations using FACs analysis. A: Scatter plot showing the gating strategy used
for TRP2 pentamer staining with CD3 on Y axis and CD8 on X axis. B: The staining of TRP-2 specific pentamers in naïve
animals. C&D: Detection of TRP-2 specific cells in both TRP-2 (SVYDFFVWL) ImmunoBody® and peptide immunised
animals F: The staining of OVA specific pentamers in naïve animals. G&H: staining of peptide specific cells in Ovalbumin
(SIINFEKL) ImmunoBody® and peptide immunised animals Fig. E. Percentage of pentamer positive cells were calculated out
of total CD8+ cells and represented as mean and SEM of 8 independent experiments in TRP-2 and six in Ova models. No
significant differences were noticed between two immunisations in both TRP-2 (N=8, P ≥ 0.05) and OVA (N=6, P ≥ 0.05)
models.
E 
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2.3.2 Characterisation of functional avidity in C57Bl/6 mouse model  
Although the generation of the peptide specific cells is the first step in measuring the vaccine 
efficacy, the functionality of vaccine generated T cells can drastically vary depending on the 
various factors such as vaccine framework, the mode and root of administrations (Okada et al., 
2001; Senovilla et al., 2013, Sandoval et al., 2013). So it is widely accepted that the quality of 
immune response is directly linked to the functionality of the vaccine generated T cells. With that 
view, we assessed the functionality of CTLs generated in both the mouse models (SVYDFFVWL 
TRP-2 melanoma differentiation self-antigen and SIINFEKL Ovalbumin foreign antigen model), 
using interferon-γ (IFN-γ) measurement assays.  
Total splenocytes were isolated after the vaccination regime was studied for their functional ability 
to recognise and respond to their cognate peptides.  Elispot assays of splenocytes isolated from the 
TRP-2 model showed differences in their ability to produce IFN-γ when challenged with TRP-2 
peptides as determined by the mean spot differences between the groups (ImmunoBody® vs. 
peptide vaccine) in ELISpot assays (Figure 2.9 A). ImmunoBody® immunised animals were found 
to be better responders when compared to the peptide group (P=0.0001, n=8). A similar study was 
conducted with an identical immunisation procedure, but using a different well characterised H-
2Kb restricted model antigenic peptide (SIINFEKL) from ovalbumin. ELISpot® assays were 
performed as described above and the mean spot differences were calculated between the peptide 
immunised and DNA immunised animals. Like the TRP-2 system ImmunoBody® immunised 
animals were more functionally superior as measured by their ability to secrete IFN - γ (n=6, P = 
0.0001) Figure 2.9 B 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure.2.9: C57Bl/6 mice immunised with TRP2 (SVYDFFVWL) and
Ovalbumin (‘OVA’ /SIINFEKL) ImmunoBody® (DNA) and peptide vaccines
were assayed by INF-γ ELISpot® assays. A. Number of spots obtained from
5x105 splenocytes of TRP-2 ImmunoBody® and peptide immunised animals
were shown as box and whisker plots (n=8) with P-value calculated between
groups. B. Similar results were obtained from 5x105 splenocytes of ‘ova’
ImmunoBody® and peptide immunised animals (n=6).
Figure.2.9. C57Bl/6 mice immunised with TRP2 (SVYDFFVWL) and 
Ovalbumin (‘OVA’ /SIINFEKL) ImmunoBody® (DNA) and peptide vaccines 
were assayed by IFN-γ ELISpot assays. A. Number of spots obtained from 
5x10
5
 splenocytes of TRP-2 Immun Body® and peptide imm nised animals 
were shown as box nd whi ker plots (n=8) with P-value calculat d between 
groups. B. Similar results were obtained from 5x10
5
 splenocytes of ‘ova’ 
ImmunoBody® and peptide immunised animals (n=6). 
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In the next step of the study, cells generated by both the immunisations were assessed for its 
differences in the functional avidity (sensitivity towards its cognate antigens). This was achieved 
by a peptide titration IFN-γ ELISpot assay, in which the cognate peptide was (TRP-2/OVA), 
titrated down to seven fold dilutions from 0.1M to 0.0000001M (Fig.2.10) and splenocytes 
obtained from the immunisations were co-cultured in ELISpot  plates with all the dilutions in 
triplicates. The experiment has been repeated with the same settings for at least three times. 
Splenocytes with no peptide was used as the control and background spots were subtracted 
from the test data before plotting as a graph and further statistical analysis (Figure 2.10).    
 
A 
A B
C D
Figure.2.10. The cells obtained from the above vaccinations were assayed for their 
functional avidity profile by IFN-γ peptide titration ELISpot assays. A. & C, 
actual number of spots obtained from 5x10
5
 splenocytes of TRP-2 DNA and 
peptide immunised animals were shown with its LogM peptide concentrations on 
the X axis (n=8 forTRP-2 and n=6 for OVA) B & D. Figure showing the 
concentration requirement for 50% maximum function (EC
50
) for ImmunoBodies 
and for peptides in TRP-2 (B) and  ‘OVA’ (D) model studied.   
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2.3.3 Intracellular cytokine staining of high and low avidity CD8+ T cells from TRP-2 
ImmunoBody® and peptide Immunised animals 
In order to validate the IFN-γ profiles of these two distinctly functionally different high 
and low avidity cells, an intracellular cytokine staining was performed. The animals were 
immunised as described previously and the splenocytes were isolated under sterile 
conditions. Cells were seeded on to a 24 well plate at a cell density of 1x106 cells/well with 
10-1 M TRP-2 peptide. IFN-γ secretion assays were then performed as described in section 
2.2.7 and the IFN- γ secreting cells were determined. A similar pattern of IFN-γ profiles 
were observed with ImmunoBody® generated cells having higher number of IFN-γ 
producing CD8+ cells in all the peptide concentrations studied (Figure.2.11).  
The nonlinear regression of both the ImmunoBody® and peptides with decreasing titration 
of logM concentration of the peptides demonstrated that there is a strong differences in the 
concentration requirement of peptides for achieving a maximum 50% activation between 
ImmunoBody® and peptide derived high and low avidity T- cells [P ≤ 0.0001] (Fig 2.10) in 
both the models studied. The LogEC50 for ImmunoBody® has been calculated as 
-4.717 ± 
0.0206 (Mean ± SEM, n=8) for TRP 2 immunobodies and -3.258 ± 0.03223, (Mean ± SEM, 
n=8) for the TRP-2 peptides. Similar results were obtained with the second model (OVA), 
however the EC50 calculated between these group has showed much more difference 
compared to TRP-2 groups with a log EC50 of  
-5.886 ± 0.1562 (n=6)  for OVA 
Immunobodies and  -2.571 ± 0.0.1582 ( n=6) for OVA peptides.  
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Figure 2.11: Intracellular cytokine staining of TRP-2 ImmunoBody® and peptide immunised animals 
showing IFN-γ production. The cells were stimulated with decreasing concentration of peptides (10-1- 10-7 M) 
in the presence of brefeldin-A and stained for CD8 surface marker and IFN-γ.  The upper panel A shows the 
density plot gated on CD8+ cells with IFN-γ on the Y-axis. The first panel represents cells with media, 
brefeldinA and no peptide, following plots represent decreasing concentration of peptides (mentioned above 
each plot) up to the concentration of 10-7. Quadrant C2 represents CD8+, IFN-γ producing cells. The 
percentage of IFN-γ producing cells were also given in the same quadrant. The upper panel represent IFN-γ 
profile of a peptide titration assay of cells derived from TRP-2 peptide immunised animals and the lower 
panel (B) represent the same assay with the cells derived from ImmunoBody® immunisations.   
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2.3.4 In vitro stimulation of TRP-2 DNA and peptide vaccine generated CTLs can 
alter its functional properties 
It has been shown by several groups that stimulation of CTLs in the lab can alter their 
functional ability as measured by the ability of cells to secrete IFN-γ. Total splenocytes 
isolated from both TRP-2 ImmunoBody® and peptide groups were stimulated by two 
concentrations of the peptides (100 µg/mL and 10 ng/mL). After one week of stimulation 
these cells were assessed for their ability to produce IFN-γ using peptide titration ELISpot 
assays. The ex vivo ELISpot  assays were done with 5x105  splenocytes per each well of the 
ELISpot  plate, whereas the ELIspot  assays done after in vitro stimulations were used only 
5x104 cells per well. Therefore all the cell counts were normalized to 5x105 cells for a head 
to head comparison. Plots were generated using these normalized values and the statistical 
analyses were performed using two way ANOVA with Bonferroni post-test.  
After a week of stimulation using high concentration (100 μg/mL) of the peptides and a 
low concentration (10 ng/mL) of the peptide, in  ImmunoBody® group, there was an overall 
reduction in the spot count in comparison to the unstimulated controls in all the 
concentration tested in the ELIspot assays (Figure 2.12). Both 100 μg/mL and 10 ng/mL 
stimulated cells showed significant reduction in the spot count (P ≤ 0.001, n=6). There was 
a complete absence of spots in the lower concentrations (10-4-10-6 M) in both the cases 
indicated the disappearance of high avidity/sensitivity cells upon stimulation. 
In contrary to the splenocytes derived from ImmunoBody® immunised animals, the peptide 
immunisation derived cells showed an opposite pattern in the interferon profile in ELISpot 
assays. In straight ELISpot (ex vivo) assays, splenocytes derived from peptide immunised 
animals produced a significantly lower number of spots in comparison to ImmunoBody 
group. However, after one week of in vitro stimulation of these cells with both high and 
low concentrations of TRP-2 peptide resulted in the production of IFN-γ in all the 
concentration tested in peptide titration ELISpot assays (P ≤ 0.001, n=3).  
One week post stimulation these cells even showed significantly higher sensitivity towards 
the lowest concentration of the peptides tested otherwise completely insensitive in the pre 
in vitro stimulations (Figure 2.12). Noticeably in both the studies there were no significant 
difference (P ≥ 0.05) observed between high and low doses of peptides used for in vitro 
stimulations.       
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Figure 2.12. Repeated in vitro stimulation in vitro stimulations of CTLs can modulate its 
functional property as assessed by peptide titration IFN-γ ELISpot assays. A. plots 
showing the number of IFN-γ producing cells in unstimulated controls (ex vivo)  and also 
after one week of  in vitro stimulations using splenocytes isolated from Immunobody
®
 
Immunised animals (n=6) with two concentrations of TRP-2 class-I peptide. Y axis 
represents the normalised number of spots. B. Plots showing the similar data obtained 
using splenocytes isolated from TRP-2 peptide Immunised animals (n=3) with same 
concentrations of peptides stimulations. In both cases the P value significance is calculated 
for each concentration in comparison to the unstimulated controls and the asterisk 
represent the level of significance (** = P ≤ 0.01 , ***= P ≤ 0.001) 
Figure.2.12: Repeated in vitro stimulation of CTLs can modulate its functional
property as assessed by peptide titration IFN-γ ELISpot® assays. A. plots
showing the number of IFN-γ producing cells in unstimulated controls (ex vivo)
and also after one week of in vitro stimulations using splenocytes isolated from
ImmunoBody® Immunised animals (n=6) with two concentrations of TRP-2
class-I peptide. Y axis represents the normalised number of spots. B. Plots
showing the si ilar data obtained using splenocytes isolated from TRP-2 peptide
Immunised animals (n=3) with same concentrations of peptide stimulations. In
both cases the P value sign ficance is calculated for ach concentration in
comparison to the unstimulated controls and the asterisk represent the level of
significance (** = P ≤ 0.01 , ***= P ≤ 0.0 1)
A
B
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2.3.5 Immunophenotyping of high and low avidity peptide specific CTLs 
Phenotypic characterisations of vaccine generated T cells are a key indicator to understand 
the nature of response and to predict the polarisation of these cells to effector or memory 
phenotype. The functional fate of these cells can be decided by the nature of the vaccine 
and its potential to stimulate the naïve population in a short period of time. In the previous 
functional characterisation of the TRP-2 immunisations, we have observed two functional 
characteristics as assessed by interferon-γ peptide titration ELISpot assays. So we 
hypothesised that the functional polarisation of these cells will be different given the nature 
of two types of vaccines used for the epitope delivery (DNA vs. peptide). In order to test 
this hypothesis we have used the surface markers (section 2.2.12) which could delineate 
the peptide specific cells into further sub classifications. The cells were stained and 
subjected to flow cytometric analysis according to the optimised gating parameters. The 
expression of markers on TRP-2 pentamer positive cells in the spleen and lymph node of 
ImmunoBody® and peptide immunised animals are given in figure 2.13 and figure 2.14. 
All the data from this immunophenotyping study was first analysed for the presence of 
TRP-2 pentamer positive cells before applying sub gating and looking for the expression of 
other markers. There was no significant differences in the percentage of pentamer positive 
cells in the spleen (1.83 ± 0.25 [mean ± SEM]) and the lymph node (1.6 ± 0.046) of 
ImmunoBody® immunised animals. However, the pentamer positive cells in the spleen 
(1.79 ± 0.18) and lymph node (0.76 ± 0.80) of peptide immunised animals were 
significantly (P ≤ 0.01; N=3) different, with more cells detected in the spleen of all the 
three animals studied. These results were generated 45 days after the first immunisation, 
compared 21 days that was used for the previous studies (Figure 2.8). These findings 
demonstrate that the percentage of pentamer positive cells were increased significantly 
with time (Figure 2.8, 2.13) except the lymph node of peptide immunised animals.     
These cells were further used for the analysis of the expression of other markers (CD44, 
CD62L, CCR7 and CD28) in order to investigate if any preferential phenotypic 
polarisation was happening over the time within the vaccine generated CD8+ T cells. 
Expression of three memory markers (CD44, CD62L and CCR7) were first assessed on 
TRP-2 pentamer positive cells especially to address the question of whether these cells 
have more polarisation toward which memory compartment (Tcm / Tem). Majority of the 
cells were showed a CD44+, CD62L+ phenotype with a very high expression of CD44 
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(mean fluorescence intensity: 110.90 ± 12.1 (Mean ± SEM) ) and low expression of CD62 
(mean fluorescence intensity 12.20 ± 2.3 (Mean ± SEM) ). Similarly, the analysis of 
CD62L and CCR7 on the same cells indicated positive staining but low expression of these 
markers were observed in the ImmunoBody® and peptide immunisations in both spleen 
and lymph node. CD44 expressing cells are also found to be expressing low amount of 
CCR7 in the spleen of both ImmunoBody® and peptide immunisations. However, a large 
number of CCR7 negative cells were found in the pentamer positive cells isolated from the 
lymph nodes of ImmunoBody® immunisations. From this analysis the predominant 
phenotype observed is CD44hi, CCR7lo, CD62lo in the spleen of both immunisations and 
the lymph node of peptide immunisations. Cells derived from the lymph node of 
ImmunoBody immunisations are predominantly CD44hi, CCR7-, CD62lo (Figure 14 and 
15).  
Expression of CD28, a costimulatory molecule, plays an important role in the T cell 
activation and proliferation. It is also reported to have a varied expression at different 
stages of antigen experience by a T cell. This study investigated the status of CD28 
expression in TRP-2 pentamer positive T cell to assess their expression as a part of 
immunophenotyping in pentamer positive cells of both ImmunoBody® and peptide 
immunised animals. In the CD28+ compartment, large proportion of antigen specific CD8+ 
cells were positively stained for CD28 with low expression levels (Figure 14 and 15 ). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13: Detection of pentamer positive cells in the TRP-2 ImmunoBody® and peptide 
immunised animals used for the immunophenotyping study. Each bar represents an average of 
three animals with the error bar showing the standard error of mean. The significant difference 
observed were indicated as (*) above the bars. 
Fig. 2.3.9 Detection of pentamer positive cells in the TRP-2
Immunobody and peptide immunised animals used for the
immunophenotyping study. Each bar represents an average of
three animals with the error bar showing the standard error of
mean. The significant difference observed were indicated as (*)
above the bars.
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Figure 2.14: Representative dot plots showing the expression of five surface markers on the 
pentamer positive cells detected on the lymph node resident pentamer positive, CD8+, CD3+ T cells 
(LNCs). All the analysis was performed on TRP-2 pentamer positive T cells 45 days the first 
immunisation. A. Expression of markers in cells (LNCs) derived from TRP-2 ImmunoBody® 
immunised animals. B. Expression of markers in cells (LNCs) derived from TRP-2 peptide 
immunised animals. 
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Figure 2.15: Representative dot plots showing the expression of five surface markers on the 
pentamer positive cells detected on the splenocyte CD8+, CD3+ T cells (Spleen). All the analysis 
was performed on TRP-2 pentamer positive T cells 45 days the first immunisation. A. Expression 
of markers in cells (spleen) derived from TRP-2 ImmunoBody® immunised animals. B. Expression 
of markers in cells (spleen) derived from TRP-2 peptide immunised animals. 
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 2.3.6 Expression of B and T lymphocyte attenuator (BTLA) in vaccine generated 
CD8+ T cells  
BTLA (CD272) is an inhibitory molecule present in the CD8+ T cells and known to play an 
important role in the functional suppression of vaccine generated T cells. With this view in 
mind this study has also assessed the expression of BTLA in TRP2 pentamer positive cells 
as a part of immunophenotyping.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16: Expression of BTLA surface molecules in TRP-2 immunised animals A. 
Representative dot plot of BTLA expression on pentamer positive cells B. Percentage of BTLA+ 
cells detected in the spleen and lymph node ImmunoBody® immunised (IM) and peptide 
immunised (PEP) animals. Significant differences observed were indicated as stars above the bars. 
The pentamer positive cells in both the vaccination showed more BTLA negative cells of 
which a significant (p ≤ 0.01; n=3) decrease was detected in peptide immunised lymph 
node (Figure 2.16). 
A 
A 
Fig.2.3.14 Expression of BTLA surface molecules in TRP-2 immunised
animals A. Percentage of BTLA- cells detected B. Percentage of BTLA+
cells detected in the spleen and lymph node immunobody immunised (IM)
and peptide immunised (PEP) animals. Significant differences observed
were indicated as stars above the bars.
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2.4 Discussion 
2.4.1. DNA vaccine (ImmunoBody®) generated CTLs with higher avidity 
characteristics.  
Despite of our understanding of cancer initiation and immune surveillance, most of the T 
cell based cancer vaccine strategies remain not completely successful. One of the reasons 
might be attributed to the nature of the antigens used for the immune targeting. Unlike 
other vaccination strategies cancer vaccines are mainly developed against the self-antigens 
and hence the tolerance mechanisms are playing a crucial role in the attenuation of T cell 
responses (Pawelec & Rees., 2002; Kyewski & Klein, 2006). Even with all the failures, 
many of the cancer vaccination trials recently conducted were able to generate noticeable 
number of antigen/vaccine specific T cells but unable to translate that into clinically visible 
outcome due to the lack of tumour recognition and target killing. Among many other 
reasons identified as the limiting factors for vaccine efficacy (such as immunosubversion 
and immunoselection devised by tumours), the nature and functional behaviour of the 
cytotoxic T cells generated through each type of vaccinations are also an important factor 
for a positive clinical outcome. One of the efficient ways to assess this quality of vaccine 
generated T cell immune responses are T cell functional avidity.     
Functional avidity is the measurement of T cells ability to respond against its 
corresponding peptide which is usually measured by peptide titration ELISpot assays or 
chromium release assays. However, these assays are laborious and can only be performed 
where the peptide responsible for the generation of this cells are known. So there is a 
pressing need to identify markers to measure a high avidity T cell response in cancer 
patients regardless of the antigen or vaccines used for the immunisations. With this in mind, 
this study used a mouse model system to mimic the vaccine response with varying 
functional avidity characteristics.  
The mouse models used for this study was able to generate high (capable of recognising 
low dose of antigen) and low avidity (capable of recognising very high dose of antigen) 
responses by using two vaccine delivery systems (a DNA and the peptide vaccine). The 
primary model was a C57Bl/6J-TRP-2 system which uses a self-peptide (180-188, 
SVYDFFVWL) derived from melanoma differentiation antigen tyrosinase related protein -
2. The DNA sequence of this peptide was inserted in to the antibody heavy chain of the 
vaccine with a CD4 helper epitope (Hep B) in to the light chain region of the vector as 
PEP Lymph 
A 
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indicated in materials and method (Section 2.2.2.2). Immunisation of this vaccine to the 
C57Bl/6J mouse induces a high avidity T cell response compared with the corresponding 
peptide vaccine. The peptide titration IFN-γ ELISpot assay clearly indicated that the 
ImmunoBody® derived cells are capable of producing IFN-γ even at the lowest 
concentration of the peptide used for the assays. In contrary, peptide vaccine derived cells 
responded poorly in the IFN-γ assays with no or little spots were observed when the 
concentration of the peptide was decreased. One of the obvious questions then asked was 
the ability of the vaccines to generate TRP-2 specific CTLs in both the vaccinations 
(ImmunoBody® and Peptide). To check that CD8+ cells isolated from both the 
immunisations were stained with a MHC class 1 TRP-2 pentamer (PE labelled) and 
noticed that both the immunisations were able to generate TRP-2 specific CTLs at 
approximately equal numbers with no significant differences. So the only difference 
observed in the study was their IFN-γ ELISpot profile which was an indication of their 
functionality.  
Half maximum effective concentration 50 (EC50) was determined for both the 
ImmunoBody® and peptides vaccines using peptide titration data. There was a 100 fold 
differences in the EC50 for peptide and ImmunoBody
® derived splenocytes indicated that 
the ImmunoBody® derived splenocytes were more sensitive when compared to peptide 
groups. Similar pattern was observed with the second model also, where the TRP-2 peptide 
was replaced with an epitope derived from foreign protein, ovalbumin peptide sequence 
(SIINFEKL, OVA257-264) in the ImmunoBody
® vaccine framework. Overall the frequency 
of peptide specific CTLs were found to be higher in the ovalbumin model compared to the 
TRP-2 model which agree with the earlier findings ((Pudney, et al., 2010). As with the 
TRP-2 system ImmunoBody® derived splenocytes showed better sensitivity towards the 
SIINFEKL peptides in peptide titration ELISpot assays. These experiments were repeated 
several times (TRP-2 model: n= 8 and Ovalbumin SIINFEKL model: n=6) and the 
difference in the functional properties between ImmunoBody® and peptide derived cells 
were highly significant (p= 0.0001), hence these models were considered as an ideal tool 
for initial avidity molecular characterisation and the identification of avidity biomarkers.      
The explanation for differences in the functional characteristics of cancer vaccine 
generated T cells are rooted in thymic selection, central and peripheral tolerance 
mechanisms. The existence of tumour reactive T cells was detected in many cancer 
patients. However, studies revealed that they were in a state of anergy/nonresponsive stage 
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partially because of keeping the low avidity-self reactive T cells under control from 
autoimmunity. Since most of the tumour antigens were also self-antigens or having a 
highest similarity to the self-proteins, it is very difficult to make the small repertoire of 
these low avidity T cells to break the tolerance mechanism and engage with the malignant 
tissues. Moreover the antigens present on the tumour surface may not be in sufficient 
quantities to evoke a positive response in these low avidity T cells since they need large 
amount of peptides to get activated.  
For a successful tumour vaccination trial the available low avidity T cell pool in the 
immune repertoire has to be effectively primed with suitable vaccine delivery mechanisms. 
Different vaccine strategies are in place for this purpose such as increasing the affinity of 
peptide MHC interactions using various amino acid substitutions on the peptide anchor 
positions (Khleif, et al., 1999; Loftus, et al., 1998), increasing the peptide TCR binding 
efficiency using the same strategy (Sette & Fikes, 2003; Fong, et al., 2001), genetically 
engineered TCRs specific to tumour antigens (Aarnoudse, et al., 2002)  and use of DNA 
vaccines (Gross, et al., 1989 ) and anti idiotypic vaccines (Pudney, et al., 2010).  
Apart from the above mentioned modifications of the antigenic peptides, different vaccine 
delivery strategies and adjuvant settings were also effective to increase the spectrum of 
high avidity CTL responses in cancer patients (Stevenson et al., 2004; 2010). One of the 
problems using the conventional peptide vaccines are their structural instability in the in 
vivo environment combined with the half-life of injected peptide, DNA vaccines such as 
ImmunoBody® which used in this study can efficiently overcome this problem by 
producing the peptide epitope with in the body and ensured the constant supply of the 
peptide antigens at a moderate level to the cellular immunity (Rice, et al., 2008; Pudney, et 
al., 2010).   
Another possible explanation for ImmunoBody's ability to generate high avidity T cell 
responses might be due to its ability to perform direct and cross (indirect) presentation of 
the antigens to the immune system (Pudney, et al., 2010;  Metheringham, et al., 2009). The 
direct presentation of the antigens was through the professional antigen presenting cells 
such as dendritic cells present at the site of vaccination. In this case ImmunoBody® DNA 
delivered intradermally transfect the DC’s and translate in to peptide fragments and finally 
presented on a class 1 MHC complex. The indirect presentation also involves APC’s,  
however in this case the DNA was first taken up by non APC’s such as skin keratinocytes 
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and produce the antigens and finally presented to the APCs as a secreted protein or through 
apoptotic vesicles (Stevenson et al., 2004; 2010). Studies suggested that ImmunoBody® 
vaccines were capable of generating the high avidity responses through presenting a low 
level of antigens to the CTLs thereby selectively expanding the population of high avidity 
T cells which can recognise the low doses of tumour antigens (Pudney, et al., 2010). 
However, it is worth mentioning that this study has not detected any preferential selection 
of high avidity TCR clones from the total repertoire in either of these vaccines. The 
pentamer positive cells were uniformly distributed in the staining with our any significant 
difference in their staining intensity.   
Though it is clear from this and other studies that using the ImmunoBody® consistently 
generate highly sensitive T cells,  the decision point (the molecular mechanism required for 
high functional avidity) of this alteration of T cell functionality is largely unknown. 
Therefore, understanding the available pool of T cell precursors which can detect the self-
antigenic epitopes and the precise mechanism to uplift their functional superiority is the 
key to the success of modern cancer vaccination strategies. In addition, understanding the 
precise molecular mechanism underlying the functional modulation of CTLs by vaccines 
might help in the generation of more effective vaccine framework and strategies. 
2.4.2 In vitro stimulations might modulate the functionality of T cells   
One constrain of this study was the number of peptide specific T cells available for the 
proteomic and genomic characterisations. So initially a separate experiment was designed 
for the in vitro generation of high and low avidity T cells by in vitro stimulation of the T 
cells with two different concentrations of the peptides. The original aim of the study was 
unfulfilled with little differences were observed between the groups. However an important 
observation was concluded from this experiment. The high avidity T cells derived from 
ImmunoBody® immunised animals which were responded to the TRP-2 peptides even at 
the lowest concentrations were disappeared after the first round of in vitro stimulations in 
both the concentrations used for the stimulation (100 µg and 10 ng). This indicates the 
fragility of high avidity CD8+ T cells towards high peptide load. We presume that this 
might be due to the susceptibility of ImmunoBody generated high avidity T cell population 
towards excessive antigen load due to serial triggering and ultimately leading to activation 
induced cell death by apoptosis. In contrary to the ImmunoBody® derived T cells, peptide 
derived cells started to secrete IFN-γ after two rounds of stimulation in both of the above 
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doses tried. These results indicated that a functionally inferior pool of CTLs exists in the 
peptide immunised animals (low avidity) and once they received high dose of peptide 
stimulations they can be brought back in to the high avidity zone by breaking their avidity 
barrier (inability to detect low amount of antigenic peptides). This study partially agree 
with the observations made by Pudney et al, 2010 that the in vitro stimulation of TRP-2 
specific T cells derived from B16- GMCSF immunised mice with low doses of peptide 
generated high avidity T cells whereas stimulation with high doses of peptide ended up in 
low avidity T cells.  
2.4.3 Phenotypic changes of immunised animals after long term antigen exposure 
The immunophenotypic of pentamer positive cells were carried out with the intention of 
studying the nature of these cells after long exposure of antigen stimulation using both 
ImmunoBody® and peptide immunisations. This study also aimed to understand there is 
any polarisation of these cells towards the central or effector memory. 
The first observation noticed that the number of antigen specific cells was increased in 
both the cases compared to the normal immunisations used for the study (21 days vs. 45 
days). There was no significant differences in the cells were observed between the spleen 
and the lymph node of ImmunoBody® immunised animals however a decreased homing of 
pentamer positive cells were detected in the lymph node of peptide immunised animals and 
were significantly lower compared to its corresponding spleen. 
 These differences might be attributed to the fundamental differences of two vaccines used 
for the immunisations. It is known in the literature that the stability of the immunisation 
and the root of administration have a knock on effect on the stimulation of naive repertoire. 
The DNA vaccine is known for their stability and once they have been taken up by the 
antigen presenting cells, there is always a constant production of the delivered antigens 
with in these cells. Because of that reason, the DCs, which express these antigens, will 
have the capacity to stimulate the T cells over a prolonged period by directly presenting the 
antigens. Apart from that, some of the plasmids, which have been taken up by the non-
dendritic cells at the place of immunisations, also might be able to produce this antigen. 
Since ImmunoBody® has been engineered in such a way that the epitope is mounted on an 
antibody secretory chain the antigens produced by non-dendritic cells can also acts as a 
depot of antigens. These antigens can enter in the DCs and feed in to the class one pathway 
by cross presentation by the DCs. This sustained stimulation, which might be given by the 
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dendritic cells, could be the reason for the increased number of peptide specific cells in the 
ImmunoBody® immunised animals.  
In contrary to the DNA vaccine peptide vaccines offers only the administered dose of the 
peptide as the source of antigen. The diffusions happening in the immunisation place (even 
with the adjuvant IFA) may add up to the availability of the antigen. The successes of 
peptide immunisations are also dependent on the efficiency with which the local DCs take-
up the antigen and its subsequent feeding in to the class I pathway. Not only that, the DCs 
once taken up the antigens they have to migrate to the sentinel lymph nodes to present the 
antigen to the T cell repertoire for further clonal expansion of the antigen specific T cells. 
The maturation and the migratory capacity of the DCs can be another influencing factor, 
since the delivery of the antigens are in the short peptide format there is a chance of DC 
maturation happening fairly quickly and consequently the loss of migratory capacity to the 
lymph nodes. In the case of DNA vaccines, probably the vector internalisation starts up the 
process of DC maturation and its mobility towards the lymph nodes. However, the 
translation and the protein production will happen only with time compared to the readily 
antigen availability of peptide vaccines. This might be probably the reason by which the 
large number of peptide specific cells in the ImmunoBody® vaccination in both the lymph 
node and the spleen.  
Among the markers studied in the pentamer positive cells isolated from ImmunoBody® and 
peptide immunised animals both in lymph node and spleen, no great differences could 
observed of the immunophenotype within the lymph and spleen. The predominant 
phenotype observed in this study was CD44hi, CCR7lo, CD62lo in the spleen of both 
immunisations and the lymph node of peptide immunisations. However, pentamer positive 
cells derived from the lymph node of ImmunoBody immunisations are predominantly 
CD44hi, CCR7-, CD62lo. 
Naive T cells are characterised with the presence of homing receptors CCR7 and very high 
levels of CD62L markers. The expression levels of these markers decreases up on antigen 
stimulation. In all the above cases pentamer positive cells showed the decreased levels of 
CCR7 and CD62L indicating they were subjected to antigen exposure. The presence of 
large number of CCR7 negative cells in the lymph node of ImmunoBody immunised 
animals indicating a possibility of chronic stimulation of pentamer positive cells. The 
predominantly observed phenotype CD44hi, CCR7lo, CD62lo is a typical effector memory 
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phenotype in mouse. However, these cells were obtained from the spleen and lymph nodes 
of immunised mice and it is a highly unlikely place to find effector memory population. 
Therefore, obvious observation is they are antigen experienced T cells and yet to be 
polarised into a memory populations with in the period of this study. High levels of CD44 
and decreased expression of CCR7 and CD62L in the spleen and lymph node derived cells 
of peptide immunisation and also in the spleen derived cells of ImmunoBody® 
immunisation showed that their similarity in marker expression and therefore their antigen 
experience. However, significant presence of CCR7- cells in the lymph node of 
ImmunoBody® immunisation suggests that these cells might have exposed to the antigen 
more efficiently. The original hypothesis was that the DNA vaccine primed the cells more 
effectively and chronically so that the functional polarisations will be quicker in these 
groups. However, the data showed that it is not the case and both of them retained a 
relatively similar marker profile with subtle changes. More studies needed with longer 
duration with additional markers and effector cytokines will be the future direction for this 
study. 
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Chapter 3  
Gene expression profiling of High and low avidity T cells 
3.1 Introduction 
As discussed in chapter 2, the nature and the functionality of vaccine generated CD8+ T 
cell responses can vary significantly depending on the vaccination strategies used to 
deliver the antigenic peptide. These differences might be attributed to the ways in which 
vaccines stimulate the naïve T cell repertoire (Cao et al., 2013). For that reason, the 
observed immune response is mainly attributed to the nature of the antigenic stimulus used, 
the way in which it is processed and presented to the T cell immune arm and also to some 
extent the precursor frequency of vaccine-specific T cells in the patient. Activation and the 
stimulation of T cells is not a single receptor ligand mediated process. The optimal 
stimulation of the naïve repertoire requires multifactorial interactions of many receptors at 
the initial point of contact with an antigen presenting cell (Friedl et al., 2005). These 
interactions include the cumulative binding strength of the primary receptor responsible for 
the detection of the antigen (TCR), other secondary and tertiary interactions of co-
receptors and all other supporting binding machinery at the synaptic complex (APC-T cell 
contact point) interface. If these signalling and interactions are not strong or stable, it 
influences the functional fate of the resulting antigen primed T cells in a more negative 
than positive way (Katzman et al., 2010).  
3.1.1 Signal requirements for T cell priming and activation  
It is well known that for any optimum activation, T cells requires a minimum of two 
signals and three signals for maximal activation (Bretsche, 1999). The first signal is 
generated from the TCR- peptide MHC interactions and the second one coming from the 
CD28 co-receptor interactions with its ligand (B7 family ligands) on the APC (Bretsche, 
1999; Baxter and Hodgkin, 2002). These two signals are thought to be essential for the 
optimum survival of an antigen experienced T cells. The third signal which comes from the 
local cytokine milieu, although not essential, is necessary for efficient clonal expansion of 
the antigen experienced T cells and also believed to be contributing towards the 
development of effector functions in these cells (Curtsinger et al., 1999). Type I 
interferon’s (∞ and β) and IL12 are believed to be key signal 3 molecules in the induction 
of complete signalling to the T cells during its expansion phase (Schurich et al., 2013). The 
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lack of signal 1 or 2 in an antigenic stimulation is known to impair the functionality of T 
cells by rendering them an anergic (non-functional state) phenotype (Schwartz, 2003) 
whereas, the lack of signal 3 leads to the reduced survival and effector function in the 
resulting clonal population (Sikora et al., 2009). So the complete and fruitful activation of 
T cells requires the synergistic signalling of all the receptor molecules, which are discussed 
in details in the following sections.   
3.1.2 T cell receptor: not a meek ‘ON-OFF’ switch but a dynamic signalling 
complex  
The journey taken by a hematopoietic stem cell  to become fully functional antigen specific 
cytotoxic T cell (CTL) in the thymus was discussed in Chapter One and Two. The antigen 
recognition, stimulation and expansion of T cells are also equally complex and highly 
organised events starting with the recognition of specific peptide-MHC among millions of 
other molecules present in their tissue micro niche that might only differ by few amino 
acids. In the lymph node where the primary antigen encounter occurs, it was observed that 
the T cells are in constant motion (Wei et al., 2003) skimming for any danger antigenic 
signals. In this process it was estimated that they meet approximately 5000 dendritic cells 
in 1 h (Fooksman, et al., 2009). Mempel et al., (2004) classified the in situ process of 
antigen recognition into three different phases. In the first phase, T cells transiently interact 
with DCs scanning for the antigenic peptides bound on the MHC molecules. These 
scanning processes usually last for few seconds to minutes depending on the antigen 
density on the DCs they engaged. Once they have locked on to an antigenic target they 
stops their constant motion, believed to be by the up-regulation of adhesion molecules such 
as LFAI. (Balkow et al., 2010). Different mathematical models are available to explain 
how this rarest of rare event of antigen recognition is possible within the ocean of millions 
of different self and few antigenic pMHC complexes, of which the most accepted is kinetic 
proof reading model (McKeithan, 1995). The details of this model are beyond the scope of 
this chapter and hence not discussed here, but have been reviewed by Goldstein (Goldstein, 
et al., 2008). The second phase is the actual signal transduction events, which lasts up to 
few hours and during which the induction of necessary gene expression and cytokine 
production takes place (Mempel et al., 2004). The third and final phase T cells gradually 
return to their transient phase, detach from the DCs, and start to expand clonally and 
finally come out of the lymphoid tissue (Mempel et al., 2004). The physical nature of these 
interactions has been studied by fixed cell imaging and other imaging techniques (Monks, 
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et al., 1998 and Freiberg et al., 2002). These studies revealed the formation of a ‘bulls eye’ 
like structure in the region of TCR receptor complex which was named ‘supra molecular 
activation complexes’ (SMAC). Three distinct positions of the SMAC were thereby 
identified. The first one is known as the centre SMAC mainly composed of TCR CD3 and 
other main co-receptors, the second one is intracellular adhesion molecule-1 (ICAM-1) and 
integrins (LFA1) rich peripheral SMAC and the last one is the distal SMAC, mainly 
enriched with CD45 molecules. The rearrangement happening in the SMAC during APC-T 
cell interaction was thought to be important for the maintenance and termination of TCR 
signalling (Nel, 2002; Huppa & Davis 2003; Smith-Garvin et al., 2009).  
3.1.3 The TCR signalling cascade from TCR CD3 complex   
The TCR complex consists of TCR and CD3 molecules (Figure 3.1). When a ligand binds 
to the TCR, it transmits the signal through the immunoreceptor tyrosine based activation 
motif (ITAM). How the signals are transmitted from TCR to the CD3 is still a 
controversial area (Guy and Vignali, 2009). The receptor deformation model suggests that 
mechanical pull force developed at the site of immunologic synapse formation and exposes 
the phosphorylatable tails of CD3 molecules otherwise buried in the membrane lipids for 
initial phosphorylation events (Marwali, 2004). The ITAM of the CD3 chains are 
phosphorylated by the two Src-Kinases, LCK and FYN acts as a docking site for Syk 
kinase proteins (Palacios and Weiss, 2004). Syk kinase family proteins ZAP70 is the next 
protein tyrosine kinase (PTK) recruited onto the phosphorylated ITAM. This distal 
signalling phosphorylation events happening at the ITAM leads to the triggering of wider 
distal signalling events which ultimately leads to the complete activation of the T cell. The 
ITAM bound ZAP recruits and phosphorylate Linker for Activation of T cells (LAT) 
protein. LAT in turn bind to SH2 domain of PLCγ1 and growth factor receptor-bound 
protein 2 (GRB-2) and other adapter proteins GAD (Schneider and Rudd, 2008). SRC 
homology2 (SH2) domain containing leukocyte phosphoprotein (SLP76) is next bound to 
the above complex through their mutual binding partner GRB2 (Huse, 2009; Houtman et 
al., 2005). The above signalling complex is then populated by three other molecules known 
as VAV1 (a proto-oncogene), NCK1 (Non-Catalytic region of tyrosine Kinase adaptor 
protein 1) and ITK (IL-2-induced tyrosine kinase). This binding ultimately leads to the 
activation of PLC-γ1 (Houtman et al., 2005; Nel, 2002). The activated PLC-γ1 then 
hydrolyse the membrane lipids and release the second messengers IP3 
(Inositolphospholipid) and DAG (Diacyl glycerol), which in turn activate two of the 
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important pathways involving ras and PKCθ. Ras activate a serine threonine kinase Raf-1 
(MAPK kinase) which phosphorylate and activate MAPK and MAPK activates  
Figure 3.1: The organisation of T cell immune receptor complex, consist of the main T cell
receptor (TCR), CD3 complex and the CD8 co-receptor on adjacent to it. The commonly
occurring TCR is a heterodimer made up of two α (dark brown) and β (red) chain joined
together by disulphide linkage (blue dotted line). It has three regions, 1. Variable region,
where the antigen recognition take place, 2. A constant region 3. Intra cytoplasmic tail as a
continuum. CD3 complex similarly consist of two hetero (εγ, γδ) and a single homodimer (ζζ).
Their intra-cytoplasmic tails carrying a immunoreceptor tyrosine based activation motif
(ITAM) (indicated as black solid lines on the cytoplasmic tails) which plays an important role
in the transmission of signals from TCR peptide MHC interaction in to intracellular cascades.
The third receptor which is closely associated with this complex id CD8 in CTLs enables the
stabilisation of interaction and also contributes towards proximal signalling pathways by
acting as a docking site for many tyrosine kinases. This illustration is the TCR complex
structure of a resting T cell and once it is activated an extensive reorganisation of these
receptors will take place which began the TCR signalling cascade.
 
intracellular signal regulated kinase 1 (ERK-1) and ERK-2 (Joshi and Koretzky, 2013).  
The kinase activity of ERK leads to the activation of activator protein 1 (AP1) (jun/fos) 
transcription complex and also leads to the activation of signal transducer activator of 
transcription 3 (STAT-3) (Nel, 2002). Ras proteins are only active in their GTP bound 
stage and the gene which influences this process is guanyl nucleotide releasing protein  
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(rasGRP) which is also up-regulate during the ras activation (Lapinski and King, 2012). 
Other pathways influenced by the DAG is PKCθ which contains a lipid domain a binding 
substrate for DAG and recruits to the proximal signalling component involving the plasma  
membrane. One of the key pathways regulated by PKCθ is the NF-κB pathway (Jamieson 
Figure 3.2: A schematic representation of TCR signalling path way. The binding of
peptide MHC complexes to the TCR and the subsequent synapse formation leads to
the initiation of proximal signalling pathway from TCR CD3 complex on the T cell
surface. the signalling begins by the p56Lck in the lipid raft of activated cells and
subsequent phosphorylation of ITAMS. The following signalling cascades
discussed in the section 3.3.5. leads to the activation of many different patways
ultimately leads to the increased Ca2+, PKC pathway and Ras and Rac mediated
pathways resulted in the functional changes in the activated T cells
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et al., 1991). NF-κB is present in the cytoplasm bound to its inhibitor IκB in a nonactive 
state in resting T cells; when the T cells received the activation signals, the inhibitor IκB 
gets phosphorylated, ubiquitinylated and degraded (Smith-Garvin et al., 2009). The NF-κB 
is then translocated from the cytoplasm to the nucleus which leads to the activation of 
genes required for the activation of genes involved in T cell homeostasis. In addition to the 
above major signalling events, TCR signalling involves the interplay of second messenger 
Ca2+, cytoskeletal components including actin and integrins which are also critical for the 
full functionality, homeostasis and development of T cells (Nel, 2002; Smith-Garvin et al., 
2009; Fooksman et al., 2009) The details of these signalling events are illustrated in 
(Figure.3.2 ).  
3.1.4 The decision point of avidity ?: role of signals and kinetics  
In cancer vaccination settings, it is important to generate high avidity T cell responses by 
breaking the tolerance of the self-antigen specific T cells (Durrant et al., 2010). Though 
much work aimed at eliciting a high avidity T cell response has been carried out using 
different vaccines and adjuvants, little is known about the molecular mechanisms which 
decide the functional fate of these cells (von Essen et al., 2012). Earlier studies of TCR 
signalling revealed that the signal requirement for naïve and primed T cells are different 
(Farber et al., 1997; Fahmy et al., 2001). The primed T cells can be sensitised with very 
low concentration of the antigen and less dependent on co-stimulatory signals (Yamaura et 
al., 2010). Similar lowered activation requirements were also noticed in effector memory T 
cells in different studies (Watson and Lee, 2004; Tanchot et al., 2004). Studies have also 
showed that, effector T cells can detect antigen in a CD8 independent manner, whereas a 
naïve T cell always require complete interaction of TCR, CD8 and peptide MHC for its 
optimal stimulation. This suggests a higher alertness of the proximal signalling complex 
due to its previous encounter (Bachmann et al., 1999). These fundamental differences 
between naïve and antigen experienced T cell clearly show the physiological and 
functional changes acquired by these cells during their first antigen encounter. And these 
acquired functional changes might be attributed to the process of ‘functional avidity 
maturation’ a process which is discussed in detail in the previous chapter. Now the key 
question is, does the signals and the kinetics taking place the first contact of a naïve T cells 
with their antigen presenting cells have any effects on the subsequent priming of these T 
cell?. This is the not fully understood, but the strength and the duration of individual signal 
originating from the TCR and its co-receptors probably have an important role to play.  
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3.1.5 Contribution of co-receptor signals towards T cell activation 
The formation of a mature immunologic synapse involved the recognition of TCR with its 
cognate antigen the initial signalling events happening in the proximal signalling complex 
create the protrusion towards the antigen presenting cells and several TCR-CD28 micro 
clusters will then aggregate towards this region. This mature immune synapse formation is 
the first and the fundamental prerequisite for the activation of a naive T cell. Studies 
conducted with different groups observed that the formation of a mature synapse is lot 
quicker in the primed T cells and it is less dependent on the primary co-receptor molecule 
CD28 (Watson and Lee, 2004). The same study also have showed that co-distribution of 
CD45 molecules and the TCR embedded in the lipid rafts in the antigen experienced 
memory T cells compared to the naive T cells indicating their membrane molecular 
organisational difference between these two cells (Watson and Lee, 2004).  Studies 
conducted by O'Keefe et al (2004) observed that the synaptic formation of naive and 
effector T cells is different, in that the effector T cells the synaptic formation is 
characterised by the presence of central supramolecular activation cluster with the 
accumulation of PKC, phospho-PKC, and phospho-ZAP70 in the effector T cells.  
The role of TCR signalling between the naive and the effector cells have been studied by 
several groups (Farber et al., 1997; Fahmy, et al., 2001; Pihlgren et al., 1996). All the 
studies have concluded that there is a difference in the TCR triggering existing between 
them with effector cells transmits the signal much efficiently than the naive population.  
An important study which highlighted the difference in the TCR signalling pathways 
between high and low avidity T cells were published (Sharma and Alexander-Miller, 2009). 
They have used an ovalbumin OT-I mice derived CD8+ cells for stimulation with different 
concentration of the peptides. A marked difference in the TCR signalling pathways were 
observed between these two functionally different cells. In high avidity T cells, an 
increased amount of phosphorylated MAPK ERK-1/2 and decreased levels of 
dephosphorylated NFAT were observed with increased Ca2+ mobilisation. They have also 
observed an efficient phosphorylation of CD3ζ phosphorylation. Interestingly, the high and 
low avidity T cells are derived from a clonal population of CD8+ cells having a similar 
TCR receptor characteristics makes the argument that the single T cell can either 
modulated into high or low avidity functional state depending up on the signals they have 
received. 
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3.1.6 Transcriptomic tools to  investigate gene expression changes 
The post genomic era has witnessed a surge in techniques to study the expression of genes, 
so that the much needed functional annotations can be achieved. Among these techniques 
high density microarrays were the first to offer an affordable and global platform to study 
all the predicted and identified genes in a single experiment in different physiological and 
functional conditions. Since then the global transcriptomic platforms have evolved and at 
the latest sequencing based transcript quantification and splicing characterisations. This 
discovery platforms offer the changes happening in a larger scale and the real-time 
quantitative PCR will help the researcher to validate these changes in multiple and 
independent samples.   
3.1.6.1 Microarrays and Affymetrix gene chips 
DNA microarrays are one of the most widely used tool for parallel gene expression studies 
using  a group of small predesigned DNA probes immobilised on a solid surface such as 
glass and it works based on the principles of nucleic acid hybridisation properties. The use 
of microarrays was first reported by Schena et al, (1998) since then, it has been the most 
widely accepted method for gene expression studies (Auer et al., 2009). Success of this 
technique is mainly attributed to its high throughput nature and also fuelled by the 
technological evolution of surface chemistry and novel spotting techniques of DNA 
materials. Two types of arrays are available depending up on the probe material spotted on 
the array surface: cDNA and oligonucleotide microarrays. cDNA arrays are prepared by 
robotic spotting of cDNA fragments amplified from cDNA libraries onto either nylon 
membrane or glass slide, whereas oligonucleotide arrays are prepared by either in situ 
synthesis the predesigned gene probes onto a silicon chip using photo lithography (Pease et 
al., 1994) or ink-jet deposition (Hughes et al., 2001), or the spotting of pre-synthesised 
oligonucleotide probes onto a suitable surface.  
The basic protocol for microarray experiments involves extraction of RNA from controls 
and test samples, labelling of the isolated RNA with dyes, and hybridisation to the 
microarray chip under suitable hybridisation parameters. Un-hybridised RNA molecules 
are then washed away and results are obtained using a laser scanner. Two types of 
detection systems are available: two-channel (Schena et al., 1998; Shalon et al., 1996) and 
single-channel detection systems (Churchil 2002). In the two-channel systems RNA 
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isolated from controls and the test samples are labelled separately by two fluorescent dyes 
such as Cy3 and Cy5.  
 
 
Figure 3.3: Schematic representation of microarray hybridisation work flow. The
isolated mRNA is first reverse transcribed in to the cDNA and labelled using
biotin. This labelled mRNA has been fragmented and then hybridised on to a chip
which hold the immobilised probe sequences. The unbound fragments were then
washed away and the slides can be scanned for acquiring the images. The pixel
intensity of the each probe location will be interpreted as the hybridisation
intensity and therefore the transcript abundance in any given RNA preparation.
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The labelled RNA molecules are then mixed together and hybridised on to a single chip, 
whereas in a single-channel systems such as Affymetrix gene chips (Affymetrix ®, Santa 
Clara) or CodeLink® (GE Health Care) control and experimental RNA molecules are 
labelled separately with only one dye and hybridised onto two separate chips (Schuize and 
Downward, 2001).  
One of the most widely accepted high density oligonucleotide array platforms is 
Affymetrix® (Santa Clara, CA), which offers several array formats such as Exon and gene 
arrays, 3’ expression arrays, micro RNA expression arrays and tiling arrays in various 
organisms. The design of the probe set, which represents each of the genes present in 
Affymetrix slides, allows the researcher to perform highly stringent hybridisation protocols. 
Each probe pair consists of a perfect match (PM) and a mismatch (MM), spotted next to 
each other. The MM probe is exactly similar to PM probe except that it carries a single 
base pair change in the middle of the probe. This PM-MM way of probe design acts as an 
internal control during the hybridisation procedure (Lockhart et al., 1996). The raw data is 
the scanned image of the slide which is normalized for overall brightness then analysed for 
the spot intensity (Illustrated workflow in Figure 3.3). Commercially available software 
such as GeneSpringTM (Agilent) can then be used for various statistical analyses. Use of 
microarrays is well established in tumour cell expression studies (Patsialou et al., 2012; 
Buehler et al., 2013) and in micro genomics (Kurimoto et al, 2006; Hartmann and Klein, 
2006). 
3.1.6.2 Whole transcriptome sequencing 
Recent studies indicate that the complexity of the human transcriptome is higher than 
expected (Kapranove et al., 2007; Sulthan et al., 2007). Along with the mRNA and splice 
variants, large numbers of non coding RNA’s were also identified, with their functions 
largely unknown (Parkhomchuk et al., 2009).   Advent of next generation sequencing 
platforms such as Illumina/Solexa®, Roche 454® and Applied Biosystems SOLiDsystems® 
can generate billions of base pairs of genomic and transcriptomic sequence information in 
days opening up a new way to understand this transcriptional complexity. These 
sequencing platforms have already started to show their utility in cancer and stem cell 
science (Sugarbaker et al., 2008, Cloonan et al., 2008).  Sequencing of the whole 
transcriptome from a single cell made possible recently with the integration of RNA 
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amplification technique (Kurimoto et al., 2007) and SOLiD system sequencing platform 
(Tang et al., 2009), which holds the promise of a new dimension for microgenomics. 
3.1.6.3 Quantitative reverse transcription real time PCR 
Unlike conventional PCR which depends on gel based techniques for product detection, 
real time PCR combines the target amplification and product detection into a single step 
(Higuchi et al, 1993; Heid et al., 1996; Morrison et al., 1998). This real time detection is 
achieved mainly because of the development of different fluorescent dyes (SYBR Green®, 
BEBO®), which can be used to relate the increase in product accumulation and fluorescent 
intensity quantitatively. Quantification is mainly done by the measurement of ‘Ct values’, 
which is the number of cycles required for the fluorescence values of each sample to rise 
above the background fluorescence (Wong and Medrano, 2005). The relationship between 
the copy number and Ct value is inversely proportional, i.e. higher the initial template 
copies, the more products accumulation and therefore more fluorescence resulting in a low 
Ct values. 
Over the recent years, quantitative real time PCR (qRT-PCR) has become the gold 
standard for gene expression studies as a method to screen the expression of a given gene 
across samples or validate microarray result. This is mainly because of its sensitivity, 
reproducibility and wide dynamic range (7 order of magnitude) of quantification in qRT-
PCR (Skrzypski 2007, Stahlberg et al., 2005). There are two ways of quantify the gene 
expression in qRT-PCR: absolute quantification and relative quantification. Absolute 
quantification is done by plotting a linear curve based on the Ct values obtained from a 
serially diluted known quantity of cDNA. Absolute quantity of the unknown samples can 
then be deduced from the standard curve obtained. This method simplifies calculations and 
avoids practical and theoretical problems currently associated with PCR efficiency 
assessment. (Skrzypski, 2007; Bernard and Wittewer, 2002).The comparative threshold 
method (Relative quantification) give the gene expression values as fold change in 
comparison with reference samples or calibrators by assuming the PCR efficiencies of all 
the samples under investigation are the same. (Wong and Medrano, 2005; Skrzypski, 2007)  
Uses of qRT-PCR in cancer gene expression studies are well established.  Lossos et al., 
(2004) used qRT-PCR to validate and identify six predictor marker genes in lymphoma. 
Similar studies in non-small cell lung cancer (Sher et al., 2005) oral cancer (Li et al., 2004) 
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and breast cancers (Bosma et al., 2002) indicate that the future diagnostic value of qRT-
PCR in cancer biology. 
3.1.7 Aim of the study 
This chapter is dedicated to studying the signals and kinetics of TRP-2 and OVA vaccine 
generated pentamer positive T cells using various genomic approaches and also attempts to 
elucidate the transcriptional landscape of these cells using global mRNA profiling. All the 
primary work has been conducted in the TRP-2 model and ovalbumin model has been used 
as an alternative model for the validation of the gene expression signatures identified in the 
first model. The specific T cells against the vaccinated antigens will be isolated using 
multimer technology for improving the quality of starting materials. The main hypotheses 
are addressing in this chapter are. 
1. Is there an inherent difference in basal level of TCR signals which can be detected 
in the ex vivo pentamer sorted cells from ImmunoBody® and peptide immunised 
animals.  
2. ELISpot® plate stimulated cells can be rescued to investigate the TCR signal 
competency between these two groups of cells using qRT-PCR. 
3. A TCR independent signal such as CD3 CD28 stimulations will be used to measure 
the signal competency between these two cell types using real-time quantitative 
PCR 
4. Affymetrix global transcriptomics profiling of high and low avidity T cell will be 
used for the identification of genes differentially expressed between the high and 
low avidity T cells.  
5. If the markers were identified, confirm them with qRT PCR and flow cytometry. 
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3.2 Materials and methods 
3.2.1 Immunisations and generation of high and low avidity T cell response 
All the immunisations were carried out as per the protocol given in section 2.2.2. The 
spleens were harvested from the euthanised animals and splenocytes were prepared as 
described in the section 2.2.3. The cells were counted and diluted at 5x106 cells per mL. 
The cells from each animal were tested for IFN- γ production with peptide titration 
ELIspot assays as described in section 2.2.4. The remaining cells (~2.0 x 108 total 
splenocytes) pooled together from three animals were pelleted by centrifugation at 300g at 
room temperature  and proceeded immediately into CD8 negative isolations using 
magnetic sorting of untouched CD8+ T cells.  
3.2.2 Isolation of CD8+ cells 
Prior to the isolation of peptide specific cytotoxic T lymphocytes, CD8+ cells were 
separated from the total splenocytes to increase the purity of the peptide specific cells. 
Approximately 2 x 108 splenocytes from three pooled immunised mice were used for the 
isolation using CD8+ T cell isolation kit (Miltenyi Biotec GmbH, Germany) which is 
specially designed for the isolation of CD8+ cells by the depletion of non CD8+ cells. The 
total splenocytes were treated with 1 mL of 1x RBC lysing solution (Sigma) and incubated 
at room temperature for 2 min followed by passing through a 30 µm mesh to remove the 
clumps and cell aggregates. The cells were then washed with 20 mL of sterile PBS by 
centrifugation at 300 g for 10 min. The cells were resuspended in 800 µL of MACS buffer 
(PBS + 0.5% (v/v) of bovine serum albumin and 2 mM of EDTA). 160 µL of non CD8+ 
antibody cocktail was added to each pool and incubated in the fridge for 15 min. After the 
incubation a further 600 µL of MAC buffer was added to each tubes followed by 300 µL 
of microbeads. Cells were incubated in the fridge for 15 min and washed with 20ml of ice 
cold MACS buffer (300g for 10 min at 4○C). While tubes were spinning, LS columns 
(Miltenyi Biotec GmbH, Germany) were prepared by assembling them into a magnet and 
added 3 mL of ice cold MACS buffer. The cells were resuspended in 10 mL of cold MACS 
buffer and applied to the above preconditioned columns. The drip through was collected 
which contains untouched CD8+ T cell, the column has been washed further three times 
with 5mL of ice cold buffer for complete recovery. Cells were counted at this stage and 
pelleted by centrifugation at 300 g for 10 min at 4○C. The enrichment purity of magnetic 
sorted cells were assessed using flow cytometry by running a small volume of purified 
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cells with FITC stained CD8+ antibodies (eBioscience). All the purifications were carried 
out at 4○ C to keep the gene expression unchanged. 
3.2.3 Isolation of peptide specific (pentamer positive) cells 
The cells isolated in section 3.2.2 represent the total repertoire of CD8+ cells with multiple 
specificities. Therefore, it was necessary to specifically isolate TRP-2 specific T cell from 
the whole CD8+ T cell population prior to any downstream molecular characterisations. For 
this, a PE (PhycoErythrin) conjugated TRP-2 pentamer (ProImmune) was used for the 
detection and isolation of TRP-2 specific T cells were used. The isolation of pentamer 
specific cells is facilitated by the binding of specific TCR to the corresponding peptide 
present on the MHC molecule. This binding might trigger partial or complete activation of 
TCR signalling pathways. Since the current study mainly focused on identification of a 
well defined phenotypic marker and not an activation marker for high avidity T cells, most 
of the isolation steps were again carried out in cold conditions in the view of minimising 
the activation of TCR signalling pathways and thereby preserving the transcriptional and 
proteomic signatures undisturbed in both high and low avidity T cells.  The CD8+ fraction 
was resuspended in 100 µL of ice cold MACS buffer in a 15 mL falcon tube, 20 µL (2 test 
volumes as per the manufacturer’s guidelines) of MHC class-1 pentamer was added and 
mixed thoroughly by gentle up and down pipetting. The tubes were incubated in the fridge 
for an hour and washed the cells with 1 mL of ice cold PBS by centrifugation at 300 g at 
4○C for 10 min. The cells were resuspended in 100 µL of cold MACS buffer, a fraction (15 
µL) of this cells were removed and kept aside for flow cytometric analysis. Into the 
remaining cell suspension, 20 µL of anti PE microbead (Miltenyi biotech) was added and 
incubated for further 15 min in the fridge. Following the incubation, cells were washed 
with 2 mL of ice cold MACS buffer and 300 g for 10 min at 4○C. While centrifuging, MS 
columns were prepared by adding 500 µL of cold MACS buffer. Once centrifugation was 
finished the cells were resuspended in 500 µL of MACS buffer and applied to the column 
mounted on a magnetic separator. The flow through containing non TRP-2 specific T cells 
were collected, columns were washed further three times with 500 μL of ice cold buffer for 
the complete removal of non specific cells. Finally the columns were removed from the 
magnet and placed on a new labelled 15 mL Falcon tube, magnetically labelled pentamer 
positive cells were flushed out using the plunger and 1mL of cold MACS buffer, the 
flushing was repeated three times with 500 µL of cold buffer and counted the cells. Cells 
were washed three times with ice cold PBS in a 1.5 mL micro-centrifuge tube and snap 
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frozen in liquid nitrogen for further downstream analysis. The overall protocol of isolation 
of CD8+ cells and pentamer positive cells were given in figure 3.4.       
 
Figure 3.4: Schematic representation of isolation of pentamer (multimer) positive TRP-2 (antigen) 
specific cells from the total repertoire of CD8+ cells 
3.2.4 RNA isolation from pentamer sorted cells and cDNA synthesis 
RNA isolation of pentamer positive cells were carried out initially using the cells isolated 
from single immunised mice. However the low number of cells recovered (~40,000 T cells 
from each animal), resulted in low yield of the total RNA and poor quality. To circumvent 
this problem all the RNA extractions were subsequently carried out by pooling three 
immunised animals together from each group as described above, which resulted in a 
threefold increase of pentamer positive cells. Cells were washed once with sterile PBS and 
immediately lysed the cells in lysis buffer containing chaotropic agent guanidinium 
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thiocyanate. The kit used for the isolation of RNA is RNAqueous® micro kit, which 
specialised in the isolation of RNA from very low number of cells (10 – 500,000 cells). 
The rest of the protocol was followed as per the manufacturer’s instructions with minor 
modifications and the final RNA was eluted in 15 µL of elution volume. Three pools from 
each group were named as Immunobody pool-1, Immunobody pool-2, Immunobody pool- 
3, Peptide pool-1, Peptide pool-2, Peptide pool-3 were prepared for further studies. The 
RNA has been isolated from both the models (TRP-2 and ovalbumin) for microarray 
analysis. From the total RNA isolated, a fraction of RNA was used for quantitative real-
time analysis (qRT) to investigate the TCR signalling status in pentamer sorted cells. 
DNAse treatment was performed to completely remove the residual DNA contamination 
prior to any cDNA synthesis.  Initial quantity and quality of the RNA was assessed in 
NanoDrop 8000TM (Thermo). 
 cDNA synthesis was carried out using Superscript III (Invitrogen Life Technologies) 
reverse transcriptase as follows, into a nuclease free microcentrifuge tube 1 µL (200 ng) of 
oligo (dT)15 , 2 µL of RNA (250 ng), 1 µL of dNTP’s (10 mM each) was added and 
adjusted to a final volume of 13µL with sterile nuclease free water. The mixture was 
heated in a thermal block at 65○C for 5 min and immediately chilled on ice for 2 min. 
Tubes were briefly centrifuged at 1000 g for 15 sec and 7 µL of RT enzyme master mix [4 
µL of first strand buffer (5X, Invitrogen) 1 µL of DTT (0.1 M, Invitrogen), 1 µL of 
RNAsin (Promega) and 1 µL of Superscript III (200 U/µL, Invitrogen)] was added. The 
reaction was mixed thoroughly by gentle up and down pipetting and incubated at 50○C for 
1 h in a water bath; the reaction was finally inactivated by incubating at 70○C for 15 min 
and stored at -20 until further use.  
3.2.5 Primer designing, synthesis and optimisation 
Genes involved in the TCR signalling pathway and the coding regions of all the transcript 
variants were downloaded from NCBI nucleic acid database. All the transcript variants 
were aligned and the region common to all the variants was selected as a target for primer 
synthesis. Primer design was carried out with primer 3.0 software (v.4.0, Whitehead 
Institute for Biomedical Research, Massachusetts, USA) (Untergrasser et al., 2011; 
Koressaar & Remm, 2007). All primers were synthesised to amplify a target region of up 
to 200 bp at the maximum in the view of using them in real time quantitative PCR (qRT 
PCR). Once suitable primers were designed they were tested for their ability to form self 
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and hetero dimer and hairpin formations in Integrated DNA technology OligoAnalyzer 3.1. 
Primers which formed the above structures were avoided and the specificity of each primer 
was further verified by NCBI primer BLAST.  All the primers were synthesised from 
Eurofins MWG Operon (Germany) at HPSF grade purity, the list of primers used for the 
present study is given in the table 3.1. 
3.2.6 Optimisation of PCR primer parameters  
All the primers were dissolved at a stock concentration of 100 pmol/µL in nuclease free 
water. A 10 pmol/µL working concentration was used for all the PCR reactions. Prior to 
conduct any real time PCR reactions, all the primers were optimised in a conventional 
gradient PCR (Thermo Scientifics) using cDNA synthesised from the RNA isolated from 
total splenocytes. The specificity of each primer was decided by running the above PCR 
products on 1.7% w/v agarose gel electrophoresis and ensured that only single specific 
bands was present from each reaction or picked the annealing temperature which yielded 
single specific band at the desired size.   
3.2.7 Primer efficiency calculations 
Efficiency of all PCR primers were assessed by running two fold dilution series of cDNA 
template synthesised from total splenocytes RNA. The efficiency of each reaction was 
calculated with manufacturer supplied software (RotorGene-6000). Comparable 
efficiencies of each primer sets were calculated in Microsoft excel by plotting the 
difference in Ct values against the logarithm of the template amount. The amplification 
efficiencies were considered as comparable when the slop of resulting straight line was < 
0.1.  
3.2.8 Gene expression profiling of TRP-2 peptide specific CD8+ T cells using qRT 
PCR 
Real time quantitative PCR was used for studying the gene expression patterns of TCR 
signalling genes in high and low avidity T cells with the template cDNA synthesised from 
pentamer sorted cells. PCR master mix was prepared by mixing 6.7 µL of cyber green, 0.5 
µL of forward primer, 0.5 µL of reverse primer, 4.25 µL of nuclease free water and 0.5 µL 
of cDNA template. Thermal cycling was carried out in a Qiagen Rotor-Gene Q real time 
PCR cycler. Quality of amplification was monitored by plotting the melt curve after each 
primer amplification with the user supplied software. Ct values were determined by setting 
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the threshold values empirically by visual inspection. Data analysis of these genes were 
done with Livak method (Livak and Schmittgen, 2001; Schmittgen and Livak, 2007) and 
independently verified with Pfaffl method (M W Pfaffl et al., 2002) using Relative 
Expression Software Tool (REST 2009, QIAGEN) with efficiencies calculated in Rotor-
Gene software. 
3.2.9 RNA isolation from CD8+ cells from ELISpot derived cells 
This study hypothesised that the gene expression changes in the TCR signalling can be 
measured with the cells after 48 h of stimulation in an ELISpot plate. In routine experiment 
the cells after 48 h of stimulation are discarded prior to developing the plates for respective 
cytokine detection. Instead, these cells were saved and CD8+ cells were isolated for RNA 
extraction. The detailed protocol is for harvesting the cells and further purification and 
isolation of CD8+ T cells and the RNA is given below.  
All the immunisations were carried out as per the section 2.3.1 in chapter 2 and an IFN- γ 
ELISpot assay was set up as per the protocol given in the section of the same chapter. After 
48 h of incubation at 37° C at 5% v/v CO2 the cells were harvested from the triplicate wells 
of the top three concentrations for both the groups by carefully mixing and pipetting out 
the cells (200 µL) without damaging the membrane. All the cells from top three 
concentrations were pooled in to a 15 mL centrifuge. Tube and pelleted down by 
centrifugation at 300 g for 10 min at room temperature. The cells were further resuspended 
in cold MACS buffer and CD8+ T cells were purified with negative isolation kit as per the 
protocol given in the section 3.2.2 and snap frozen the cells in liquid nitrogen. RNA 
isolations were performed in the next day from the frozen pellets as per the protocol given 
in section 3.2.4 and eluted in 10 µL nuclease free water. Quantification of the isolated 
RNA and cDNA was carried out as per section 3.2.4. The quantitative real-time PCR has 
been carried out as per the protocol given in section 3.2.8.   
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Table 3.1. PCR primer sequences used for qRT PCR Studies  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sl. No  Primer name  Sequences 5’-3’ TM 0C 
1 m-LCK-F ATGGAGAACGGGAGCCTAGT 58.0 
 m-LCK-R GGCCGTGTACTCATTGTCCT 58.0 
2 m-FYN-F TGCAAGATTGCTGACTTTGG 58.0 
 m-FYN-R TTGGTGACCAGCTCTGTGAG 58.0 
3 m-ZAP70-F CTGGTATCACAGCAGCCTGA 60.0 
 m-ZAP70-R TTCCCATAGACCAGGGACAG 60.0 
4 m-LAT-F CCCTGTTGTCTCCTCTGCTC 61.0 
 m-LAT-R CTCTGCGCTCTCCTCACTCT 61.0 
5 m-MAPK1-F TCTCCCGCACAAAAATAAGG 58.0 
 m-MAPK1-R GCCAGAGCCTGTTCAACTTC 58.0 
6 m-NFkB-F TCAGACACCTCTGCACTTGG 58.0 
 m-NFkB-R GCAGGCTATTGCTCATCACA 58.0 
7 m-AKT1-F CCCTTCTACAACCAGGACCA 58.0 
 m-AKT1-R ATACACATCCTGCCACACGA 58.0 
8 m-HPRT-F TGCTCGAGATGTCATGAAGG 58.0 
 m-HPRT-R TATGTCCCCCGTTGACTGAT 58.0 
9 m-GAPDH-F AACTTTGGCATTGTGGAAGG 58.0 
 m-GAPDH-R ACACATTGGGGGTAGGAACA 58.0 
10 m-ACTB-F AGCCATGTACGTAGCCATCC 58.0 
 m-ACTB-R CTCTCAGCTGTGGTGGTGAA 58.0 
11 m-TBP-F TGACTCCTGGAATTCCCATC 58.0 
 m-TBP-R TGTGTGGGTTGCTGAGATGT 58.0 
12 m- HRAS-F ATGGCATCCCCTACATTGAA 61.0 
 m-HRAS-R ACAGCACACATTTGCAGCTC 61.0 
13 m-KRAS-F TGCAATGAGGGACCAGTACA 61.0 
 m-KRAS-R TGCTGAGGTCTCAATGAACG 61.0 
14 m-NRAS-F TGGACACAGCTGGACAAGAG 59.0 
 m-NRAS-R CTGTCCTTGTTGGCAAGTCA 59.0 
15 m-RASGRP-1-F TGTCACAGCTCCATCTCCAG 61.0 
 m-RASGRP-1-R TTCACCTTCCCATCTTCCAG 61.0 
16 m- RAF1-F CTACACCCCATGCCTTCACT 61.0 
 m- RAF1-R GCTGAAGGTGAGGCTGATTC 61.0 
17 m- JNK2 -F CGCCACCACCTCAAATTTAT 61.0 
 m- JNK2 -R TGTGCTCAGTGGACATGGAT 61.0 
18 m- VAV1-F CTACGGGATCTGCTGATGGT 59.0 
 m- VAV1-R CTGCCGTAGGGTTTCATTGT 59.0 
19 m-NFAT1-F TCTGCTGTTCTCATGGATGC 59.0 
 m-NFAT1-R TCCTCTCCTCCTGCTCAGAT 59.0 
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3.2.10 CD3, CD28 stimulation of pentamer positive cells for studying signal 
competency 
This experiment was designed to identify the differences between high and low avidity T 
cells in response to a uniform peptide independent signal given to them. Antibodies against 
CD3 of TCR-CD3 complex and the co-receptor CD28 were known to be used for the 
stimulation and culturing of T cells by giving them pseudo-stimulation. The hypothesis for 
this experiment was that if there is an inherent difference between these two functionally 
different cell types, they transmit the signals differentially if given a uniform signals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: 3.5. Schematic representation of experimental procedure followed for anti-CD3, 
anti-CD28 stimulation studies 
All the immunisations were carried out as normal; the details of immunisations were given 
in figure 3.5. A total of nine animals were immunised in each group. Three animals were 
pooled together creating three pools of immunised animals and three for peptide 
immunised animals. The pooling strategy has been employed to obtain enough number of 
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pentamer positive TRP-2 specific cells. Total CD8+ cells were sorted using magnetic 
sorting using Miltenyi negative isolation kit from each pool using a large format column 
(LS columns) as per the protocol given in the section 3.2.2. Once the CD8+ cells were 
sorted they were stained with TRP-2 pentamer (20 µL per pool) and were sorted as per the 
protocol given in the section 3.2.2. The sorted cells were used for the stimulation kinetic 
studies with CD3, CD28 coated micro beads (Miltenyi Biotec, GmbH) in 1:1 ratio. The 
cells were harvested three time points of stimulation at 0, 1 and 2 h in to a micro centrifuge 
tube (Fig 3.5). The beads were removed immediately following the harvest using a magnet 
and centrifuged at 1500g at 4○C. The supernatant was removed from the centrifuge tubes 
immediately and snap frozen using the liquid nitrogen for RNA isolation. Once all the time 
points were harvested as mentioned, RNA isolations were carried out using Ambion 
RNAaqueous micro kit. The isolated RNA was quantified, equalised by diluting everything 
to the lowest concentration using nuclease free water and reverse transcribed as per the 
protocol given in the section 3.2.4. qPCR has been carried out as per the section and the 
fold change has been calculated as per ∆∆CT method.  
3.2.11 Gene expression studies using Affymetrix cDNA micro arrays of TRP-2 and 
OVA pentamer sorted cells 
mRNA isolated in step 3 was used for large scale gene expression studies using Affymetrix 
array platform. The experiment was carried out externally at NASC arrays (The University 
of Nottingham, UK). Briefly, the protocol followed for the array data generation is as 
follows.  Quality checking had been carried out using Agilent Bioanalyzer and RNA6000 ® 
nano kits. The biotin labelling of this products was performed using Whole Transcript 
Sense Target Labelling from Affymetrix® (Santa Clara, CA) with 16 h incubation. The 
labelled RNAs were checked for their quality using Agilent Bioanalyzer®, fragmented and 
hybridised to Affymetrix Gene Chip Mouse Gene 1.0 ST Arrays (Figure 3.6). The arrays 
were scanned after hybridisation and washing and the .CEL files were generated. These 
files were used for further analysis.   
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Figure. 3.6. Schematic representation of probe design of GeneChip® Mouse Gene 1.0 ST Array 
used for this study. A total of 28,853 genes are present on the array with each gene represented by 
unique 25 base pair probes spreading across the full length of the gene. Red boxes represent Exons 
of single gene with introgenic regions represented by solid lines. Short solid lines under each red 
boxes represented individual probes (the number of probes are arbitrary in the diagram for 
illustration purpose and it may vary between the genes). The expression of single gene is the 
cumulative signal values obtained from all the probe sets of a gene after hybridisation.   
3.2.12 Microarray data analysis  
The Affymetrix CEL file contained intensity values derived from the raw image (.dat) file 
calculated for each probe on the chip after hybridisation. It was necessary to summarise 
and transform all the probe set IDs in to genes and perform normalisation using suitable 
algorithms available. Two type approaches were used for data analysis, first CEL files 
were imported in to GeneSpring-GX11 microarray data analysis software and the samples 
were normalised with RMA (Robust multichip analysis) and Baseline Transformation to 
Median of all Samples. An experimental group was created with Immunobody as one and 
peptide as a second group. Fold change was calculated with a cut-off value ≥ 2 and p value 
≤ 0.05. In the second approach analysis were performed with regression based method, 
which calculated the residuals and the standard residuals and the genes were ranked based 
on their expression values. P values for each gene were calculated with multiple testing 
correction using Boneferroni correction method to minimise the false discovery rate 
(FDR). All the array data were assessed for their quality before analysis using Affymetrix 
Expression console software®. All the spiking controls were tested and the correlations of 
arrays across the experiments were compared with Pearson correlation for its linear 
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dependence. The reported differential expression in this study was from the regression 
based approach since the differences between the two cells types were minimum regression 
allowed to look for the most and least differentially expressed genes. 
3.2.13 Proteomic confirmation of two markers identified by transcriptome profiling 
using antibodies and flow cytometry 
Two of the markers identified by gene expression profiling and confirmed with qRT PCR 
are granzyme A and B. These genes were upregulated in the ImmunoBody® high avidity 
group significantly. The proteomics confirmation of these markers was carried out with 
flow cytometry and intracellular staining. The workflow followed for the confirmation is 
given in figure 3.7. Briefly, 6-8 weeks old C57BL6 female mouse were immunised with 
TRP-2 ImmunoBody® and peptide for the generation of high and low avidity T cell 
response. Three animals were used in each group and immunisation regime followed was 
as described earlier in the second chapter (section 2.2.2).  
 
 
  
    
 
 
 
 
 
 
 
 
Figure 3.7: Workflow showing the protocol followed for the Proteomic confirmation of 
two markers identified by transcriptome profiling using antibodies and flow cytometry. 
 
Fig 4.7.  Work flow showing the protocol followed for the Proteomic confirmation of 
two markers identified by transcriptome profiling using antibodies and flow cytometry
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Animals were terminated by cervical dislocation and splenocytes were harvested from each 
animal separately. 5 X 106 total splenocytes were seeded on to the wells of a 24 well plate 
in triplicate for each animal. Cells were incubated with 0.01 μg of TRP2 peptide per well 
of the plate (at a concentration of 0.005 μg/mL of the media) for 3 h at 37○C at 5% v/v CO2. 
After 3 h protein transport is blocked by adding 10 μg/mL of brefeldin A (Sigma), and 
mixed each well by gentle up and down pipetting. Cells were further incubated overnight 
(~ 16 h). The next day the plate was taken into a sterile hood and the cells were harvested 
using a 1000 mL pipette tip with gentle pipetting procedures. Intracellular cytokine 
staining was carried out with IntraPrep® Permeabilisation Reagent (Beckman Coulter) 
according to manufactures instruction. The stained cells were analysed immediately in a 
Gallios multicolour flow cytometer. Percp (Peridinin chlorophyll) conjugated Granzyme A 
(Santha Cruz, Biotechnology, Germany) and Alexa Fluor conjugated Granzyme B 
(Biolegand, UK) antibodies were used for the staining of the cells with anti CD3 and CD8 
antibodies. Granzyme B has been used at 5 μL/106 cells and Granzyme A has been used at 
1 μg/106 cells. 
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 Results 
3.3.1 RNA Isolation from pentamer positive cells  
Initial RNA isolations were carried out using the pentamer positive cells isolated from 
single mouse. The number of cells obtained from one immunised mice were in the region 
of 30-40K. The initial quality assessment (QC) was carried out using NanoDrop 8000® and 
found to be good quality, however subsequent analysis using the Agilent Bioanalyser 
showed considerable degradation of the isolated mRNA. Increasing the cell number from 
30K to 100K by pooling three immunised mice yielded good results both in NanoDrop and 
Agilent Bioanalyser®. The representative results are given in Figure 3.8.   
 
Figure 3.8: Agilent bioanalyzer results of RNA isolated from the pentamer sorted cells. A. RNA 
extracted from cells sorted from single mice (~ 3x104cells) showing the degradation of RNA with 
no distinct 18S and 28S RNA peaks. B. RNA isolated from pentamer positive cells purified from 
three animals pooled together (≥ 10x104cells). Both 18S and 28S RNA peaks are clearly visible and 
no sign of degradation is visible. 
Fig. 3.3.1. Agilent bioanalyzer results of RNA isolated from the penamer sorted cells. A.
Showing the results of RNA extracted from cells sorted from single mice (~ 30K cells)
showing the degradation f RNA with no distin t 18 and 28S RNA. B. RNA isolated
from cells isolated from thre animals pooled together (≥ 100K cells). Both 18s and 28S
RNA peaks are clearly visible and no sign of degradation is visible.
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3.3.2 Gene expression studies of TCR signalling pathways in pentamer sorted peptide 
specific cells using quantitative real time PCR 
RNA was isolated from TRP-2 model system and was used for the gene expression studies 
Initial studies were conducted with the genes involved in the TCR signalling pathway to 
interrogate any possible alterations during the cell sorting using TRP-2 class 1 pentamer 
which bind to the TCR. Replicate Ct values generated with each primer pairs with an 
arbitrary allocated threshold by visual inspection. The expression values were normalised 
to the expression of housekeeping genes. Relative expression is calculated using Livak 
method and no significant differences in TCR signalling pathways were detected between 
high avidity (ImmunoBody®) and low avidity group (n=3, P ≥ 0.05) Figure 3.9. 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Expression of genes involved in the TCR signalling pathways in pentamer positive cells 
isolated from Immunobody and peptide immunised animals. The result is the representation of qRT 
PCR data of three independently TRP-2 ImmunoBody® (IM) and peptide (PEP) immunised 
animals and each bar represents the mean ± SEM. 
 
Fig. 3.3.2. Expressio f genes involved in the TCR signalling pathways in
pentamer positive cells isolated from Im unobody and peptide immunised
animals. The result is the representation of qRT PCR data of three independently
TRP-2 ImmunoBody(IM) and peptide (PEP) immunised animals and each bar
represents the mean  SEM.
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3.3.3 Gene expression studies of TCR signalling pathways in ELISpot plate derived 
CD8+ cells using quantitative real time PCR 
Gene expression profiling of ELIspot plate stimulated cells using selected genes involved 
in the TCR signalling pathway did not reveal any significant differences between the 
stimulated groups studied (n=3, P ≥ 0.05). However a significant up-regulation of VAV 
has been noticed in stimulated peptide immunisations in comparison to its unstimulated 
control (Figure 3.10).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: qRT PCR results showing the relative expression of selected genes in CD8+ 
cells obtained from ELISpot plate after 48 h of stimulation. The groups were the cells 
obtained from ImmunoBody® (IM) and peptide immunisation (Pep) of which IM and Pep 
are cells derived after the peptide stimulation and IM Ctrl and Pep Ctrl are the cells without 
peptide stimulations. Significance were calculated with one way ANOVA with Bonferroni 
post-test. The results are the representation of three independently immunised mice in each 
group and the bars represent Mean ± SEM. 
 
Fig.3.3.3. qRT PCR results showing the relative expression of selected genes in CD8+ cells
obtained from EliSpot plate after 48 hrs of stimulation. The groups were the cells obtained
from Immunobody (IM) and peptide immunisation (Pep) of which IM and Pep are cells
derived after the peptide stimulation and IM Ctrl and Pep Ctrl are the cells without peptide
stimulations. Significance were calculated with one way ANOVA with bonferroni post test.
The results are the representation of three independently immunised mice in each group and
the bars represent Mean  SEM.
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3.3.4 Gene expression kinetic studies of TCR signalling pathway genes on TRP2 
pentamer positive peptide specific cells 
To investigate the signal competency between the high and low avidity T cells, this study 
used isolated TRP-2 specific pentamer positive CD8+ T cells from the Immunobody and 
peptide immunised animals. These cells were subsequently stimulated with anti CD28, 
CD3 coated microbeads as described in the section 3.2.9. A total of 12 genes (VAV, RGRP, 
RAF, NRAS NF-κB, FYN, NFAT, MAPK14, MAPK1, LAT, JNK and ERK) were studied 
for its expression after three time point of stimulation in triplicates. Among all the above 
genes studied there is no significant differences in the expression were noticed with FYN 
(F (5, 12) =0.7727, p=0.5874) and LAT (F (5, 12) = 1.197, p=0.3673) in both high and low avidity 
groups. However the rest of the genes were significantly differentially regulated between 
the groups studied: the result of one way ANOVA are,  NFAT (F (5,12) = 18.21, p ≤ 0.0001), 
MAPK1 (F (5,12) = 29.45, p ≤ 0.001), MAPK14  (F (5,12) = 63.37, p ≤ 0.001) ERK (F (5,12) = 
14.40, p ≤ 0.0001), RAF (F (5,12) = 17.74, p ≤ 0.0001) RGRP (F (5,12) = 33.16, p ≤ 0.001), RAS (F 
(5,12) = 8.357, p ≤ 0.0013), NF-κB (F (5,12) = 11.74, p =0.0047), VAV (F (5,12) = 16.08, p=0.002), 
JNK2 (F(5,12)=15.86, p=0.001) [Gene name(F (df between the group, df within the group)=F 
value, ANOVA p value] (n=3).  
The overall results indicated that there was a considerable increase in the expression of 10 
out of nine genes studied in ImmunoBody® group compared to the peptide counterpart 
(Figure 3.11, 3.12, 3.13) after 2hours of stimulation. Even though there was an increasing 
trend in these genes in the peptide group they were not found to be statistically significant  
with the analysis performed. The results of all pair wise comparisons are given in table. 3.2. 
 NS- Not Significant, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001 
Table 3.2. Summary of significant differences observed within each group. The significance were calculated by 
comparing 1h and 2h stimulations to its control 0h 
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Figure 3.11: qRT PCR results showing the relative expression of selected genes in TRP-2pentamer +ve cells isolated from both ImmunoBody® and peptide immunisations. 
The cells isolated from each group subjected to a brief time course stimulation measuring their signal competency. The most relevant differences are marked with in each 
graph. The results are the representation of three independently immunised mice in each group and the bars represent Mean ± SEM.
Figure 3.10. qRT PCR results showing the relative expression of selected genes in TRP-2 pentamer +ve cells isolated from both
Immunobody and peptide immunisations. The cells isolated from each group subjected to a brief time course stimulation measuring their
signal competency. The most relevant differences are marked with in ech graph. The results are the representation of three independently
immunised mice in each group and the bars represent Mean  SEM.
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Figure 3.12: Heat map showing the expression pattern of the genes studied using qRT PCR. The colour gradient is between blue to red with yellow 
in the middle. The name of the genes are given on the right hand side of the heat map in the rows and the samples are given on the top. 
 
VAV
RGRP
RAF
RAS
NfkB
FYN
NFAT
MAPK14
MAPK1
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Peptide group ImmunoBody® group
Figure 3.11 Heat ap showing the expression pattern of the genes studied using qRT PCR. The colour gradient is 
between blue to red with yellow in the middle. The name of the genes are given on the right hand side of the heat map in 
the raws and the samples are given on the top 
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Figure 3.13: Major up regulated pathways in the kinetic gene expression study of murine TCR signalling. Signals involving the highlighted regions are highly up-regulated 
in the ImmunoBody® group after 2 h of stimulation using anti CD3, CD28 beads. Pathway courtesy: KEGG pathways. 
Figure 3.12: Major up regulated pathways in the kinetic gene expression study of murine TCR signalling. signals 
involving the highlighted regions are highly up-regulated in the Immunobody group after 2 h of stimulation using anti 
CD3, CD28 beads. Pathway courtesy: KEGG pathways 
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3.3.5 Gene expression profiling of high and low avidity peptide specific CD8+ T cells 
with Affymetrix® gene arrays 
Global gene expression profiling was carried out on pentamer sorted peptide specific CD8+ 
T cells using Affymetrix® high density oligonucleotide microarrays to identify the most 
differentially expressed genes between high and low avidity T cells. The cells were first 
CD8 sorted using the negative isolation kits followed by the isolation of peptide specific 
cells using magnetic beads. The protocol, used for the isolations were given in section 
3.2.2 and carried out at 4° C to minimise the change in expression while the isolation was 
taking place. The first isolations were carried out using the TRP-2 model and the RNA has 
been subjected to both NanoDrop and Agilent Bioanalyser quality checking. The RNA 
quantity determined with NanoDrop 8000®, was in the range of 2.2 – 3.5 µg from each 
pool and 1µg of total RNA has been used for the array labelling and hybridisations. The 
Agilent Bioanalyser results were similar and the RNA integrity number was found to be 
above 8.0 with good 18s to 28s ratios in all the samples and therefore suitable for a reliable 
array experiment. 
Two model systems were used in the gene expression profiling of high and low avidity T 
cells. The first model is the well characterised TRP-2 model to identify the differential 
gene expression between the groups and a second model, the ova (SIINFEKL) was used 
for validating the differentially expressed genes identified in the TRP-2 model. The array 
quality controls were performed in Affymetrix Expression console software. 
Good correlations were observed between the arrays studied suggested by good Pearson 
correlations between all pair-wise comparisons (between 0.97-0.99). These correlations 
were calculated with the raw signal values of 28,000 genes and other transcripts and 
therefore justify a regression based analysis for identifying differentially expressed genes. 
The Pearson correlations of individual chips compared in a pairwise manner are given in 
Figure 3.14. 
The data analysis was performed in the Microsoft excel with linear regression. Individual 
TRP-2 Immunobody RNA hybridised arrays were regressed on the Individual TRP-2 
peptide RNA hybridised arrays with residuals and standard residuals (SR) generated 
subsequently. The average of SR of independent residuals was taken and reordered in the 
entire matrix in a descending order and thereby generated the most differentially expressed 
genes between the two groups studied. Similar procedures were followed with the ova 
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model and analysed independently. The genes which have a differential expression and the 
Bonferroni multiple testing correction p value 0.01 or less were considered as significantly 
differentially expressed. The complete list of the genes was given in appendix.           
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Reproducibility of arrays as showed by the correlation of 28,000 genes studied 
between high and low avidity T cells. A. Pair wise comparison of the expression value of these 
genes are expressed as Pearson correlation (PC) of the raw signal values between the array data. A. 
PC of TRP-2 array data. B. Correlation of OVA array data. The colour legend (marked by arrows) 
indicating the degree of PC calculated between each of the pair wise comparisons. The colour 
indicate extend of correlations between the samples (Refer to the colour legend for further 
information). 
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The genes were ranked based on their differential expression and the ones which fell above 
the multiple testing p value criteria (P ≤ 0.01) were separated out from the main matrix in 
both the models. 338 genes were fulfilled these criteria in TRP-2 model after removing the 
noncoding transcripts and other internal control probes from the top rank ordered probes. 
Similarly, 239 genes were shortlisted in the ovalbumin model which showed significant up 
or down regulation between the groups.  
3.3.6 Differential gene expression in TRP-2 specific high and low avidity T cells 
The first array data for this study were generated with TRP-2 specific pentamer positive 
cells isolated from ImmunoBody® and peptide immunised animals. The complete list of 
the genes based on the rank order is given in the appendix.  The major candidate genes up 
regulated in the ImmunoBody® group was identified with this study were Granzyme A 
(7.8), CD5 antigen-like (fold change: 6.02), Spi-C transcription factor (5.39), AXL 
receptor tyrosine kinase (5.1), EGF-like module containing, mucin-like, hormone receptor-
like sequence 1 (fold change: 5.2), Fas apoptotic inhibitory molecule 3 (4.6), CD38 antigen  
(3.4), Granzyme B (3.4), Telomerase RNA component  (3.58). Major down regulated 
genes in ImmunoBody group includes CD28 receptor (-3.07) (Regression standard residual 
distances are given in the bracket). The major differentially expressed genes which were 
ontologically relevant to the study are given in Figure. 3.15. 
3.3.7 Differential gene expression in OVA specific high and low avidity T cells 
Among the differentially expressed genes in ova model, the major up-regulated genes in 
high avidity group were cytotoxic effector molecules granzyme A (2.5), granzyme B (3.3), 
a GDP exchange factor Dennd2d (3.07), a cell cycle regulatory protein Cdk5rap1 (2.94), 
the down regulated ones included CD38 (- 2.2), LY6A (- 4.4), Cyclin A2 (-4.2), FOSB (-
3.8) and Derlin 3 (-3.3). Although the data indicated considerable difference between the 
groups the magnitude of differences were not as high as the differences seen in the TRP-2 
model. For the complete list of the genes refer the appendix. Genes were further 
hierarchical clustered in gene pattern software and the heat maps were generated using the 
visualisation module in the same software is given in Figure 3.16. 
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Figure 3.15: Heat map showing differentially expressed genes between TRP-2 high and low avidity 
peptide specific cells. The functionally important genes are highlighted. The colour code for the 
expression is given in the figure. Top panel represent the up-regulated in ImmunoBody® group and 
the bottom panel represent down regulated genes.  
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Fig. 3.3.8 Heat map showing differentially expressed genes between TRP-2 high and
low avidity peptide specific cells. The functionally important genes are highlighted The
colour code for the expression is given in the figure. Top panel represent the up-
regulated in immunobody group and the bottom panel represent down regulated genes.
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Figure 3.16: Heat map of genes differentially expressed between high and low avidity groups of 
OVA model. Functionally important and highly different genes are highlighted with its relative 
position in the main picture. The legend for colour code is also given with the picture (red the 
minimum value and green is the maximum expression). The top panel indicates the up regulated 
genes in the ova ImmunoBody® high avidity group and the bottom panel is the down regulated 
genes in the same group. 
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Fig.3.3.9. Heat map of genes differentially expressed between high and low
avidity groups of OVA model. Functionally important and highly different genes
are highlighted with its r lat v position in th main picture. The legen for
colour code is also given with the picture (red the minimum value and green i
the maximum expression). The top panel indicates the up regulated genes in the
ova ImmunoBody high avidity group and the bottom panel is the down regulated
genes in the same group.
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3.3.8 Common genes showed differential expression between TRP and OVA model 
The next question was whether any of these differentially expressed genes were shared 
between the two model systems (TRP-2 and OVA. A Venn diagram was created to 
highlight the genes which had a similar expression pattern between the 2 models and also 
the genes uniquely expressed in each model. 305 genes were uniquely associated with the 
TRP-2 model and 205 for the OVA model. However 33 genes were shared between the 
two models studied and these genes were taken for further characterisations (Figure 3.16). 
 
 
 
 
 
 
Figure 3.17: Venn diagram showing the number of genes which showed unique and shared 
expression patterns between the two models studied. The black area represents the number of genes 
having a unique expression changes in the TRP-2 model and the pink shaded area is the same for 
the OVA model system. The region overlapping with the brown shade representing total number of 
genes uniquely having an expression changes in both the models.  
The expression of these genes were then further visualised in Gene Patterns (Broad 
institute) and the expression values were plotted as a heat map in the visualisation module 
of the same software. The expression pattern of these genes was given in Figure.3.18.  
3.3.9 Real-time qPCR confirmation of shortlisted candidate genes  
Even though the two model systems (TRP-2 and OVA specific high and low avidity T 
cells) differentiated the high and low avidity T cells only 33 genes were commonly found 
between the two models. Further literature curation of these along with the most 
differentially expressed genes but only present in one of the model (TRP-2 model) has also 
been short listed for the validation. Along with statistical relevance and rank order of these 
genes functional associations were also looked into before shortlisting the final list for 
PCR confirmation. The gene expression analysis result of these genes in the RNA of TRP2 
pentamer sorted T cells are given in Figure. 3.19.  
TRP-2 Model OVA Model 
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Figure 3.18: The expression pattern of 33 differentially expressed genes found common in 
both the models. A. TRP-2 model, B. Ovalbumin model. The red colour indicates over 
expression and the blue colour expressed the under expression.  
 
A B
Fig. 3.3.11. the expression pattern of 33 differentially expressed genes found common in
both the models. A. TRP-2 model, B. Ovalbumin model. The red colour indicates over
expression an the blue colour expressed the under expression. Colour leg nd als given for
the r lative indication of the expression of these genes.
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Figure 3.19: qRT PCR confirmation of the shortlisted candidate genes. The dark box represent the 
expression of Each genes in ImmunoBody® derived (High avidity) pentamer positive cells and the 
light box represent the expression of each gene in peptide derived (Low avidity) pentamer sorted 
cells. The data is a representation of three immunised animals in each group, the y-axis represent 
the normalised CT values with house keeping gene (HPRT). The relative expression is represented 
as 2- ΔΔCT with the mean and SEM. Significance were calculated between the group using student 
t-test and indicated wherever is significant as asterisk. (* = p ≤ 0.05, ** = p ≤ 0.01)  
  A. GranzymeA(GZMA), B. GranzymeA(GZMB), C. FAS apoptotic inhibitory molecule (FAIM), 
D. CD5 antigen like (CD5L), E. SPI-C transcription factor (SPIC), F . Telomerase RNA 
component (TERC). 
 
 
Fig. 3.3.12 Realtime quantitative PCR confirmation of few of the shortlisted
candidate genes. The dark box represent the expression of each genes in Immunodody
derived (High avidity) pentamer positive cells and the light box represent the
expression of each genes in peptide derived (Low avidity) pentamer sorted cells. The
data is a representation of three independently immunised animals in each group and
the y-axis represent the normalised CT values with the house keeping gene. The
relative expression is represented as 2^-ΔCT with the mean and SEM, significance
were calculated between the groups using student t – test and indicated wherever is
significant using star.
A. Granzyme A(GZMA), B. Granzyme B (GZMB), C. Fas Apoptotic Inhibitory
Molecule FAI ), D. CD5 Antigen-Like (CD5L), E. S i-C Transcription Factor
(SPIC), F. Telomerase RNA Component (TERC)
A B
C D
E F
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3.3.10 Proteomic confirmation of two markers identified using gene expression 
profiling using flow cytometry 
The gene expression studies using Affymetrix oligonucleotide arrays in the previous 
chapter have shortlisted genes which were differentially expressed between high and low 
avidity T cell responses in two models and further confirmed by real time quantitative PCR. 
Among all the genes two genes- granzyme A and B (Gzma & Gzmb) showed a significant 
up regulation in the ImmunoBody® group. These observations were further confirmed 
using flow cytometry in TRP2 model systems with ImmunoBody® group giving a 
significantly higher number of Gzma+  Gzmb+ cells (Figures 3.20, 21 and 22) in low CD8 
expressing cells (presumably antigen experienced cells). The expression of these cells were 
completely absent or low in CD8high cells (antigen in experienced cells) (Figure 3.21 and 
22). The gating strategy and the complete data is given in Figure 3.21 and 3.22.  
 
Figure 3.20: Expression of granzyme A and B on TRP-2 ImmunoBody® (IM) and peptide (Pep) 
immunised animals. All the immunisations were done as standard protocol given in chapter 2. The 
cells were given a brief stimulation with the cognate peptide and the expressions of both the 
proteins were measured using intracellular cytokine staining. A. % of Gzma+ Gzmb+ positive cells 
on CD8 low gate. B. % of Gzma+ Gzmb+ positive cells on CD8 high gate. Each bar represents the 
mean of three mice independently immunised and analysed. The error bar represents SEM and the 
significance were calculated between the group using a student t test (n=3). 
A B
Fig. 4.11. Expression of granzyme A and B on TRP-2 Immunobody® (IM) and
peptide (Pep) immunised animals. All the immunisatio s were done as stan ard
protocol given in chapter 2. The cells were given a brief stimulation with the
cognate peptide and the expressions of both the proteins were measured using
intracellular cytokine staining. A. % of Gzma+ Gzmb+ positive cells on CD8 low
gate B. % of Gzma+ Gzmb+ positive cells on CD8 high gate. Each bar represent
the mean of three mice independently immunised and analysed. The error bar
represents SEM and the significance were calculated between the group using a
student t test.
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Fig.4.12. Figure showing the staining of Gzmb and Gzma gated on CD3+, CD8 low (A) and CD3+CD8 Hi  cells isolated from 
Immunobody® immunised animals  
A B
Figure 3.21: Figure showing the staining of Gzmb and Gzma gated on CD3+, CD8 low (A) and CD3+CD8 hi cells isolated from ImmunoBody® 
immunised animals. 
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Fig. 4.13.  Figure showing the staining of Gzmb and Gzma gated on CD3+, CD8 low (A) and CD3+CD8 Hi  cells isolated 
from peptide immunised animals  
Figure 3.22: Figure showing the staining of Gzmb and Gzma gated on CD3+, CD8 low (A) and CD3+CD8 Hi cells isolated from peptide immunised 
animals. 
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3.4 Discussion 
3.4.1 Pooling strategies are necessary for obtaining sufficient number of pentamer 
positive cells for quality RNA isolations 
Isolation of specific CTLs generated using the vaccination is important in their 
characterisation using any downstream approaches. The early observations of vaccine 
generated T cells were carried out either with the pool of cells either derived from PBMC 
in clinical samples or from the total splenocytes for the preclinical models. This 
approaches mainly draws the conclusions from comparison of the stimulated and non-
stimulated cells with their cognate peptides using the whole pool of cells. However, the 
picture often gets clear if the CTLs are purified from the total pool either by magnetic 
separation or by flow cytometry based cell sorting methods.  
The development of multimer technology which enabled many of the immunologists to 
specifically detect the CTLs with desired specificity has allowed to go further and isolate 
the specific subpopulation of T cells from the total CD8 compartment. However, in 
majority of cases the frequency of specific CTLs remains small in comparison to the whole 
immune compartment of all the innate and adaptive immune cells. So detecting and 
purifying these cells from such a large and heterogeneous population is still a challenge.  
To circumvent the problem of purifying specific CTLs this study made use of a two-step 
strategy using the total splenocyte of immunised animals. First, CD8+ populations were 
separated out from the total splenocytes population of a single mouse using magnetic beads 
using a separation kit which can separate everything but the CD8+ T cells. This procedure 
helped in such a way that no antibody was bound to the CTLs during the separation time. 
Therefore the CTLs were untouched and minimum changes were imposed on their gene 
expression patterns. Once the CD8+ cells were isolated, the pentamer molecules were used 
to bind the specific cells and hence specifically tag the peptide specific CTLs from the total 
enriched population of CD8+ cells. These cells were subsequently isolated using magnetic 
separation and lysed immediately for further RNA isolations.   
Initially the isolation of peptide specific cells were carried out using the splenocytes 
obtained from a single mouse. A total of 25-35K cells were isolated in this way and 
immediately preceded for the RNA isolation using a kit specialized for the handling small 
number of cells. However our experience found that the quantity and the quality of RNA 
was inferior at every occasion when only single animal was used for CTL purification. The 
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outcome of this result lead to the decision of pooling multiple animals together for 
isolating the CD8+ cells first. The pooling strategy has been done with pooling the total 
splenocytes from three independently immunised animals together creating three pools of 
three animals in each group (ImmunoBody® and peptide immunised). Total RNA was 
isolated from pentamer positive cells and this strategy increased the number of pentamer 
positive cells to more than 100K and yielded good quality RNA. One of the potential 
problems in the pooling strategy is the uncertainty of functional property information of 
CTLs. So all the animals were treated separately and an ex vivo IFN-γ ELISpot  was 
performed simultaneously. This helped for the confirmation of the animals used for the 
pooling were high or low avidity.  
Any animal showed unanticipated ELISpot results was discounted from the final study and 
the pool in which the respective animal belongs was also not considered for further 
molecular characterisation. Similar strategy has been followed for the isolation of OVA 
specific CTLs and the quality of RNA was analysed with the Agilent Bioanalyser®.  
The low number of peptide specific CD8+ T cells added difficulties to the project. One 
possible alternative is to isolate CD8+ T cells from TCR transgenic mice where all T cells 
expresses same peptide specific TCR. These cells can be adoptively transferred into a wild 
type C57Bl6/J mice and the vaccine response can be studied with more number of vaccine 
specific precursor population of cells. However this fixed TCR responses may not 
represent the in vivo response happening in a natural setting where the vaccine specific 
repertoire selection and further functional fine-tuning are happening within a highly 
diverse CD8 repertoire. So this study aimed to keep to the natural setting as close as 
possible to draw the conclusions on a vaccine generated T cells and therefore pooling 
strategy has been considered as the best method to increase the cell number for further 
downstream processing.  
3.4.2 TCR signalling gene expression studies did not detected any differences between 
high and low avidity ex vivo pentamer sorted T cells or ELISpot plate stimulated cells 
Delayed response against DNA vaccines compared to the protein or peptide vaccine have 
been reported (Hassett, et al., 2000) in viral models. This might be due to the time taken by 
the APCs to take up the naked DNA and subsequent migration to the lymph nodes before 
they start producing the antigen for processing and presentation to the T cells. The 
delivered antigen unlike peptide, once incorporated in to APCs can act as a continuous 
  
145 
 
production unit of target antigen (Corr et al., 1996). Whereas the peptide vaccines are 
limited by their half-life at the site of injection due to various other mechanisms as 
discussed in the introduction. 
If the DNA vaccines can persist in the system for longer period of time than the peptide 
vaccines and act as a vaccine depot we hypothesised that the TCR signalling differences 
would be detected in ex vivo isolated CTLs and therefore the ImmunoBody® immunised 
cells will be in a more activated state than their peptide counterpart and hence the residual 
TCR signalling differences would also be detected. We tested this hypothesis by ex vivo 
RNA profiling of pentamer sorted high and low avidity TRP-2 specific cells for their TCR 
signal status. The profiling using 15 genes involved in this pathway did not showed any 
signal differences. This indicated that majority of vaccine generated cells were in a resting 
stage at the time of their isolation. This study was conducted with the cells isolated from 
ImmunoBody® and peptide immunised animals with a primary and two booster 
immunisations a week apart with the cells isolated seven days after the final immunisation.  
Mempel et al., (2004), have demonstrated that the activation and the proliferation of T 
cells are a three step process using adoptively transferred T cells and multiphoton imaging.  
They have calculated the dendritic cells and T cell dwelling time for the initial recognition, 
homing, activation and clonal proliferation. Within the eight hour of adoptive transfer the 
T cells homed onto the antigen bearing dendritic cells and subsequently established a 
mature synapse. At 20hrs much of the T cells started to produce IFN-γ and IL-2, 1 day 
after the initial encounter these cells were detached from the DCs and clonally proliferated 
many times. This experiment approximated the kinetics of T cell activation and kinetics in 
an antigen dependent manner.  
If the kinetics of activation and proliferation nearly follow the above path in this study 
most of the cells were assessed for their residual TCR signal differences might be either in 
the clonal proliferation or resting stage after antigen encounter. This might be the probable 
reason why no differences could detected in the TCR signalling pathways of ex vivo 
isolated cells. However, this expression values were used as a baseline for further 
activation kinetic studies which will be discussed in the later sections.  
In vitro activation with the cognate peptide is an efficient way to study the signal 
competency between the high and low avidity T cells. With this in mind we have harvested 
the stimulated cells from ELISpot plate after 48 h of stimulation with two concentrations of 
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the peptides. CD8+ cells were subsequently sorted from these stimulated cells and TCR 
status was assessed between the high and low avidity T cells. Again no gross differential 
regulation of any genes were detected except VAV, which was upregulated significantly in 
the control group. The window used for this experiment did not capture any of the signal 
differences, it is possibly the cells are exhausted with long stimulation (48 h) in the culture 
plate and attained a transcriptional homeostasis. These two studies indicated the 
importance of studying the gene expression kinetics in a time course manner with a shorter 
antigen exposure time prior to mRNA extraction and expression profiling. 
3.4.3 Gene expression kinetics studies using anti CD3, CD28 magnetic beads revealed 
different signal competency between high and low avidity T cells 
It is widely accepted that the way in which a naive T cells received their first stimulus has 
an impact on their subsequent activation by antigen encounter. This study used two 
radically different vaccination strategies (DNA and soluble peptide) for the delivery of a 
melanoma differentiation antigenic peptide (TRP-2) into the mouse. Presumably these two 
vaccine frameworks encountered the naive T cell repertoire in a different way and 
therefore they might be primed differently. If so, we hypothesised that the signal 
competency of these cells also going to be different if a TCR independent signal was 
delivered. Otherwise the signalling components of high avidity T cells are in a better 
equipped state compared to the low avidity one.  
To test this hypothesis, all the immunisations were carried out normally and pentamer 
positive cells were isolated as per the pooling strategy discussed above. The cells were 
then stimulated with CD3, CD28 coated micro-beads in a ratio of 1:1. The cells were 
harvested post stimulation at 0hr, 1hr and 2hrs of stimulation and TCR signal status has 
been studied between these cells. Results showed that ImmunoBody® derived T cells had 
increased expression of genes associated with TCR signalling compared to the peptide 
counterpart after two hours of stimulation. Except for two of the genes (FYN and LAT) 
studied all other genes have showed significant upregulation in high avidity group 
indicating all the pathways involved in the TCR signalling responded to the CD3, CD28 
stimulation quicker in ImmunoBody® derived cells than in the peptide counterpart. 
The major genes up-regulated in the high avidity groups were from MAP-MAPK pathways 
and cytoskeletal remodelling with many of them previously known to influence the 
functionality of T cells during their activation and proliferation. VAV is a major SH2 
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containing proto-oncogene (Gouy et al., 1995) which is involved in the cytoskeletal 
remodelling and also modulate the Ras/MEK/ERK pathways in T cells (Villalba et al., 
2000). The upregulation of VAV has been reported in the IL2 gene activation (Wu et al., 
1996) and later confirmed by RNA interference (Zakaria et al., 2004).  
Activation of RAS is pivotal in the T cell stimulation and signal processing (Genot et al., 
2000; Katz and McCormick, 1997) by positively promoting the MAP kinase pathways. 
The activation of RAS requires the conversion of its GDP bound state to the GTP bound 
stage and mainly mediated by the expression of Ras guanyl nucleotide-releasing protein 
(RasGRP). So the upregulation of both of these transcripts in high avidity T cells suggests 
the existence of an active RAS signalling pathway in high avidity T cells.    
The upregulation of mitogen activated protein kinase pathway (MAPK) is one of the 
characteristic of T cell activation and is the direct consequences of RAS activation 
(Franklin, et al., 1994). Activation of RAS leads to the Raf-1 activation which, in turn, 
leads to the upregulation of MEK pathways (MAPK or ERK kinase) (Genot et al., 2000). 
All the classic molecules involved in this cascade were also up regulated in the 
ImmunoBody® group in comparison to the peptide group, including RAF, ERK1(MAPK3), 
ERK2 (MAPK1), p38α (MAPK14) and JNK. The importance of this pathway in the T cell 
activation, clonal proliferation and survival has been demonstrated previously (D'Souza et 
al., 2008)      
The fundamental difference in the RAS/MEK pathways in functionally different T cells is 
mainly down to the activation status. A recent study by Adachi and Davis (2011) have 
demonstrated that naive T cells depend more on ERK pathway than the p38 pathway which 
is more important for the primed T cells. Studies conducted on a single TCR transgenic 
mouse model derived high and low avidity T cells observed an increased phosphorylation 
level of the MAPK/ERK pathways in the high avidity T cells. However no transcriptomic 
studies were performed to study the differences in signalling pathway in the context of 
high and low functional avidity and to our knowledge this is the first study to report this 
difference in these two functional types.     
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3.4.4 Affymetrix gene expression studies revealed differentially expressed genes 
between the two groups (high and low avidity) both in TRP-2 and OVA model 
systems 
Among the upregulated genes the most important genes upregulated were Granzyme A&B, 
CD-5 and Fas apoptotic inhibitory molecule-3. Granzyme A & B are the two main 
enzymes expressed in cells involved in the Th1 responses and have close similarity to the 
family of serine proteases. The main function identified with these enzymes are their 
cytolytic function on infected or tumour cells. Granzyme A is only detected in most mature 
CD8+ CD4- cells and its non cytolytic functions include lymphocyte survival and immune 
tolerances (Chowdhary and Liberman, 2008).  
 CD5 is a transmembrane protein mainly present on the T cells, having a cytoplasmic 
domain carrying potential sites for threonine, serine and tyrosine phosphorylation. It was 
reported that CD5 rapidly phosphorylate after successful TCR-CD3 engagement (Perez-
Villar, et al., 1999). This event allows ‘lck’ another tyrosine kinase to bind more efficiently 
through its SH2 domain (Raab, et al., 1994), which might result in increased catalytic 
activity. The differential regulation of TCR-CD3 signalling through CD5 was 
demonstrated in Jurkat T cells (Carmo et al, 1999). Therefore the upregulation of CD5L 
molecules in high avidity T cells might be an important role in their functionality.  
It was reported in the literature that apoptosis plays an major role in T cell homeostasis by 
eliminating excess antigen-specific T cells after an immune response in the peripheral 
tissues. A recent study by Huo, et al (2010) showed  that Fas apoptotic inhibitory molecule 
(FAIM)  is up regulated in T cells upon TCR engagement and Faim _/_  T cells were 
highly susceptible to apoptosis mediated cell death by increased levels of capsase-8 and 9. 
So the role of FAIM in the regulation of high and low avidity T cells need to be 
investigated further. 
Another observation made from the array data was the consistent up regulation of small 
nucleolar RNAs (SNOR) and small nuclear RNA (Rnu) molecules in the ImmunoBody 
groups. Studies with skin and bone marrow failure syndrome dyskeratosis congenita (DC) 
patients showed that the significant reduction in the pseudouridylation and telomerase 
pathways correlated with the accumulation of a particular class (H/ACA) of SNOR 
(Mochizohi, et al., 2003). The commonality of telomerase RNA and the SNOR is the 
presence of a highly similar domain called H/ACA in both the cases, however no 
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conclusive evidences were available for the direct relation of SNORA and the telomerase 
activity in humans except the above study. It is interesting to observe that telomerase RNA 
component (TERC) is also upregulated in ImmunoBody groups along with SNORs along 
with small nuclear RNA (Rnu), which is consistently up regulated in the ImmunoBody 
group. The main function of these small RNA molecules includes RNA splicing, regulation 
of transcription factors and also maintenances of telomerase. So it is worth investigating 
the cellular senescence pathways in high and low avidity T cells with special emphasis to 
small nuclear RNA (Rnu) and small nucleolar RNAs (SNORs) and telomerase RNA 
components (TERC).  
The qRT-PCR confirmation of the above genes further narrowed down the six genes to 
three with GZMA, GZMB and CD5L showing significant difference between high and low 
avidity groups. These markers were shortlisted for further protein confirmation. 
3.4.5 Expression of granzymeA and B (GzmA & B) could be used as a marker for 
high avidity in the current model studied  
The global Affymetrix studies of high (ImmunoBody®) and low (peptide) avidity peptide 
specific cells have identified granzyme A and B upregulated in the high avidity group. 
Further qRT PCR confirmed this at the gene level. Intracellular cytokine staining (ICS) of 
high and low avidity T cells using antibodies against both granzyme A & B were carried 
out for further confirmation of these observation at the protein level. ICS were performed 
with a brief stimulation of these cells with one concentration (0.01 µg/mL) of peptides with 
the assumption that if the cells were differentially expressing the above markers then it will 
be clearly visible by stimulating them. As expected more granzyme A and B production 
was observed in the high avidity T cells. This confirmed the observations gained from the 
gene expression studies that these proteins could be used as a marker for differentiating 
high and low avidity T cells in the current model system used.  
Granzymes are serine proteases secreted by cytotoxic T cells and NK cells capable of 
performing cell mediated cytotoxicity (Chowdhury and Lieberman, 2008). Several classes 
of granzymes were identified (GzmA, B, C, D, E, F, G, L, M & N), of which GzmA & B 
are the ones well studied for their effector functions (Joeckel and Bird, 2014). Other Gzm’s 
are known as orphan granzymes since their precise role yet to be elucidated (de Koning et 
al., 2009; Bovenschen and Kummer, 2010). Up-regulation of GzmB was reported in many 
vaccine settings (Ranasinghe et al., 2007; Wang et al., 2013; Liu et al., 2013). Up 
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regulation of GzmB was detected in earlier studies using microarray profiling of flow 
cytometry sorted CD8+ cells in a vaccine trial involving Ipilimumab in metastatic 
melanoma (Wang et al., 2013). In another study, employed cDNA microarrays to identify 
differentially expressed genes in a T cell in vitro stimulation study using a naive and 
agonist peptide had shortlisted granzymeB as one of the most differentially up regulated 
transcript in agonist group (Palena et al., 2003). Unlike GzmB, GzmA is not studied 
extensively. However few studies indicated their role in CD8+ T cell mediated cytotoxicity 
(Shacklett et al., 2004; Kelso et al., 2002).  
3.4.6 Conclusions and future directions 
The isolation and purification of pentamer positive cells were carried out from the enriched 
population of CD8+ cells to minimise the total splenocyte contamination. Gene expression 
kinetic data revealed differences in the signalling competency between high and low 
functional avidity cells indicating these differences probably acquired during the priming 
with two radically different vaccine delivery systems. However, more studies are necessary 
to see the phosphorylation status of these two primed cells before reaching final 
conclusions. From these data it was hypothesised that the physiological and molecular 
changes happening during the naïve T cell priming leave the molecular machinery for 
better activation in high avidity cells. Whether these molecular machinery is diluted out 
during the clonal proliferation is another intriguing question.  
Gene expression micro array data has successfully carried out with low number of peptide 
specific cells with out any stimulations. The data indicated there is a transcriptional 
differences between these two cell types. However the differences were subtle and 
probably the reason might be the studies were not conducted on the activated peptide 
specific T cells. And this will remain a future priority for this section.  
Confirmation of two transcriptomically identified candidate genes (GzmA and GzmB) 
using antibody mediated method could be easily be the highlight of this study. Though one 
of them (GzmB) was well known cytotoxic molecule the second one is not reported in the 
literature in a greater extend. So it is ideal to confirm these markers in human vaccine trial 
settings to derive clinically relevant correlations. 
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Chapter 4.  
Proteomic characterisation of high and low avidity T 
lymphocytes 
4.1. Introduction  
4.1.1. The Proteome – the functional end of the genome 
Proteins are the ultimate cellular machines, the “working class” of cellular molecular 
framework. Proteome is the name coined by Wilkins et al., in 1996 by combining the two 
terms PROTEin and genOME to collectively denote the protein compartment of a cell or 
living system. The emergence of this new field of molecular sciences coincides with our 
ability to study genes in detail. Until the discovery of DNA by Watson and Crick, genes, 
for biologist, were an abstract metaphoric entity, having no defined physical location. The 
invention of PCR by Karry Mullis (1990) and the subsequent large scale identification of 
the genes and their mapping of their physical location in the genome made a huge stride in 
the understanding of the genetic underpinning of many diseases and traits. The decoding of 
sequence information holding in the rather static DNA in humans and many other 
organisms left the biologist with a new set of problems, which is the functional annotation 
of each gene in many disease and physiological functions (Venter, 2001). Many of the 
answers for this functionality of the genetic information lies the protein information and 
therefore post genomic era exclusively demand the understanding of proteome in a wider 
scale. Unlike the genome, which is static, the proteome is dynamic and changes over time 
in response to the external stimuli. Adding to this paradigm RNA splicing (Modrek and 
Lee, 2002; Xing and Lee, 2007) and post translational modifications (Cerný et al., 2013; 
Jensen, 2004; Mann, and Jensen, 2004) further diversify the genetic information therefore 
the complexity of proteome is several order higher than its genomic counterpart. 
With this diversification happening at the mRNA and protein level, the nearly 20-25,000 
genes (Collins et al., 2001, International Human Genome Sequencing Consortium) present 
in the human genome much less than the previously predicted number of genes, finally 
ended up in the production of over 100,000 proteins which is the functional end product of 
the genetic information (Gstaiger and Aebersold, 2013; Hochstrasser et al., 2002). The 
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disparity between the number of genes and the proteins are unimaginable (Collins et al., 
2001) and the process involved in this complexity is illustrated in figure 4.1. 
4.1.2. Proteomics  
Proteomics is defined as “the study of the proteome of a living entity” (Wilkins et al., 
1996).  It has emerged as a systematic discipline in the last few decades along with our 
increased ability to study large numbers of proteins in parallel.  
Figure 4.1: Increasing complexity and diversification of genetic information from DNA to proteins. 
Each stages of this central dogma of molecular biology is adding a higher level of diversification of 
the gene by RNA splicing mechanism and post translational modification. 
 
Proteomics can be divided into many categories depending on the type and nature of the 
samples and methodologies used for any particular study.  Two main categories are 
“functional proteomics” (Monti et al., 2005; Strosberg, 2001) and “structural proteomics” 
(Jhoti, 2001). The former is the systematic study of function of the proteins and the latter 
exclusively elucidates the structural basis of the proteins and thereby determines the 
structure and the binding characteristics of a given protein.  Depending upon the nature of 
starting material used for the study, proteomics can either be targeted (Boja and Rodriguez, 
2012) or global (Tomlinson et al., 2002); targeted proteomics looks for the particular 
compartments of proteins whereas global proteomics study the whole proteome complexity 
and changes. Subcellular fractionation (Huber et al., 2003), antibody mediated immune 
Fig. 4.1 Increasing complexity and diversification of genetic information from DNA to
proteins. Eac tages of this central dogma f molecular biolo y is adding a higher level
of diversification of the gene by RNA splicing mechanism and post translational
modification.
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precipitation (Le Guezennec et al., 2005), affinity purification (Mechref et al., 2008) are 
some of the tools to enrich particular fraction of the global proteome for targeted 
evaluation. The main advantage of global proteomics is the ability to detect novel 
pathways and proteins in disease versus non disease conditions, normal versus drug treated 
cell line and various other biologic scenarios (Vaudel et al., 2011). No prior knowledge of 
protein expression and/or modification are necessary for global profiling. A drawback to 
this type of analysis is the availability of a suitable analytical platform for analysing such 
large numbers of proteins (≥ 100K) in one go (Tomlinson et al., 2002; Vaudel et al., 2011). 
Traditionally, both targeted and global proteomics were studied with both one- and two-
dimensional gel based approaches (O’Farrell, 1975; Molloy, 2000; Vanrobaeys et al., 2005) 
to identify differentially expressed proteins between different conditions and subsequent 
identification of the protein by mass spectrometry (Gomes, et al., 2013). 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Graph showing the number of journal articles returned from a Pubmed search 
using the keyword ‘protein profiling’. The data shows an exponential increase in the 
publication during the last 10 years. 
Though 1 and 2-D gel based proteomics have been the mainstay of the proteomics over the 
years, it is limited with its detection ability and the proteome coverage. This limitation 
leads to the quest for gel free proteomics and finally leads to the introduction of a new tool 
set known as mass spectrometry (MS) for the quantitative and qualitative detection of 
proteins. During the past decade huge interest has been generated in the area of proteomic 
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Fig 4.2. Graph showi g the number of journal articles returned from a
Pubmed search using the keyword ‘protein profiling’. The data shows an
exponential increase in the publication during the last 10 years.
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profiling (figure 4.2) and mainly fuelled by the generation of novel mass spectrometric 
based platforms to study large number of proteins in one experiment. This study used mass 
spectrometry based global proteomics; therefore the subsequent literature will be restricted 
to mass spectrometry and shotgun proteomics. 
4.1.3. Mass Spectrometry (MS) based proteomics 
4.1.3.1. Origin and development of the mass spectrometer 
A mass spectrometer is an instrument capable of measuring the mass to charge (m/z) ratio 
of a substance in its ionised state. Usually these measurements are done in the vacuum, 
free of any other materials, so that the ions can travel from one place to another without 
any obstruction.  The developmental history of modern mass spectrometry (MS) has been 
long.  At the beginning, substances with high vapour pressure only are analysed in the 
spectrometers due to their existence in the gaseous phase and hence easy to move from one 
place to another for the measurement of their mass. Later the development of disruption 
ionisation techniques in 1970’s allowed the ionisation of substances in the solid/condensed 
state, so that they can also be analysed in the MS. The early ionisations were “hard”, using 
chemical and electron ionisations methodologies. While these ionisations are good for 
studying small chemical molecules they were not very useful for the analysis of biological 
macromolecules. Most of the biological molecules are heat sensitive and easily fragmented 
upon any hard ionisation methods. The real alternative known as “soft” ionisation was first 
invented by Fenn (1989) in the form of electrospray ionisation (EI) and followed by 
Matrix-assisted laser desorption/ionisation (MALDI) (Hillenkamp F et al., 1991; 
Hillenkamp, F. and Peter-katalinic J, 2007). This breakthrough in soft ionisation 
techniques lead to the development of mass spectrometers exclusively used for studying 
large biological molecules without the problem of unintended molecular fragmentation. 
4.1.3.2. Basic Components of a mass spectrometer  
The basic structure of a modern spectrometer contains 3 parts - an ion source, a mass 
analyser and a detector (Hillenkamp, F. and Peter-katalinic J, 2007) as seen in figure 4.3. 
The ion source is the place where the ionisation of the biological samples takes place, the 
mass analyser is where the resolution of the ionised biological fragments happening and 
finally the detector complete the story by recording the m/z of the fragment.  
 
  
155 
 
4.1.3.2.1 The Ion source 
In MALDI, the ionisation of biological samples is achieved by mixing biological samples 
with a solid matrix compound. This matrix helps in the protonation of the biological 
samples when a low energy UV is fired on to them and lifted in to a strong electric field 
and migrate towards the detector and finally hit the detector. The rate of migration of the 
ions is represented as the m/z ratio (Hillenkamp et al., 1991; Hillenkamp, F. and Peter-
Katalinic, 2007).  ESI is probably the most commonly used method used for the ionisation  
of biological samples in proteomic mass spectrometry. Samples are subjected to a high 
voltage electric field to create charged droplets (Lin et al., 2003). These charged droplets  
 
can enter in to the inlet of mass spectrum for mass characterisation in the mass analyser. 
The charging can either be applied as positive or negative, however most peptide/proteins 
are ionised with positive charge due to their molecular structure. The sample is introduced, 
usually following separation by high pressure liquid chromatography (HPLC) or nano-flow 
chromatographic separation (nLC) (Postle, et al., 2007). The volume of the flow also can 
be varied from few nL/min to mL/min for generation of the droplets. 
4.1.3.2.2 The Mass analyser:  The resolution of a mass spectrometer is the ability of its 
mass analyser to separate the charged biomolecules produced in the gaseous/ vapour phase 
carrying different m/z values effectively. The primitive type of mass analyser is the 
magnetic sector mass analyser (Hart-Smith and Raftery, 2012) used widely in the early 
Fig.4.3. Schematic representation of the basic design of a mass spectrometer. The
instrumentation starts with an ion source which is capable of ionising fragile biological
samples by a process known as soft ionisation in MALDI or an electrospray ionisation.
The ionised fragments then enter the next section of the instrument which is a mass
analyser capable of resolving the fragment based on mass to charge ratio (m/z). Finally
the resolved ions hit the photomultiplier detector; the signal is amplified and recorded as
a peak or ‘mass spectrum’.
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stages of MS. This had been soon replaced by different mass analysers developed by 
different vendors in the pursuit of enhancing the resolution of the mass spectrum such as 
quadruple, ion traps, orbitraps, Time-of-Flight, Fourier Transform Ion Cyclotron 
Resonance (FTICR) Mass Analysers are most commonly used in present day MS and 
extensively reviewed (Zhang  et al ., 2013; Hart-Smith G and Blanksby S J, 2012). 
 4.1.3.2.3 The Detector 
Once the ions pass through the mass analysers, it hit the detectors and each of the ions 
record electronically to generate the mass spectrum of that particular ion. The most 
common detector used in biological mass spectrometry is an electron multiplier (Ver 
Berkmoes et al., 2004) which works by generating a multitude of electron or photon when 
an ion hit the detector surface. The initial signals are amplified a million fold and finally 
the conductor measure the current and amplify it before converting it in to a measurable 
peak or mass spectra (Rubakhin and Sweedler, 2010).  
These are the basic components of a basic MS instrument; however modern MS machines 
employ a wide array of improvement to improve the speed, resolution and mass accuracy. 
These improvements are more evident in electrospray MS machines than MALDI MS 
instruments (Scigelova and Makarov, 2009; Campbell and Le Blanc, 2012). This study 
used MALDI-TOF and liquid chromatography coupled MALDI-TOF for global profiling, 
therefore next few sections are dedicated to the LC-MALDI    
4.1.3.3 Matrix-assisted laser desorption/ionization (MALDI) Time of Flight MS.  
(MALDI-TOF MS) 
The working principal of MALDI –Tof MS is based on the capacity of a matrix to ionise 
(protonate) the biological molecules using a short wave laser power in vacuum. The 
ionised molecules are subsequently pushed (guided) into the mass analyser, in this case a 
Time of flight (TOF) analyser with the help of an electrostatic field generated by the 
electrode positioned opposite to the sample ionisation plane. Once they passed the 
acceleration electrodes they enter the drift tube where they travel towards the detector 
under the condition of vacuum. Depending on the mass and charge on each ion they move 
in slightly different velocities in the drift region and the m/z of each ion can be calculated 
from the acceleration voltage and the length of the flight tube. MALDI-Tof MS 
measurements can do either in linear or reflector mode. Measuring the ions in linear mode 
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is more often result in poor resolutions (ability to discriminate ions with similar m/z values), 
therefore a reflector has been fitted towards the end of drift tube which deflect the 
incoming ions into a different direction effectively increasing the flight time and path.  
The normal MS in a MALDI-TOF instrument can only yield the information of the m/z 
value of any particular peptide fragment, but unable to give any structural information 
about the sequence of that peptide. Studies conducted by Kauffmann et al in observed an 
important property of this ionised biological molecule in the MALDI MS instrument 
known as Post Source Decay (PSD). This is a phenomenon by which the parental ions 
(original peptide fragment) decompose in to its fragment ions in the flight tube and this 
decomposition has been influenced by the initial kinetic energy holding within the parental 
ions. The latest MALDI-TOF instruments have exploited this PSD and used it for 
effectively deriving the sequence information of the peptides in the mass spectrometer. 
There are patented technologies available (LIFT in case of Bruker Daltonics) which 
selectively filter the ion of interest in to the drift tube and also increase the kinetic energy 
of the parental ions to obtain the complete sequence. The working principle of the MALDI 
machine and LIFT technology is given in Figure 4.4.  
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A
B
Fig.4.4. Figure representing the working of a MALDI-TOF MS. A. a MALDI MS
identifying mass spectra for a peptide ion. The trpsinised peptide fragment obtained from
single protein/ protein complexes/ global proteins were spotted on a ground steel plate
with appropriate matrix. A short lasure impulse protonate the peptide fragment by impart
them with a positive charge. An acceleration electrode positioned above the ionisation
plane guide the protonated peptide fragment towards the drift tube (Tof tube). Modern
machine fitted with the reflector deflect the ion path and thereby increase the resolution of
the spectra B. Figure showing the extraction of sequence information of a selected
(interested) parent peptide mass to identify its associated proteins. Once the peptide ion
differentially expressed between the test control samples were identified and assigned for
obtaining sequence information, the parent ions were selected and further energy is added
to the ion before let the ion in to the drift tube for sequencing. Due to the increased kinetic
energy attained after the parent ion selection (which happened in the LIFT cell of Bruker
Daltonk Machines) the parental ions start to decompose by a process called post source
decay (PSD). C. Extraction of sequence information from the mass spectra. PSD induced
MS MS spectra contain ‘b’ and ‘y’ ions depending on the representative terminal from
which the ions are represented. B ions originate from the amino terminus and the y ions
from the carboxyl terminus. This allow the experimenter to determine the peptide structure
in both the directions
C
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4.1.3.4 MS approaches to study the proteome 
Three main approaches are used in the general MALDI Tof MS and other MS platforms. 
They are bottom up or shot gun proteomics, top down proteomics and middle down 
approach. Bottom up proteomics referred to the characterisation of the proteome by 
fragmentation of the proteome by specific enzymes such as trypsin. This is also known as 
shot gun proteomics in analogy to shotgun DNA sequencing (Zhang et al., 2013). The 
digested peptide fragments are fractionated with liquid chromatography followed by the 
identification of mass spectrometry (Koutroukides et al., 2013). The tandem mass 
spectrum generated after each mass spectrum analysis are then compared to the theoretical 
mass spectra generated in silico  databases such as MASCOT (Nesvizhskii, 2007). The 
bioinformatics analysis of mass spectrum derived peptide sequences are then assigned 
either uniquely or shared with specific or many proteins depending on the sequence. The 
overall work flow of bottom up proteomics are given in the figure 4.5. 
There is no enzymatic fragmentation and the proteins used as intact as possible. The main 
advantage of this approach is the ability to detect post translational modifications (PTM) 
and protein isoform (Lanucara and Eyers, 2013; Peng et al., 2013). Another advantage is 
the ability to give more proteome coverage and therefore eliminate the ambiguity in the 
sequence assignment to a specific protein. The major disadvantages of top down 
approaches are the difficulty of fragmenting and ionising large proteins in the ion source 
(Zhang et al., 2013). These two approaches are illustrated in figure 4.5. 
4.1.3.5 Reducing sample complexity for increased proteome coverage by MS   
One of the bottleneck for studying global proteome using mass spectrometry is their 
complexity. Several pre fractionation techniques are therefore employed to reduce this 
complexity. They are either electrophoresis or liquid chromatographic separation of 
proteins and peptides based on their physical and chemical attributes. Two methods are 
widely employed for reducing the overall complexity in the sample are the selective 
depletion method (Fang and Zhang, 2008) and combinatorial ligand libraries (Santucci et 
al., 2012). This enrichment is mainly used in the profiling of serum proteomics where the 
complexity and the dynamic range of the proteome is enormous (Ly and Wasinger, 2011).  
 
Year 
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Advances in analytical chromatographic technologies and improvement in column 
chemistries enabled the separation and elution of digested peptide mixtures before 
subjecting to ESI or MALDI MS profiling. These pre fractionation techniques can further 
enhance the proteome coverage several folds (Van Riper et al., 2013). 
Fig 4.5. Two approaches used for mass spectrometry based proteomics are given.
Bottom up proteomics is most widely used approach because of its simplicity. It is
also known as ‘shot gun’ proteomics (analogy to DNA shot gun sequencing),
involved several steps. The protein obtained from different sources can be
fractionated (optional) prior to trypsinisation and the whole proteins are cleaved in
to manageable chunks before subjecting to another round of fractionation. Each
fractions coming out of the LC, can either constantly sprayed in to an electro spray
ionisation source for identifying the peptide sequences and associated proteins
using a tandem mass spectrometer or spotted on to an anchor chip for using in a
MALDI mass spectrometer. In contrary to bottom up approach top down
proteomics involved no trypsinisation but an optional LC or Gel fractionation can
be carried out before subjecting to mass spectrometric analysis.
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The most widely used chromatographic separations for pre fractionations are size 
exclusion (separations based on size), affinity chromatography (separations based on 
affinity tags) ion exchange chromatography (separations based on charge) and reverse-
phase chromatography (separations based on hydrophobicity) (VerBerkmoes et al., 2004). 
Most of the above separations can be performed to reduce the complexity either 
independently or in combination. Liquid chromatography (LC) using reverse phase 
columns are favoured for normal ESI and MALDI MS workflow because of its advantage 
for using straight away for MS analysis. LC instrumentation such as nanoLC which can 
handle nano litre volume flow rate can either be used in line with ESI by continuous 
injection of the eluted peptides in to the MS instrument or offline with MALDI MS by 
spotting on to a ground steel target plate for analysing later. Among this the most favoured 
one over the conventional LC which is limited by its inability to maintain a lower flow rate 
and poor separation (Gaspari and Cuda, 2011). None of this techniques are isolated and in 
many studies they have been used in different combination to improve the depth of 
fractionation (Zhang et al., 2013) 
4.1.3.6 MS based quantitative proteomics  
Traditional quantitative proteomics has been done with gel based techniques where the 
proteins are separated on a one or two dimensional gel followed by transfer them on to a 
nitrocellulose membrane before probing with the antibodies against the interested protein. 
The quantity of the interested proteins can be deduced by comparing the densitometry of 
the normal and the test sample after normalising with the internal standard housekeeping 
proteins known as western blotting (Burnette 1981). One of the inherent problem with this 
technique is its low throughput nature. The emergence of MS based quantitative 
proteomics enabled the experimenter to study thousands of proteins in parallel with the 
quantitative information (Liang et al., 2012). There are two main areas of MS based 
quantitative proteomics have emerged recently known as labelled and label free 
quantitative proteomics. Labelling approaches can either be used for the relative 
quantification of the proteins or can be used for the absolute quantitation (Coombs, 2011). 
Several libelling approaches are used routinely for quantitation such as in vivo labelling 
(SILAC) (Ong, 2012), isotopic (Mirgorodskaya et al., 2000) or isobaric (Sturm et al., 2012; 
Liang et al., 2012) tags or spike in controls (Kuhn et al., 2004). Once labelling has been 
done with any of the above approach the peak intensity differences between the control and 
test samples are used to compute the relative abundance of the peptide fragments (Coombs, 
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2011). Label free quantitative proteomics mainly carried out by ion peak intensities or 
spectral counting (Lundgren et al., 2010; Old et al., 2005). Ion peak intensity based 
quantitation is entirely dependent on the quality of the LC MS data generated by the LC 
separation and spectrometer and simply measuring the peak intensity at a given retention 
time of the test samples against the control samples for a given ion peak (Old et al., 2005). 
Spectral counting on the other hand counting the number of single MS MS spectra 
associated with a single protein between the test and control runs. The number of MS MS 
spectra generated for a given protein is highly correlated with the abundance of that protein 
in the solution (Liu et al., 2004). 
4.1.4 Aim of the study 
T cell development and differentiation is a tightly controlled process. Many of these 
processes are controlled at the protein level rather than the genetic level. Even though 
genetic analysis is useful in analysing the general trend of a process, it is the proteome that 
gives a comprehensive idea of the functional status of the cell. With this view in mind this 
chapter intends to carry out a global profiling of TRP-2 specific pentamer sorted cells 
using shot gun bottom up proteomics using liquid chromatography-matrix assisted laser 
ionisation desorption time of flight mass spectrometry (LC-MALDI-TOFTOF). The 
resulting data will be used to study the differences between high and low avidity T cells 
qualitatively and semi quantitatively based on ion peak intensity.  
 The hypothesis is global proteome analysis can distinguish high and low avidity T 
cells based on the proteome profiles. Once it is achieved the identified markers can 
be used for the rapid detection of high avidity T cells (measure of a quality immune 
response) in the vaccine generated T cells.   
 Group uniquely identified proteins through LC-MALDI-TOFTOF as functional 
categories and investigate their pathway association using database searching. 
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4.2 Materials and method 
4.2.1 Isolation of peptide specific cells for proteomic characterisation  
Isolation of peptide specific cells was carried out using the same way described in section 
3.2.2 and 3.2.3 and counted using 10 µL of cell suspension and 10 µL of trypan blue. Cells 
were washed three times with cold PBS 3 times to remove any residual BSA from MACS 
buffer used for the magnetic sorting of these cells. After the final wash cells were snap 
frozen in liquid nitrogen and immediately transferred into -80○ C until cell lysis. 
4.2.2 Cell lysis and protein quantitation 
Frozen cells were taken out of the -80○ C freezer and immediately added 15 µL of cell lysis 
buffer (9.5 M Urea + 2% Dithiothreitol + 1% octyl b-D-glucopyranoside) tubes were 
subjected to repeat sonication (5 min) and chilling on ice (5 min) three times.  15 µL of 
0.1% TFA is added to the cell lysate and sonicated again for 5 min centrifuged the whole 
mixture at 7000 g and transferred the lysate into a new tube and left the pellet undisturbed 
and stored at -80○C.  Protein quantity determination of cell lysate was carried out using 
Bio-Rad Bradford protein assay kits with modifications. A twofold standard dilution series 
starting from 200 µg/mL – 6.125 µg/mL of BSA was prepared by diluting the stock 
solution of 2 mg/mL in lysis buffer and used for the generation of linear curve in 
NanoDrop 8000 ® prior to unknown sample measurement. 5 µL of each sample and dye 
reagent was used for setting up the calorimetric reaction in a PCR plates; blank reaction 
was prepared by replacing the cell lysate with 5 µL of lysis buffer. The reaction was mixed 
thorough and incubated briefly for colour development. NanoDrop 8000® was prepared by 
blank measurement and a linear curve had been established using the serially diluted BSA 
samples by pipetting 2.5 µL of each standard to the sample pedestals. Samples were 
prepared the same way as that of standards and quantity is estimated with the previously 
established standard curve. All the samples were equalised to the lowest concentration 
prior to subjecting any proteomic analytic techniques.    
4.2.3 Trypsinisation and sample clean-up 
Prior to any liquid chromatography and mass spectrometric experiments all the samples 
were digested with proteolytic enzyme Trypsin (Trypsin Gold, Promega) which cleave the 
proteins specifically by hydrolysing the peptide bond connecting any lysine and arginine 
residues. Trypsinisation reactions were set up by adding 16.6 µL of ammonium 
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bicarbonate, 7.6 µL of water, 8 µL (0.7 µg) of protein lysate and 0.7 µL of trypsin. The 
tubes were mixed by brief vortexing and incubated at 37○C for 16 h (overnight) in a 
temperature controlled hot air incubator. On the next day the reaction was stopped by 
adding 1 µL of 1% TFA and thorough mixing by vortexing. After trypsinisation the 
digested samples were subjected to clean up and concentration using ZipTipTM (A C18 
immobilised chromatography pipette tip, Millipore). The ZipTip clean-up protocol was 
carried out by wetting the ziptips in 80% acetonitrile by up and down pipetting three times 
using a 10 μL pipette, followed by equilibration of the tips in 0.1% TFA three times. In the 
next step sample clean-up was carried out by gentle up and down pipetting of the sample 
using the equilibrated tip 15 times without introducing air bubbles, Unbound peptides and 
salts were washed out by pipetting the ZipTips in 0.1% TFA 15 times. The bound peptides 
were finally eluted into 5 µL of 80% acetonitrile and diluted with 0.1% TFA prior to LC 
separation.  
4.2.4 Nano LC fractionation of the peptides and robotic spotting on MALDI target  
The optimised work flow of John van Geest proteomics laboratory has been followed for 
peptide mass profiling with LC-MALDI Tof (Liquid chromatography – Matrix Assisted 
Laser Desorption/Ionisation Time of Flight) spectrometry. This is a powerful technique in 
proteomic analysis by combining the physical separation capability of liquid 
chromatography and the analysis capability of mass spectrometry. A nanoflow HPLC 
system was used for this study (Proxeon EASY-nLC system, Bruker Daltonics, UK) and 
the separated sample fractions were spotted on to a 384 anchorchip plate (Bruker Daltonics 
GmbH) using a robotic spotting system (PROTEINEER fcII, Bruker Daltonics, UK) with a 
matrix solution 748µl of TA95 (95% acetonitrile, 5% water, 0.1% Trifluoroacetic acid), 36 
μL of saturated CHCA matrix (α-Cyano-4-hydroxycinnamic acid) solution in TA 90 (8 μL 
of 10% TFA in water, 8 μL of 100 mM NH4H2PO4 in water). The LC gradient used has a 
total run time of 86 min with 30 nL/ min, flow starts with 98% of solvent A (0.1% TFA in 
H2O) and 2% of solvent B (0.2% TFA in acetonitrile) with an initial time delay of 15 min 
followed by a 10 s time slice segment of 64 min. At least three blanks were run between 
the sample runs to avoid cross contaminations. A commercially available peptide standard 
digest was used with each plate for the calibration of mass accuracy. Care was taken to 
minimise the anchor chip plate contamination by following dedicated washing and 
handling protocols of the plates between the runs.  
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4.2.5 Generation of MS and MS/MS profiles in MALDI-TOF 
After spotting the peptide fractions using the robotic systems the calibration standards were 
spotted to the designated place of the anchor plate. After drying the plate was taken into 
MALDI-Tof (Bruker UltrafleXtreme). A new run was created in user supplied software 
WARP LC (Workflow Administration by Result-driven Processing) for each sample. Laser 
power was optimised by manually firing on a single spot for each samples and calibrants. 
Mass accuracy of each calibrants were manually checked and automatically assigned.  MS 
profiling of the samples were carried out by automated running with set parameters 
followed by the MS/MS on top 10 peaks. MS/MS data of each automated runs were used 
for searching in in-house protein database MASCOT server through BiotoolsTM and finally 
displayed the matching proteins with its Mascot score and number of peptides in 
ProteinBrowserTM. 
4.2.6 Data analysis and generation of differentiating peaks between the sample 
groups 
Two data analysis strategies were followed for analysing the proteomic data.  First one is 
more conventional differential analysis in which the peptide which was uniquely identified 
with each group was shortlisted by manually comparing the protein identities obtained 
from each run. Second strategy involves a statistical modelling and the identification of the 
MS peaks which shows maximum differences between the samples were carried out in 
Profile AnalysisTM software. These peaks were then used as precursor ions for MS/MS and 
the generation of protein identities. For the T test model generation, MS data from two 
groups, High (DNA vaccine generated) and low (peptide vaccine generated) avidity with 
three samples in each groups were analysed in the same software. T test modelling was 
carried out with following bucker generation parameters m/z 800 – 40000 with advance 
bucketing and get parameters and time alignment selected, normalisation followed is the 
sum of bucket values in analysis ≥ 6. With these parameters a T test had been performed 
and the most significant ions were organised with P value ≤ 0.05 and fold change ≥ 4. A 
separate list was created with this ions and this list was used as a shortlisted precursor list 
for MS/MS peptide and protein identification in tandem mass spectrometry. The 
distribution of these top ions in the population was then assessed manually from the 
retention time and m/z value arranged matrix table. The complete list of the shortlisted 
peptides were given in the appendix  
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In a separate approach the protein identities generated from each MS/MS experiments were 
grouped together in ImmunoBody™ group and in the peptide group separately using Venn 
diagrams (http://bioinfogp.cnb.csic.es/tools/venny/index.html.). The protein identities 
common to all the biological replicates were then selected from each group. These 
common proteins from within each group (ImmunoBody™ and peptide) groups were used 
for the generation of a separate d Venn diagram which differentiate the unique proteins 
identified with immunology and peptide groups separately. These unique proteins were 
then used for further functional characterisation using Protein ANalysis THrough 
Evolutionary Relationships (PANTHER) functional classification tools 
(www.pantherdb.org/).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.6. Schematic representation of proteomic workflow for the
characterisation of peptide specific cells
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4. 3 Results 
4.3.1 Isolation of pentamer positive cells, Protein quantitation in Nanodrop 8000® 
TRP-2 specific pentamer positive cells were isolated from the TRP-2 model after pooling 
three animals were lysed for global proteomic profiling in LC MALDI platform. The 
number of cells obtained and the protein quantity obtained are given in the table 4.8. The 
quantity determination has been done in Nanodrop 8000®  with the linear graph fitted with 
diluted BSA. The result of Nanodrop quantitation of protein is given in appendix.  
Table 4.3.1.  Protein quantitation obtained from pentamer positive cells 
Name Number of Cells Proteins Quantity (ng/µl) 
IM Pool 1 1.2 x 104 128 
IM Pool 2 0.9 x 104 113 
IM Pool 3 0.8 x 104 85 
Pep Pool 1 1.13 x 104 117 
Pep Pool 2 1.06 x 104 155 
Pep Pool 3 1.3 x 104 128 
 
The number of cells used from three animals was within a range of 0.8 x 104 – 1.3 x 104 
cells from each of the pool. The normal protein quantitation kits were not ideal for this 
study due to its larger sample volume requirement and sensitivity. The normal assay works 
with a 1 in 10 ratio of the Bradford dye and sample, however the Nanodrop protein 
quantification protocol was modified with a ratio of sample to dye as 1:1 to increase the 
sensitivity.  All the proteins were normalised to the lowest concentration (i.e. IM pool 3, 85 
ng/µL) and 8 µL of this protein equalised solutions from each samples were used for 
trypsinisation. 
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4.3.2 LC separation and MALDI-TOF profiling of high and low avidity pentamer 
sorted cells 
8 – 10 μg of total proteins were obtained from each animal pool and pentamer sorted cells 
the gradient used for the LC separations created a good spread of the peptides and spotted 
almost uniformly on to an anchor chip plate (figure 4.7). The MS data generated from the 
LC MALDI run was used for principle component analysis and the ImmunoBody and 
peptide groups were well separated from each other in the first and second component 
(PC1& PC2)  (Fig 4.7). 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: A. Gel view showing the LC separation of the peptide fragments of six samples, 
(picture generated from the MS data) B. Principle component (PC) analysis of ImmunoBody® and 
peptide group based on two component PC1 and 2 showing separation of two groups. 
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Fig. 4.8. A. Gel view showing the LC separation of the peptide fragments of six
samples, (picture generated from the MS data) B. Principle component (PC) analysis
of immunob dy and peptide group based on two component PC1 and 2 showing
separation of two groups.
A 
B 
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4.3.3 Pre-selection of ions prior to MS/MS using profile analysis identified nine 
candidates 
Highly up regulated ions were subjected to further fragmentation and the amino acid 
sequences were searched against highly curated protein database and the unique proteins 
associated with the that peptide fragment was identified. The m/z values which showed 
consistent expression within the groups (figure 4.9), the proteins which showed any 
previous functional association with the CD8+  T cells were shortlisted for further analysis. 
Table 4.2.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Candidate ions identified with LC MALDI profiling and its intensity distribution between the 
high and low avidity TRP-2 specific CD8+ cells. The proteins identified are given under each ion and the 
intensity is given as log scale in the Y axis. Error bars showing the mean and SD. 
 
Fig 4.9. Candidate ions identified with LC MALDI profiling and its intensity
istribution between the high and low avidity TRP-2 specific CD8+ cells. The
proteins identified are given under each ion and the inte sity is given as log
scale in the Y axis. Error bars showing the mean and SD.
  
170 
 
Table 4.2: Candidate protein identified for future studies using LC MALDI profiling  
Protein  
 
Protein function  Peptide sequence m/z  
Plastin 2 Crucial role in the formation of immunological 
synapse, Involves in TCR/CD3 and CD2 or CD28 
mediated stimulation, cytoskeleton remodelling 
up on serine phosphorylation. 
 
VYALPEDLVEVNPK 
AYYHLLEQVAPKGDEEGIPAVVIDMSGLR 
1585.84 
3170.61 
 
Coronin-1A T cell survival and Ca2+ mobilization capabilities. 
When  T cell is activated, helps in the 
generation of inositol-1,4,5-trisphosphate from 
phosphatidylinositol-4,5-bisphosphate 
 
HVFGQPAKADQCYEDVR 
KGTVVAEKDRPHEGTRPVHAVFVSEGK 
1962.91 
2930.55 
Annexin A6  
 
Membrane-binding protein, Interacts with 
GTPase-activating protein p120GAP  
 
SELDMLDIREIFR 
GIGTDEATIIDIVTHR 
 
1636.83 
1710.90 
 
14-3-3 protein 
beta/alpha  
 
An adapter protein known to binding to 
phospahatases and kinases, influence the 
expression of RAF-1 and AKT 
YLSEVASGENKQTTVSNSQQAYQEAFEISKK 3464.68 
GTPase IMAP 
family member 1  
 
Trans membrane protein. Plays a critical role in 
the T cell differentiation 
YVALTSPGPHALLLVVPLGR 
 
2073.22 
 
Lymphocyte-
specific protein 
1  
 
Phosphoprotein bind to F-actin. Main reported 
functions are cell - cell interactions and 
mobility.  
SSELDEDEGFGDWSQKPEPR 2308.00 
Moesin  
 
Actin cytoskeleton organisation, role in T cell 
activation by helping in cell polarity during 
synaptic complex formation 
 
SGYLAGDKLLPQR 
GSELWLGVDALGLNIYEQNDRLTPK 
1417.77 
2801.44 
 
Ras-related 
protein Rap-1A  
 
A Ras-like GTPases, play an important role in 
the cytoskeleton reorganisation during T cell 
activation 
SKINVNEIFYDLVR 1709.92 
Mucosa-
associated 
lymphoid tissue 
lymphoma 
translocation 
protein 1 
homolog  
 
Helps NF-kappa-B in a BCL10 mediated manner 
also helps in integrin adhesion in T cells 
RLSESLDRAPEGR 1485.77 
4.3.4 Differential analysis identified 42 unique proteins in high avidity group  
MALDI shotgun approach using the tryptic digests obtained from TRP-2 specific pentamer 
positive cells have identified large number of proteins in both the groups through LC 
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MALDI spectrometry. The LC MS run conducted using three independently isolated TRP-
2 pentamer positive cells in each group have identified 408 ± 15 proteins in the 
ImmunoBody group and 498 ± 8 proteins in peptide group. Three of the runs in each data 
set were combined together using a Venn diagram to identify the common proteins 
between all the three runs. 294 proteins were identified as common between all the three 
samples in the peptide group and 312 proteins were identified as common between the 
ImmunoBody® runs.  
SL.No ID NAME Pathway, cellular function/Proceses/Component #
peptides
1 Bax Apoptosis regulator BAX Apoptosis signaling pathway 4
2 Creb1 cAMP response element-binding protein p38 MAPK pathway 2
3 Ptprc Leukocyte common antigen JAK/STAT signaling pathway, T & B cell activation 6
4 Grap2 GRB2-related adaptor protein 2 PI3 kinase & Ras  pathway, T & B cell activation 6
5 Rac2 Ras-related C3 botulinum toxin substrate 2 p38 MAPK, Integrin & Ras pathway, T & B cell activation 4
6 Cdc42 Cell division control protein 42 p38 MAPK pathway, T cell activation, Integrin signalling 3
7 Stmn1 Stathmin Cytoskeletal regulation by Rho GTPase 1
8 Ywhah 14-3-3 protein eta P53 & PI3 kinase pathway 3
9 Rap1a Ras-related protein Rap-1A Heterotrimeric G-protein signalling, MAPKKK pathway 2
10 Cltc Clathrin heavy chain 1 Heterotrimeric G-protein signalling 18
11 Gnai2 Guanine nucleotide-binding protein PI3 kinase pathway, 3
12 Fkbp2 FK506-binding protein 2 TGF-beta signaling pathway 4
13 Cox6b1 Cytochrome c oxidase subunit VIb isoform 1 oxidative phosphorylation 5
14 Bub3 Mitotic checkpoint protein BUB3 chromosome segregation 2
15 Pdcd6ip Programmed cell death 6-interacting protein induction of apoptosis 2
16 Psmb1 Proteasome subunit beta type-1 proteolysis 3
17 Samhd1 SAM domain and HD domain-containing protein hydrolase activity 11
18 Tardbp TAR DNA-binding protein 43 regulation of transcription 4
19 Thrap3 Thyroid hormone receptor-associated protein 3 receptor activity,  transcription factor activity 6
20 Eef1g Elongation factor 1-gamma immune system process, Response to toxin 4
21 Nedd8 Nedd8 proteolysis 2
22 Ubtf Nucleolar transcription factor 1 transcription factor activity 6
23 Cpne1 Copine-1 intracellular protein transport 5
24 Lgals1 Galectin-1 receptor binding 4
25 Il16 Interleukin-16 Immune response 11
26 Cct2 T-complex protein 1 subunit beta chaperonin 8
27 Otub1 Ubiquitin thioesterase OTUB1 hydrolase activity 2
28 Gimap4 GTPase IMAP family member 4 immune system process 2
29 Fkbp2 FK506-binding protein 2 immune system process 4
30 Gdi1 Rab GDP dissociation inhibitor alpha 5
31 Cct7 T-complex protein 1 subunit eta chaperonin 7
32 Got1 Aspartate aminotransferase, cytoplasmic transaminase activity 3
33 S100a10 Protein S100-A10 calcium ion binding 2
34 Sub1 transcriptional coactivator p15 transcription factor activity 4
35 Kpnb1 Importin subunit beta-1 transmembrane transporter activity 4
36 Psma2 Proteasome subunit alpha type-2 Proteolysis 4
37 Cct4 T-complex protein 1 subunit delta chaperonin 4
38 Pml Probable transcription factor PML ubiquitin-protein ligase activity 5
39 S100a11 Protein S100-A11 calcium ion binding 1
40 Sept1 Septin-1 small GTPase 6
41 Ran GTP-binding nuclear protein Ran GTPase activity 5
42 Ranbp1 Ran-specific GTPase-activating protein G-protein modulator 3
Table 4. 2: List of Unique proteins identified in Immunobody® Pentamer positive cell  
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These commonly identified proteins in each group were further used for shortlisting 
uniquely identified protein in each group.  183 proteins were common to both the group 
 
Figure 4.10: The shared identities obtained from each LC MALDI runs in ImmunoBody® and 
peptide groups. The common identities obtained from each groups were combined in a separate 
Venn diagram to obtain unique identities for each groups (129 identities for ImmunoBody® groups 
and 111 for peptide group).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Panel showing their functional classification of unique proteins based on their 
enrichment in two major ontological classes (Biological processes and Molecular function). 
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Figure 4.12: Panel showing the classification of these unique proteins based on their 
 cellular component. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.13: Panel showing the classification of these unique proteins based on 
 their biological process. 
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with 111 unique proteins identified only in peptide group and 129 identified in the 
ImmunoBody® high avidity group. The proteins identified in the high avidity groups were 
further filtered by removing any of the protein identities having only single peptide 
fragment associated and also by literature driven functional classification. This qualitative 
analysis shortlisted 42 protein identities associated with TRP-2 derived pentamer positive 
high avidity T cells. The detailed list of the proteins along with its functional association 
and number of peptide fragment identified in each of the protein are given in the table 4.2. 
4.4 Discussion 
4.4.1 Proteomic characterisation and the identification of candidate markers for 
high avidity responses 
Proteomic characterisations of the peptide specific cells were initially conducted with 
peptide specific cells isolated from single mouse. One of the bottlenecks of this study was 
the quantity of the proteins obtained from these cells were very low typically within the 
range of 5-10µg. Most of the proteomic techniques which involved any gel separations or 
fractionations need much higher quantity of proteins for a reproducible experiment. The 
only available technique to study this limited amount of proteins was separation in nano-
HPLC and analysis with MALDI-TOF. The initial studies done with LC-MALDI 
experiments yielded low number of identities (100-190 identities) combined with poor 
reproducibility between the runs indicated the protein quantity problems. To overcome this 
problem three animals were pooled together in to one and repeated the study which 
resulted in three times higher peptide specific cells and protein quantity. The experiments 
were repeated with good reproducibility and higher number protein identities (420-550 
identities) were obtained from these studies. The candidate peaks identified as 
differentially expressed between the groups were shortlisted and the identities for those 
peaks were obtained. Nine proteins were identified by these experiments as potential 
candidates. The detailed functional roles and their possible significance in avidity are given 
in the following section.                          
Plastin-2 also known as L-plastin or lymphocyte cytosolic protein is having a known 
functional association with the immune synaptic complex formation. This is an actin 
binding protein which relocalises to the immune synapse upon activation by TCR-CD3 
complex (Janji et al., 2006). The phosphorylation of plastin also facilitates the surface 
transport of the T cell activation molecules CD69 and CD25 (Wabinitz, et al., 2007). 
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Coronin 1A plays a crucial role in the cytoskeletal reorganisation of highly active and 
motile cell by forming invaginations of large plasma membranes (Ferrari, et al., 1999). 
Recent study showed the importance of coronin 1A in αβ T cells. The αβ T cells produced 
by  coronin 1A deficient mice leads to the development of poor quality T cells with 
impaired signalling properties such as decreased TCR-induced Ca2+ influx and 
phosphorylation and poor IFN-γ production (Mugnier, et al., 2008). 
Annexin A6 also known as Calphobindin-II is a calcium-dependent membrane-binding 
protein.  This protein interacts with signalling proteins such as GTPase-activating protein 
p120GAP which is considered to be one of the most important inactivators of Ras (Grewal, 
et al., 2005). They are Ca2+ dependant phospholipid binding proteins which act as 
membrane-membrane or membrane cytoskeleton linkers. So it may play an important role 
in the APC CTL interaction.     
14-3-3 protein beta/alpha protein is an adapter protein mainly involved in the modulation 
of signalling processes by binding to different binding partners usually involving 
phosphoserine and phosphothreonine motifs. The role in T cells yet to be addressed.    
GTPase IMAP family member-1 is the member of a new family of cell survival regulators 
(through apoptosis regulation) especially expressed on T lymphocytes. Studies have shown 
that these proteins played a crucial role in the survival of T cells during its development. 
Lymphocyte-specific protein 1 also known as 52 KDa phosphoprotein mainly reported to 
be present in the neutrophils involved in the phosphorylation events. Not many reports 
were available about its function in T lymphocytes. Since it is involved in the 
phosphorylation events heavily, therefore, it is worth investigating its role in T cell 
functionality further. 
Moesin with its partner ezrin plays an important role in the cytoskeletal organisation of 
activated T cells and the formation of synaptic complexes. Main function of these proteins 
was linking proteins to the actin cytoskeleton. Studies demonstrated that the deficit in ezrin 
and moesin in T cells leads to the decreased production of IL-2 and also low level 
production of phospholipase C-γ-1 phosphorylation and calcium flux (Shaffer, et al., 2009). 
So upregulation of this protein may play a crucial role in the T cell functional avidity.  
Ras related protein RAP 1 was first reported that it operates as an antagonist of Ras, 
competing c-Raf-1 (Dhillon, et al., 2005). More recently it was reported that Rap1 plays 
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additional roles such as activation of the ERK/MAP kinase pathway via B-Raf, promoting 
cell-matrix adhesion through the activation of integrins, and regulation of cell-cell 
junctions (Dhillon, et al., 2005). So it is an ideal candidate to investigate its role in high 
avidity T cells.  
The above candidate proteins identified were broadly involved in the functional category 
of cytoskeletal signalling and Ca2+ mobilisations, hence it is necessary to investigate the 
role of above identified proteins in the T cell activation events using time lapse confocal 
microscopy and FACS analysis in detail.  
The differences in functional avidity might attribute to the difference in the cell to form 
rapid cytoskeletal reorganisation (the ability to form quick synaptic complexes between 
high and low avidity T cells. It is also worth noting from the previous studies done else 
where highlighted the importance of membrane rafts and Ca2+ mobilisations in determining 
the functionality of T cells (Oh-hora and Rao, 2009), however, no one has ever 
investigated the role of these components in functional avidity maturation of antigen 
specific T cells. Apart from the above broad objectives all these protein identities will be 
studied further specifically in high and low avidity T cells with an objective of translate 
this data in to a clinically valid tool.  
4.4.2 Identification of uniquely expressed proteins in ImmunoBody® and peptide 
group using qualitative approach 
One of the potential limitations of LC MALDI based proteomics is that it’s not inherently 
good for quantitative studies. Often qualitative analysis is a useful tool for the 
identification of the proteins uniquely associated with one or other group. This qualitative 
segregation of the proteins were based on the assumption that if a protein is expressed high 
abundant, then the chances of identifying that protein is higher in shotgun bottom up 
proteomics given the fact that the control and test group were prepared in the same manner. 
This study has identified 111 unique proteins only in peptide low avidity group and 129 
identified in the ImmunoBody® high avidity group. 
The functional classifications of uniquely identified proteins in ImmunoBody® and peptide 
groups were checked for its functional (ontogenic) properties using PANTHER ontology 
classification programme (Thomas et al., 2003). This classification allowed the grouping 
of the proteins in to three basic functional terms known as molecular function, biological 
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processes and cellular components. This will allow us to detect the enrichment in each 
class by looking in to the whole identities qualitatively. 
In the functional class of molecular function major differences were identified in the 
number of proteins identified with cellular component organisations (17.9% vs. 12.3%), 
metabolic process (24.6% vs. 34.1%) and transport associated proteins (8.5% vs. 5.1%) 
(ImmunoBody® Vs. Peptide). In the biological processes class the most differences were 
observed are in the receptor activity (3.10% vs. 1.5%), Transcription regulator activity and 
translation (5.0 % vs. 2.9 %)) regulator activity (3.10% vs. 1.5%). Based on the location at 
which the identified proteins predominantly employ the function, the cellular component 
classification showed that the identified proteins were highly different between the high 
and low avidity group (ImmunoBody® and Peptide). ImmunoBody® group has identified 
mostly protein complexes (25% vs. 4.8%) whereas the most predominant class identified in 
cellular component ontology class in peptide group was ribonucleoprotein complexes 
(7.1% vs. 28.6%) . 
The regulation of T cell activation and function by ribonucleoproteins were studied and 
found their significant regulatory role in those processes (Mukherjee et al., 2009). 
However, how these complexes affect the positive or negative regulation of T cell 
functionality is not yet known. The enrichment of protein complexes in ImmunoBody® 
(high avidity) group might be due to the better priming of these cells using the DNA 
vaccine. It is evident from the literature that T cell activation and priming leads to the 
assembly of many protein complexes to complete the extracellular signals in to 
intracellular processes (Hartgroves et al., 2003) 
 By removing high abundant cellular proteins from the list 42 proteins were uniquely 
shortlisted which also showed previous T cell functional association. The  protein identities 
and their unique pathway association studies using literature survey suggested that some of 
these proteins have unique association to the pathways involved in T cell activation and 
functionality (Table: 4.2). Protein with most peptide fragment identified were clathrin 
heavy chain (18 peptides), IL16 (11 peptides), T complex protein 1 subunit beta and eta (8 
& 7 peptides respectively), ptprc (6 peptides), and Grap 2 (6 peptides).  
Clathrin heavy chain is involved in the receptor trafficking and endocytosis with in the 
cells (Brodsky, 2012) is a key molecule in T cell activation. This molecule is involved in 
the receptor internalisation of TCR after its activation by antigen (Crotzer et al., 2004).   
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IL16 is widely known as lymphocyte chemoattractant factor has been secreted by many 
immune cells including CD8 and CD4 T cells (Laberge et al., 1996). They present as an 
inactive form and required caspase mediation to get the active protein (Cruikshank et al., 
2000). The role of this cytokine in T cell functional modulations was not well studied. 
Ptprc (CD45) is a trans-membrane tyrosine phosphatase known to regulate various 
functions of T cell activation (Turka et al., 1992). Early studies showed its importance in 
preventing programmed cell death of T cells (Poggi et al., 1996), and also have the ability 
to modulate the TCR-CD3 mediated stimulation (Turka et al., 1992). The quantitative 
differences of CD45 has been also reported to have an influence on B cell development, 
survival and functionality (Zikherman et al., 2012), and in general a key controller of 
signal requirement (threshold) for the activation of many immune cells (Hermiston et al., 
2003).  
Grap2 also known as GADS is a SH2 & 3 containing adaptor protein which acts as a 
scaffold for many phosphorylation events during T cell activation. This is also involved in 
the activation of NFAT pathway (Law et al., 1999) and also plays an important role in the 
calcium mobilisation within the T cells (Yankee et al., 2004). So the identification of these 
proteins uniquely with high avidity group might be associated with the better signal 
competency of those cells. 
In general the enrichment of large number of proteins associated with T cell functionality 
such as small adaptor proteins and GTPases suggesting a better active and sensitive 
machinery of T cell are operating in high avidity TRP-2 ImmunoBody® derived pentamer 
positive cells. This might be probably due to the way these cells are primed using a DNA 
vaccine in an antigen specific manner. However further studies are required for the 
conformation of these observations using supporting experiments.    
5.4.3 Conclusions and future directions   
Global proteomic profiling of high and low avidity T cells using purified TRP-2 specific T 
cells were achieved successfully using LC MALDI platform. Good number of proteins was 
identified with this limited number of cells showing the utility of high throughput platform 
to study the limited but more meaningful biological samples in large scale. Looking into 
the immune cell profiling only few studies have looked the protein signatures in such a 
detail with very pure vaccine induced T cells. Many studies on T cells usually conducted 
with transgenic TCR bearing CD8+ cells such as OT1 (Ovalbumin TCR transgenic), or 
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Jurkat cell lines mainly because of the availability of large number of cells for sample 
demanding proteomic studies.  
Though the platform was able to identify large number of meaningful information from the 
high and low avidity samples, the inherent inability of LC MALDI to precisely quantify 
the proteins make the analysis difficult. Therefore, this studies employed a ‘pseudo-
quantitation’ approach to quantify the proteins by aligning the retention time across the 
samples and then looking for peak intensity differences between the samples. Even though 
it is a crude way of doing quantitation, it is the only label free method available for the 
machine setup used for the study. The qualitative differential analysis revealed more 
biologically relevant information associated with high avidity T cell, by identifying 
multitude of proteins associated with functionally important associations in many T cell 
pathway. These proteins were completely absent in the peptide group indicating these 
proteins were less abundant in the low avidity (Peptide) group. 
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Chapter 5 
Summary of Discussion 
5.1 Functional avidity (sensitivity) can be different in peptide specific cells having 
single epitope specificity. 
The goal of cancer immunotherapy is to help one’s own immune system to detect and 
destroy the malignant transformations happening within the body. However the hope for a 
successful therapeutic intervention still remains marginal, with only one successful FDA 
approved dendritic cell vaccine Sipuleucel-T (developed by Dendreon) providing a modest 
increase in life span of 4.1 months (median survival) with a huge therapy cost 
($90,000/treatment) in asymptomatic or minimally symptomatic metastatic castrate 
resistant (hormone refractory) prostate cancer. 
Over the past few decades, identification of tumour antigens as potential vaccine targets 
has become routine in the field of tumour immunology. Despite this, most T cell based 
cancer vaccine strategies remain unsuccessful (Jonuleit et al., 2001; Anichini et al., 1999; 
Lee et al., 1999). Some of these failures can be attributed to the nature of the antigens and 
the immune avoidance mechanisms operating in patients. Unlike prophylactic vaccinations 
using foreign antigens, tolerance mechanisms plays a key role in the attenuation of T cell 
responses in many therapeutic vaccine trials (Pawelec & Rees., 2002; Kyewski & Klein, 
2006). Trials conducted with many of these antigens generated sufficient numbers of 
antigen specific T cells, however, in the majority of cases the success was hampered by 
poor clinical efficacy. Antigens that performed well in preclinical models unfortunately did 
not translate into clinical outcome and some were even found to generate T cells which did 
not recognise and kill targets (Kudrin and Hanna, 2012).  
Detailed studies looking for the cause of these failures attributed mainly to 
immunosubversion and selection strategies devised by the tumour and its micro- 
environment (Zitvogel et al., 2006). Despite these immune suppression mechanisms, the 
type and functionality of the cytotoxic T cells generated through each vaccination are also 
important for mounting an efficient clinical outcome (McKee et al., 2005). There are many 
ways to assess the quality of T cell responses in vaccine trials. Among them affinity and 
structural avidity are two important indicators of T cell binding capacity at two different 
levels with the former indicate TCR binding strength and the latter being the overall 
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interaction strength between T cell and antigen presenting cell. Though in many cases the 
above two are good indicators of a good T cell functional prediction, it is functional avidity 
(biological readout of a T cell up on antigen stimulation) which is widely considered as the 
efficient way to assess the quality of T cell immune responses. Functional avidity, also 
known as “functional sensitivity”, is the measurement of a T cell’s ability to respond to its 
cognate antigen in a dose dependent manner (Viganò et al., 2012; von Essen et al., 2012; 
Amoah et al., 2012). The measurement of this functional property is usually carried out by 
T cell functional assays such as ELISpot, and chromium release killing assays in a dose 
dependent (titrating down target antigenic peptide concentration) manner (Pudney et al., 
2010; McKee et al., 2005). Depending on the antigenic stimulus requirement for half 
maximal activation (EC50), the T cell population can be generally classified into high 
avidity (requiring < 1 nM peptide), medium (requiring < 1-100 nM peptide) or low avidity 
(requiring >100 nM peptide) T cells (Snyder et al., 2003). In more generalised terms high 
avidity T cells requires very low concentration of antigens for their activation and vice 
versa for low avidity T cells.  
Success of an immunotherapy could be measured by the generation of high avidity T cells 
(Viganò et al., 2012; McKee et al., 2005). However, the current assays to measure these 
responses are laborious and need millions of PBMCs to generate the necessary titration 
curves. The difficulty increases if the peptide(s) responsible for the generation of these 
cells are unknown, such as with whole protein or cell vaccines and anti-checkpoint 
therapies. Therefore, there is a need to identify surrogate markers which can quickly and 
reliably identify high avidity T cell response in cancer vaccination settings. This study 
precisely focused on the identification of markers for a high avidity T cell response and 
investigating the mechanism at the gene and protein level using high throughput genomic 
and proteomic platforms.  
With the previously discussed need in mind, two mouse models, kindly provided by Prof. 
Lindy Durrant (Scancell Ltd., Department of Clinical Oncology, The University of 
Nottingham, UK) was used for this study. The first model was the C57Bl/6J-TRP-2180-188 
system which uses a self-peptide (SVYDFFVWL) derived from melanoma differentiation 
antigen tyrosinase related protein-2 (TRP-2). The DNA sequence of this peptide was 
inserted into a vaccine framework known as ImmunoBody®, developed by Scancell Ltd., 
known to generate a high avidity response in mouse compared to its peptide counterpart 
(Metheringham et al., 2009; Pudney et al., 2010). The second model, uses a foreign (non-
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self) peptide (Ovalbumin (OVA257-264) (SIINFEKL) antigen and was also used in this study 
to confirm the results. 
The first question to be answered in this study was the reproducibility of the model, and it 
was confirmed with multiple experiment that the ImmunoBody® vaccinations are 
consistently higher avidity than their peptide counterpart in both self (TRP-2) and foreign 
(OVA) peptide as measured by IFN-γ ELISpot assays (section 2.3.2). ImmunoBody® 
derived cells are capable of producing IFN-γ even at the lowest concentration of the 
peptide used for the assays. The EC50 calculated for ImmunoBody
® and peptide 
immunisations showed a two log difference for their antigen requirement for maximal 50% 
of activation in both TRP-2 and OVA. These sensitivity differences were further confirmed 
by intracellular cytokine staining and flow cytometry. These observations were in 
agreement by the previous observations made by Pudney et al., 2010 on this model. 
The only functional readout used for this study was peptide titration ELISpot assays 
against IFN-γ. This assay to measure functional avidity has been used widely in the 
literature (Berger et al., 2011; Draenert et al., 2004; Chen et al., 2009). Killing assays with 
TRP-2 specific high and low avidity T cells were conducted by Prof. Lindy’s group 
showed that ImmunoBody® generated high avidity T cells kill the antigen pulsed target 
cells more efficiently than the peptide counterpart (Pudney et al., 2010).  
The differences in spot count in ELISpot might be due to the differences in number 
(frequency) of peptide specific cells generated by both the vaccinations. To test this 
hypothesis, the splenocytes obtained from ImmunoBody® and peptide immunised animals 
were stained with TRP-2 or OVA pentamer depending on the antigen used. In both the 
OVA and TRP-2 immunised animals there was no significant differences were noticed 
between the group. However, OVA immunised animals generated more pentamer positive 
cells in both the peptide and ImmunoBody® model, indicating that it is more immunogenic 
in this settings. The low frequency of TRP-2 specific cells due to its self nature and 
therefore, T cells might be more tolerogenic towards TRP-2 compared to OVA. 
Although both vaccination strategies could induce the same number of TCR positive CD8+ 
T-cells, as assessed by the number of CD8+ T-cells stained for peptide-specific pentamer 
by flow cytometry, only the ImmunoBody®-vaccinated mice could induce T cells capable 
of secreting IFN-γ in response to very low concentration of peptides. If both immunisations 
generated the same overall number of peptide-specific T-cells then one might think that the 
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ImmunoBody® derived-T cells have more TCR on their surface and therefore less peptides 
are required for a signal to be triggered and the IFN-γ to be secreted. However, if this was 
the case the fluorescence intensity of the pentamer staining should be stronger with the 
ImmunoBody® derived-T cells but this was not observed so it appears that the difference 
between the T cells generated by these two very different vaccine strategies lies within the 
special organisations of the TCRs on the surface of the T cells with the CD3 and other 
molecules forming a sort of “pre-arranged/pre-functional” groups of TCR machinery 
which would then be extremely sensitive to the next peptide/MHC encounter or solely 
down to a more efficient signalling. However, this study hasn’t carried out a multimer 
decay assay to validate this assumptions.  
The presence of similar number of peptide specific cells in peptide and ImmunoBody® 
group and their differences in functionality towards the peptide assays suggesting that 
functional avidity maturation is the possible mechanism operating in ImmunoBody® high 
avidity group. The nature of the vaccine delivery might have played an important role in 
this process. Conventional peptide vaccines are known for their structural instability in the 
harsh in vivo environment full of peptidases (Slingluff, 2011). On the other hand, DNA 
vaccines are not susceptible to this problem since they are producing the encoded peptide 
epitope with in the transfected cells of the body and therefore ensure a constant supply of 
the peptide antigens at a moderate to low level to the cellular immunity (Rice, et al., 2008; 
Pudney, et al., 2010). The T cells are then constantly getting a chance to expose to this low 
but continuous antigenic stimulus for a longer period of time. This continuous stimulation 
of the repertoire is probably improving the sensitivity of T cells over the time. In contrast, 
peptide vaccines usually deal with periodic dosage of high concentration of the peptide and 
this might be selecting the low avidity T cells which required high concentration of 
peptides for its stimulation.  
Another possible reason for the ImmunoBody® vaccine generating high avidity T cell 
responses may be the coverage of the antigen presentation pathway. The ImmunoBody® 
are capable of perform direct and cross (indirect) presentation of the antigens to the 
immune system (Pudney, et al., 2010; Metheringham, et al., 2009). In the direct pathway, 
the injected plasmid can be taken up by dendritic cells and the ImmunoBody® produced 
within the dendritic cell before undergoing an endogenous processing pathway. The cross 
presentation route is by through exogenous processing of secreted ImmunoBody® epitopes. 
This epitopes has an antibody FC region which binds to the FCgR1 (CD64) present on the 
  
184 
 
dendritic cells and internalised by receptor mediated endocytosis (Durrant et al., 2011). 
This leads to the exogenous antigen processing pathway of DCs and cross present to the 
cellular immunity (Durrant et al., 2011; Pudney, et al., 2010; Stevenson et al., 2004; 2010). 
This way the antigen visibility is greater in ImmunoBody® compared to the peptide 
counterpart. The quantity of ImmunoBody® produced within the cell and the number of 
target peptide MHC complexes on the dendritic cells has not been previously studied. It is 
reasonable, based on this research to suggest that ImmunoBody® vaccines are capable of 
generating a high avidity response through presentation of low level of antigens to the 
CTLs, thereby selectively expanding the population of high avidity T cells (which can 
recognise the low doses of tumour antigens) (Pudney, et al., 2010). 
In vitro stimulations of both high and low avidity T cells at two different and extreme 
concentration (100 μg/mL and 10 ng/mL) of peptides reinforce the above argument that the 
high avidity repertoire in the ImmunoBody® immunised animals was shaped by the 
exposure of a precursor T cells to low concentration of the antigens. In both the 
concentrations tested in the above stimulations, high avidity T cells showed an overall 
reduction in the spot number indicating that they are susceptible to in vitro stimulations 
with relatively high concentration of peptide (section 2.3.4). This reduction in the spot 
number may be due to activation induced cell death (Vigano et al., 2012) due to serial 
triggering. Contrasting results in the peptide group by giving large number of spots in all 
the concentration tested after a week of in vitro stimulation with (100 μg/mL: and 10 
ng/mL) of peptides (section 2.3.4) suggesting that antigen sensitivity of T cells can be 
extensively modified depending on the nature stimulations they have received.  
In viral systems, it has been showed that the T cells can undergo functional maturation 
during the course of infection, without selecting high affinity receptors (Slifka & Whitton 
et al., 2001). Similarly, functional avidity maturation might be happening in tumour 
vaccination settings as well, but it is not well studied. Instead tumour vaccination strategies 
always looked in to the improvement of TCR affinity to achieve maximum clinical 
outcome (Wooldridge et al., 2012). Unfortunately tumour immunologist choose another 
path of transfecting the T cells with high affinity receptors for making a super affinity T 
cell which can detect and mobilise immediately to the tumour site and eradicate them 
(Savoldo and Dotti 2013) However, like dendritic cell based vaccines this is also expensive 
and requires an expert skill set and advanced laboratory conditions to perform the adoptive 
transfer of engineered T cells (Kodumudi et al., 2012). 
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The immunophenotype of pentamer positive cells revealed there was no noticeable 
phenotypic polarisation of these cells after 45 days of initial immunisation (section 2.3.5). 
Probably longer exposures might be required for this to be happened. One inhibitory 
molecule studied (BTLA) also showed only less pronounced differences between high and 
low avidity T cells indicating these cells are undergoing a more or less similar 
developmental path up to 45 days. However studies with these models by Brentville et al., 
2012 found that after 70 days of initial immunisation with TRP-2 ImmunoBody® high 
avidity T cells are selected in to the memory and the recalling of memory with 
ImmunoBody® boost results in the resuming of the function. However, peptide boosts lead 
to the rapid reduction in the avidity. All these data indicating the plasticity of avidity as a 
functional property, now it is up to the tumour immunologist to tap in to this area to 
modify physiologically occurring T cells properties against the TAAs with low avidity into 
higher functionality. 
5.2 Global and targeted transcriptomic changes could differentiate high and low 
avidity T cells 
Normally, gene expression studies of immune cells are carried out using bulk immune cells 
such as PBMC’s, whole blood cells or total splenocytes. Though such studies are useful at 
times, the cellular heterogeneity in the initial sample population is very high. This 
heterogeneity often leads in to misinterpretation and hence modern gene expression studies 
demand purified or enriched starting cell populations. (Espina et al., 2006; Demou & 
Hendrix, 2008). Therefore this study decided to enrich the population of antigen specific 
CD8+ T cells from the total CD8 repertoire and so that any observed expression changes 
can be clearly attributed to the cellular phenotype.  
The successful enrichment of TRP2 and OVA peptide specific cells were carried out using 
the magnetic separation (section 3.2.3). The enriched populations were further studied 
using various expression platforms to interrogate the expression differences between high 
and low avidity T cells (sections 3.2.8-3.2.11). At first the basal expression of TCR 
signalling was investigated real time quantitative PCR. Even though some differences 
could be observed in general, none of them were statistically significant. This may be due 
the resting stage of the TRP-2 specific cells or that the differences were very subtle and not 
to be resolved by the relative quantitation method used in this study. 
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If there is any differences in the signal competency between these cells, activation of these 
cells ex vivo would be an ideal mechanism to study the signal difference upon exposure to 
the antigenic peptide. In the lab ELISpot has been routinely used for measuring the 
functional avidity of the T cells. The CD8+ T cells isolated from these ELISpot plates can 
be an ideal material for assessing TCR status was assessed between the high and low 
avidity T cells. No significant differences could also be detected between these cells, 
indicating the time used for harvesting the cells (48 h after the initial stimulation as per the 
normal ELISpot protocol) were not ideal for studying the gene expression differences, 
though they were appropriate for secreted protein studies such as IFN-γ.  
In the next stage of this study, a more structured approach was followed, with the TCR 
signalling competency were studied at three stages of activation (0h, 1h and 2h). CD3, 
CD28 coated micro-beads were chosen to avoid the TCR stimulation so that cells in each 
group (high and low avidity) will receive a uniform signal. If there are differences in their 
cellular machinery, they would transmit the signals differentially. TRP-2 pentamer purified 
population of T cells from ImmunoBody® and peptide immunised animal were used for the 
study with the assumption that these the naive T cell repertoire was shaped in a different 
way between the two vaccine strategies (Peptide/ ImmunoBody®) because these two 
vaccines might have primed the T cell differently. This kinetic study yielded some 
surprising results with up regulation of predominantly all the genes studied in the 
ImmunoBody® group compared to the peptide group. The genes used for these studies can 
be broadly classified into three categories as 1) genes involved in the proximal signalling 
(beginning of TCR signalling) 2) the ones which associated with the distal signalling 
(further down the cascade) 3) T cells associated transcription factors (final point). The two 
genes which did not showed any differences were associated with the proximal signalling 
events in TCR signalling and this suggested that the signalling starts uniformly and when it 
cascaded down the molecular machinery of ImmunoBody® derived cells are better 
equipped and therefore transmitted the signals more efficiently leads to the up regulation of 
other genes. The major genes that were upregulated were associated with MAP-MAPK 
pathways and cytoskeletal remodelling with many of them previously known to influence 
the functionality of T cells (Villalba et al., 2000; Wu et al., 1996). So upregulation of these 
pathways can be used as a good marker for functional avidity.  
Global gene expression profiling was carried out with TRP-2 and OVA specific pentamer 
sorted high and low avidity CD8+ T cells using Affymetrix® high density oligonucleotide 
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microarrays to identify the most differentially expressed genes. The array hybridisation has 
been successful with low number of cells (1x105 cells) and the analysis performed between 
the high and low avidity groups have identified genes which have a differential expression 
(338 genes in TRP-2, 239 genes in OVA model) pattern between high and low avidity T 
cells. Though there are differences between the two groups they were very subtle. This 
might be probably due to the resting stage of these cells. 
The major genes identified using these global platforms, which are also functionally 
important for T cell biology were Granzyme A, Granzyme B, Fas Apoptotic Inhibitory 
Molecule, Telomerase RNA Component, CD5 Antigen-Like, Spi-C Transcription Factor. 
The up-regulation of Granzyme transcripts was unanticipated. One possible explanation for 
that might be attributed to the constitutive expression of TRP-2 ImmunoBodies® in the 
mice compared to the peptide counterpart. As discussed in the previous section the 
constitutive expression of a DNA vaccine has the possibility of priming the naive, already 
antigen experienced and clonally proliferated T cells again and again. 
 At this point it is worth mentioning that the gene gun immunisations on the shaved 
abdomen of the mice resulted in vitiligo at the site of immunisation in the majority of the 
prophylactic strategies we have tried (Pudney et al., 2010). This vitiligo is the destruction 
of melanocytes by T cells indicating that they are in a more activated state in the 
Immunobody immunised mice compared to the peptide immunisation, where no indication 
of depigmentation was observed. Selected microarray shortlisted markers (Granzyme A, 
Granzyme B, Fas Apoptotic Inhibitory Molecule, Telomerase RNA Component, CD5 
Antigen-Like, Spi-C Transcription Factor) were subjected to qRT PCR for confirmation. 
Only three out of six genes tested showed positive correlation with the array data which 
included granzyme A and B, CD5L. Further proteomics confirmations were done on these 
cells using murine granzyme A and B. Initial studies failed to detect any significant 
changes between high and low avidity groups without stimulation probably due to the low 
abundance of the protein to be detected by intracellular staining. Hence the cells were 
stimulated with a low concentration of TRP-2 peptide and the study carried out with the 
assumption that if there were any differences in granzyme A and B expression, these 
differences should be amplified by peptide specific stimulation. The initial data suggested 
that there was a difference in the protein expression of granzyme A and B between high 
and low avidity T cells and therefore could be used for an ideal marker for differentiation 
of high and low avidity T cell response. If it is successfully validated, they could be used 
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as a marker for monitoring avidity in patients on vaccine trials, since they are the effector 
molecules of cellular cytotoxicity. The expression of these molecules is also an indication 
of how effectively they would be at killing the target. Granzyme B is a classically studied 
molecule of T cell cytotoxicity; however granzyme A is not reported very well in the 
literature in association with CTL function. In this respect it is worth investigating the dual 
role of these molecules in ImmunoBody® generated T cells by selectively blocking one or 
other using antibodies in killing assays. 
5.3 Successful global proteome profiling of pentamer sorted T cells identified 
uniquely expressed protein in high avidity group 
 Studying low number of cells using global proteomic characterisation is a huge challenge; 
still within these limitations, this study successfully produced a global proteomic data for 
antigen specific T lymphocytes using around 1x 105 cells. Protein concentrations were low 
(Table 4.1), however, LC fractionation was successful. 420-550 proteins were identified 
from these set of samples. A ‘pseudo’ quantitative method based on the peak intensity was 
employed to identify candidate precursor mass which was different between Immuno- 
Body® and peptide group, these peaks were subsequently fragmented using MS/MS and 
protein identities were obtained. The protein identities obtained are Plastin-2, Coronin 1A, 
Annexin A6, 14-3-3 protein beta/alpha protein, Lymphocyte-specific protein 1, Ras related 
protein RAP1 and Moesin. Plastin and coronins are involved in the cytoskeletal 
remodelling (Janji et al., 2006; Wabinitz, et al., 2007) and coronin along with annexin 
involved in Ca2+ signalling and also interact with GTPase-activating protein p120 GAP an 
inactivators of Ras (Grewal, et al., 2005). GTPase IMAP family member-1 contributes 
towards the enhanced survival of T cell. Identification of these proteins with higher peak 
intensities in the ImmunoBody® vaccinated group indicated that these proteins might be 
highly expressed in high avidity group. These studies further looked with the unique 
identities identified with ImmunoBody® group (Table 4.3). Ontology classification allowed 
further dividing these proteins in to three functional ontologic classes (molecular processes, 
biological function and cellular component) to investigate any enrichment of particular 
functional classes of the proteins in the total differentially identified proteins. Generally 
large no large differences were observed, however, the ImmunoBody® vaccinated group 
showed significant functional enrichment in proteins involved in the intracellular regions 
(mainly signalling components) again indicating that these cells may be constantly exposed 
to a low dose of ImmunoBody® antigen within the body. This might be possible since 
  
189 
 
these vaccine has been incorporated into the cellular system of the host; hence it is 
reasonable to imagine that the cells will get a constitutive stimulation. This argument was 
again reinforced in the qualitative analysis, where 129 protein identities identified in the 
ImmunoBody® high avidity group. Among the proteins identified, the pathway 
associations of these molecules were Investigated in to literature and found that some of 
these proteins were associated with pathways related to T cell activation and differentiation 
(Table 4.3). Molecules such as IL16 (11 peptides), T complex protein 1 subunit beta and 
eta (8 & 7 peptides respectively), ptprc (6 peptides), and Grap 2 (6 peptides) were involved 
in the T cell functionality when they are in active stage. The identification of Clathrin 
heavy chain particularly significant since it was involved in the receptor trafficking and 
endocytosis within the cells (Brodsky, 2012) might be playing an important role in the 
TCR recycling (Crotzer et al., 2004) in the ImmunoBody® derived cells. Overall, an 
enrichment of large number of small adaptor proteins and GTPases and GADS pointing 
towards a better active and sensitive machinery of high avidity T cell in ImmunoBody® 
derived pentamer positive high avidity T cells. However, further studies are required for 
the conformation of these observations using further experiments such as western blots or 
FACS. However this work has proved that it is possible to get a glimpse of the proteome of 
antigen specific T cells and study more than 400 proteins in a single experiment. 
5.4 Conclusions and future directions 
The two different vaccination strategies generated equal number of peptide specific cells as 
measured by pentamer staining. However only one of them (ImmunoBody®) was capable 
of producing IFN-γ in peptide titration ELISpot assays, indicating that they are 
functionally different in their response to the cognate antigenic stimulus. The avidity 
measurement indicated that ImmunoBody® derived high avidity, and peptide derived low 
avidity, has a 2 log difference in their antigen requirement for maximal activation. 
However, low avidity T cells were shown to restore their functionality once exposed to the 
antigenic stimulus in vitro whereas the low avidity ones die, possibly due to activation 
induced cell death. This suggests that great care should be taken while designing the cancer 
vaccines and appropriate consideration must be given to determine the avidity of vaccine 
generated T cells to avoid the killing of high avidity T cells. Gene expression kinetic 
studies indicated that there are significant differences in the signalling competency 
between high and low functional avidity T cells with high avidity transmit the signals more 
efficiently. However more studies are necessary to examine the phosphorylation status of 
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these two primed cells before reaching final conclusion. A new hypothesis can be derived 
from this study is that the physiological and molecular changes happening during the naïve 
T cell priming leave the molecular machinery for better activation in high avidity cells, so 
that they will respond to the subsequent activation much efficiently. Gene expression 
microarray analysis was successfully carried out with low number of peptide specific cells 
with observed transcriptional changes between high and low avidity T cells types. 
However the differences were subtle and the reason may be that the studies were not 
conducted on the activated peptide specific T cells and this will be a future priority for 
global gene expression profiling of resting and activated high and low avidity T cells. 
Global proteomic profiling of high and low avidity T cells using purified TRP-2 specific T 
cells were successfully completed. Though several identities were obtained, the 
quantitation still remains a problem because of the inherent inability of LC MALDI to 
precisely quantify the proteins. Future work will be needed utilising more appropriate 
quantitative mass spectrometry instrumentation. 
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Chapter 7 Appendix 
 
 
Appendix:  
Figure 7:1 Pictures of ex vivo IFN-γ ELISpot Plates from TRP-2 and ova antigen 
immunisations 
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Figure 7.2:   Pictures of IFN-γ ELISpot Plates from TRP-2 and ova antigen 
immunisations after in vitro stimulations 
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Figure 7.3: Binding specificity of MHC multimer used for this study 
 
Figure:7.3. Binding specificity of the pentamer used for this study. A. Staining of 
CD3 and CD8 markers showing CD8+ CD3+ T cells. B. Staining of MHC pentamers 
on the cells isolated from the spleen of a naive mice (Gated on CD8+ CD3+ cells). C 
and D Staining of MHC pentamers on the cells (spleen) isolated from Immunobody 
and peptide immunised animals (Gated on CD8+ CD3+ cells) after 45 days of the 
first immunisation.  E and F MHC pentamers tested on the TRP-2 SVYDFFVWL 
TCR transgenic splenocytes kindly provided By Prof. Arthur Andrew Hurwitz, 
National Cancer Institute, USA. E. Detection of high structural avidity T cell 
(SVYDFFVWL specificity) C. Detection of low avidity T cell 
(SVYDFFVWLspecificity).  
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Figure showing the enrichment of CD8+ cells prior to the isolation of 
pentamer positive cells. The left side panel shows total splenocytes and 
the right side shows purified fraction  
 
Figure 7.4: Purity of CD8 enrichment 
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Figure: Effective binding of the antibodies used for immuno-phenotyping. Top panel 
showing a histogram plot with positively stained population. Bottom panel is showing the 
positive gating of these cells as a density plot. For the purpose of identifying positive 
staining the cells were gated on t. otal CD8+ CD3+ population and not on antigen specific 
pentamer positive cells 
Figure 7.5:   Binding specificity of antibodies used for immune phenotyping 
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Appendix VI Genes up-regulated in Immunobody. Raw expression values are given in a log scale (TRP-2 model) 
NAME Descrption TRP-2 IM1 TRP-2 IM2 TRP-2 Pep1 TRP-2 Pep2 NAME Descrption TRP-2 IM1 TRP-2 IM2 TRP-2 Pep1 TRP-2 Pep2
10412211 Gzma 9.589867 9.08598 5.731719 7.910787 10593198 Fam55b 8.56933 8.533388 6.607595 8.381689
10517513 C1qc 9.915211 10.07822 5.80855 9.193348 10525365 Hvcn1 9.249723 10.69202 8.991926 8.90536
10572897 Hmox1 10.87203 11.17641 7.251457 10.20731 10528207 Cd36 8.380288 9.683527 7.571501 8.418983
10541605 Clec4n 7.82252 8.360159 4.335455 7.207325 10562812 Spib 8.696977 10.4688 8.364212 8.759653
10517508 C1qb 10.29355 10.54361 6.732691 9.586124 10406928 Cd180 9.066186 10.93495 8.977813 9.003679
10354374 Slc40a1 9.374151 10.05637 6.020717 8.896749 10467979 Scd1 9.226393 11.42562 9.375266 9.272377
10501608 Vcam1 9.940613 10.07201 6.774196 9.313292 10557399 Sbk1 8.115637 9.212299 7.525062 7.745033
10492964 Cd5l 7.999214 7.922586 4.941354 7.083319 10602372 Alas2 8.861356 7.982565 6.247273 8.537067
10480849 Fcna 9.464057 9.581237 6.44323 8.831555 10444291 H2-Ab1 12.54194 13.16456 11.40329 12.44177
10517517 C1qa 9.426667 9.470099 6.348067 8.9394 10360684 Ephx1 7.802707 9.163388 7.598841 7.335053
10371662 Spic 8.086142 8.361504 5.5297 7.458381 10531610 Rasgef1b 8.74185 9.797302 8.015669 8.530432
10432176 Snora34 9.773756 10.79492 8.46547 8.787658 10382844 Snord1c 6.273273 7.03448 5.694345 5.50728
10389894 Abcc3 7.823934 7.958979 5.513885 6.856365 10386093 Snord1c 6.273273 7.03448 5.694345 5.50728
10461162 Snord22 9.405281 10.35747 8.280205 8.16065 10439312 Cd86 7.842793 8.885528 6.795788 7.906504
10446282 Emr1 8.210877 8.678833 5.523114 8.043721 10461158 Snhg1 8.462978 8.651784 7.393661 7.705073
10561104 Axl 8.773106 8.826503 6.169617 8.179367 10512669 Pax5 8.150686 10.03154 8.134851 8.056373
10590628 Ccr3 7.182745 8.04994 5.042803 6.902711 10432178 Snora2b 6.24492 7.502478 5.908464 5.749757
10461148 Snhg1 6.847205 8.113957 5.876047 5.804968 10380571 Gngt2 6.999265 8.341341 6.43324 6.854496
10487588 Il1a 6.580138 6.957129 4.286168 5.994854 10420308 Gzmb 9.922928 8.828732 8.345399 8.446661
10475890 Mertk 7.997388 8.232366 5.7192 7.35084 10460392 Pold4 8.111415 9.717979 7.891159 7.960004
10571840 Hpgd 8.124514 8.688388 6.084416 7.617432 10562132 Cd22 8.115824 10.34049 8.534281 7.964089
10516906 Snora73b 12.67959 13.12858 11.10118 11.80032 10416340 Gfra2 7.534735 7.674738 6.012338 7.170517
10576757 Fcer2a 7.054664 10.36507 7.722066 6.66023 10549647 Ncr1 6.21598 8.352924 5.640357 6.890463
10362674 Rnu3a 11.68785 12.06138 10.18383 10.71121 10404840 Cd83 10.60115 11.41025 9.939986 10.20299
10604076 Snora69 9.504164 10.70633 8.840189 8.452264 10565813 Snord15a 9.744101 10.61673 9.14128 9.314711
10376887 Snord49a 9.310322 10.78306 8.543922 8.639715 10359754 Mpzl1 7.898453 7.716675 6.276272 7.331823
10498367 P2ry13 7.589698 8.129551 5.499421 7.226751 10444298 H2-Eb1 12.27614 12.92093 11.21675 12.19009
10508719 Snora16a 10.19817 11.49014 9.330112 9.520072 10456071 Csf1r 9.208694 9.498959 7.884416 8.899006
10349593 Faim3 10.37903 11.51175 9.273946 9.784533 10556206 Snora3 10.85592 11.62804 10.4058 10.24237
10445758 Treml4 9.258013 9.518743 7.164486 8.745387 10570432 Snora3 10.80808 11.59458 10.37434 10.1937
10420758 Blk 8.778323 10.11146 7.749572 8.294958 10365559 Igf1 6.34639 6.68378 4.884417 6.103601
10516908 Snora73a 12.71691 12.91903 11.11018 11.83317 10552380 Siglecg 7.398795 9.102331 7.078908 7.457997
10377429 Snord118 9.840086 10.91598 8.680268 9.278258 10446553 Epb4.1l3 6.304914 6.314565 4.90934 5.65973
10399428 Snord118 9.840086 10.91598 8.680268 9.278258 10450363 Snord52 6.313813 7.771177 5.987106 6.08076
10557928 Itgad 8.493612 8.792257 6.380451 8.042044 10391649 Slc4a1 11.1644 9.719302 7.972857 11.05589
10445953 Emr4 7.24434 7.905445 5.316432 6.990599 10500295 Plekho1 9.880741 10.7892 9.092258 9.722798
10603860 Cfp 9.903337 10.47845 7.880783 9.784018 10489204 Tgm2 8.704157 8.638174 7.064716 8.365243
10572669 Fam129c 8.095046 9.628594 7.173551 7.785551 10515429 Snord55 10.50967 11.53235 10.15942 10.07807
10434932 Fam43a 7.934694 9.46143 7.222821 7.437933 10509002 Rhd 9.879602 7.918889 6.282712 9.61893
10444284 H2-Ob 9.369182 11.00211 8.717368 8.991334 10358733 Rgl1 7.230938 7.912672 6.167732 7.027921
10567863 Cd19 8.841819 10.62243 8.383888 8.433625 10455015 Vaultrc5 9.33708 9.856716 8.397053 8.940981
10347335 Slc11a1 9.182103 9.442764 7.292714 8.667005 10545192 Rprl1 9.500235 9.78429 8.707607 8.723711
10481101 Snora43 10.14342 10.5157 8.620813 9.429207 10353034 Snord87 10.09444 11.04696 9.651169 9.690675
10368277 Rps12 8.732088 9.439003 7.665389 7.87585 10408600 Serpinb6a 6.863996 6.959473 5.373998 6.503882
10508721 Snora44 11.85772 11.34685 9.985884 10.70804 10573054 Gypa 9.39338 7.996819 6.213872 9.311585
10369301 Chst3 6.309884 8.257577 6.1151 5.766916 10465831 5730408K05Rik 9.47921 9.33142 8.336817 8.689937
10444223 H2-Oa 8.446677 10.14124 7.687684 8.317366 10563085 Fcgrt 8.543394 8.544001 7.291391 7.975061
10494413 Rnu1b1 10.39444 10.66964 9.224343 9.312216 10443506 Fgd2 8.512315 9.472265 7.746667 8.441962
10494421 Rnu1b1 10.39444 10.66964 9.224343 9.312216 10590267 Snora62 7.850598 8.264646 6.976917 7.304422
10500343 Rnu1b1 10.39444 10.66964 9.224343 9.312216 10506488 Ppap2b 5.858487 6.673142 4.997478 5.625985
10500358 Rnu1b1 10.39444 10.66964 9.224343 9.312216 10351781 Kcnj10 6.516372 6.943178 5.111654 6.487891
10512937 Rnu1b1 10.39444 10.66964 9.224343 9.312216 10600355 Snora70 8.458153 8.631198 7.441567 7.872429
10489246 Mafb 6.983207 7.065101 5.351636 6.046548 10417526 Dnase1l3 9.511496 10.04841 8.234589 9.612614
10421128 Adamdec1 6.924807 7.544652 5.016084 6.820369 10376885 Snord49b 12.65885 13.37 12.18243 12.28089
10583312 Taf1d 9.524443 10.5322 8.402685 9.176725 10537909 Rny3 13.53883 13.73761 13.05898 12.6803
10592888 Cxcr5 6.944347 8.681185 6.64759 6.4082 10557895 Itgax 8.169209 8.522425 6.814348 8.104808
10419674 Snord8 9.96397 11.1686 9.324019 9.38326 10515425 Snord38a 5.942158 7.205748 5.720703 5.580857
10501922 Snhg8 10.67548 11.28314 9.419006 10.14829 10489235 9430008C03Rik 8.865037 9.365599 8.030067 8.472673
10360145 B930036N10Rik 9.97566 10.52721 9.297438 8.802517 10563099 Snord35b 11.72145 12.65988 11.47022 11.34032
10491058 Rprl2 11.79775 12.20421 10.77675 10.90046 10363860 Slc16a9 6.660229 6.819273 5.583716 6.085406
10492971 Fcrl1 7.082126 9.05241 7.070755 6.574193 10563112 Snord33 11.84336 12.51105 11.41631 11.37053
10548504 Klra8 5.414029 6.884009 4.315355 5.411291 10484987 Nr1h3 6.931929 7.356722 5.92274 6.577335
10494411 Rnu1b1 10.39305 10.61123 9.367935 9.269728 10576784 Cd209a 6.929454 8.057871 6.354747 6.860675
10494417 Rnu1b1 10.39305 10.61123 9.367935 9.269728 10390505 Snora21 9.019244 9.406793 8.174484 8.560115
10500356 Rnu1b1 10.39305 10.61123 9.367935 9.269728 10502335 Bank1 8.499734 10.86738 8.937159 8.760662
10358399 Rgs13 4.197691 6.447623 4.083524 3.988812 10534935 Pilrb1 7.546444 7.687526 5.719011 7.757407
10590031 Itga9 7.138973 7.679647 5.471708 6.8682 10352000 Kmo 7.207993 8.886125 6.966573 7.39296
10566258 Hbb-b2 13.30799 13.08477 10.84867 13.34158 10470555 Gbgt1 6.179564 6.093713 5.23596 5.217745
10566254 Hbb-b1 13.35606 13.08733 10.87341 13.38039 10565811 Snord15b 12.18854 12.55946 11.61969 11.58797
10444306 H2-Eb2 8.130914 9.729858 7.742852 7.757351 10450154 H2-Aa 12.15588 12.94525 11.22451 12.35182
10444236 H2-DMb2 10.33709 11.63158 9.590322 10.11351 10477250 Hck 8.511951 9.59916 7.773345 8.657495
10492983 Fcrl5 7.623876 8.733533 6.881544 7.087032 10469358 Mrc1 7.579521 7.964271 6.441591 7.364956
10351515 Rnu1b1 10.1555 10.4423 9.176587 9.128 10478678 Cd40 7.321283 8.333824 6.842777 7.078229
10351043 Snord47 11.232 12.12241 10.6244 10.51655 10556297 Adm 8.249062 7.596461 6.313666 7.802503
10562720 Siglece 7.643154 7.809888 5.537147 7.541424 10548422 Klri2 5.12991 6.528691 4.293539 5.547582
10445293 Pla2g7 8.115096 8.500911 6.434896 7.878008 10596148 Trf 9.555169 9.783866 8.281093 9.416269
10544523 Rny1 10.7967 11.84141 10.6095 9.878319 10556244 Snora23 8.911791 9.615429 8.844393 8.023393
10461487 Cybasc3 9.10546 10.26627 8.551228 8.60676 10553559 Siglech 6.211782 7.411462 5.850393 6.005884
10579331 Gdf15 7.632402 7.790726 5.888381 7.250942 10519607 4930420K17Rik 9.196369 10.57047 9.098394 9.053179
10512470 Cd72 9.874437 11.35883 9.51758 9.563251 10533720 Niacr1 7.15239 7.385021 5.763688 7.050668
10531952 Abcg3 7.469491 8.123319 6.006011 7.31124 10402512 Scarna13 10.76602 10.82987 9.710416 10.32201
10466172 Ms4a1 9.925154 11.6663 9.636942 9.8137 10415857 Fam167a 6.739068 7.718857 6.255171 6.486626
10461154 Snhg1 6.231544 7.05336 5.097746 5.864447 10363475 Prf1 8.123374 8.358061 7.274094 7.540363
10500345 Terc 12.29068 12.83291 11.28422 11.79408 10604743 Snord61 7.891029 8.807808 7.501167 7.543459
10529732 Hs3st1 6.124646 8.403053 6.528101 5.756297 10551025 Cd79a 10.65185 12.17768 10.67324 10.64272
10368675 Marcks 8.461849 9.336082 7.343792 8.287498 10484888 Ptprj 9.16923 10.13482 8.682972 9.031823
10404606 Ly86 10.18803 11.47179 9.554667 10.03653 10454807 Snora74a 11.32218 11.6171 10.66083 10.77147
10560624 Apoe 10.87007 11.33939 9.33447 10.81945 10576034 Irf8 10.01123 10.88662 9.256189 10.09975
10375360 Ebf1 8.180679 10.34128 8.248497 8.155461 10361292 Cr2 6.299931 9.565512 7.80933 6.418388
10521678 Cd38 8.964314 10.36575 8.573173 8.657997 10531407 Cxcl9 8.429946 8.140371 6.534154 8.418097
10505071 Tmem38b 9.208268 9.514099 8.422078 8.199805 10497481 2810416G20Rik 7.191314 7.635533 6.195167 6.976489
10433578 Snn 6.965196 8.216871 6.639387 6.364717 10444229 H2-DMa 10.22089 11.49057 9.649928 10.56882
10430186 Apol7c 8.113007 8.366554 6.600251 7.734829 10593473 1810046K07Rik 9.230952 9.145272 7.581236 8.70209
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Appendix VII Genes down-regulated in Immunobody. Raw expression values are given in a log scale (TRP-2 
model) 
NAME Descrption TRP-2 IM1 TRP-2 IM2 TRP-2 Pep1 TRP-2 Pep2 NAME Descrption TRP-2 IM1 TRP-2 IM2 TRP-2 Pep1 TRP-2 Pep2
10569017 Ifitm3 9.637287 9.857903 10.49467 11.11666 10386058 Sparc 6.287923 6.142701 8.378756 6.516499
10403821 Tcrg-V3 8.820829 8.122258 10.04784 8.955576 10385428 Itk 9.477957 7.72432 10.30216 9.473875
10457733 B4galt6 6.308984 6.334962 7.227243 7.386437 10385518 Tgtp1 8.056376 7.760482 9.476921 8.885838
10365749 Lta4h 7.987337 7.987864 8.896038 9.127562 10379633 Slfn1 6.96968 6.542465 8.299047 7.711625
10596279 Dnajc13 5.071257 5.796882 6.716968 6.087835 10554094 Igf1r 7.451108 6.377673 8.207121 8.135328
10396712 Fut8 8.004765 7.836905 9.405346 8.489271 10421517 Cysltr2 4.871775 4.164931 6.199124 5.27795
10589654 Als2cl 6.149069 5.42206 7.431859 6.097953 10402981 Gm900 5.859273 6.108444 7.756779 6.749736
10596543 Rad54l2 5.747794 5.739632 7.052429 6.398836 10597098 Camp 7.109243 7.993564 8.040306 9.68683
10415784 Trim13 7.051756 6.623665 7.983385 7.708501 10488382 Cd93 6.893817 7.489754 8.906891 8.14621
10551815 Zfp260 6.093111 6.250867 7.638571 6.697249 10472235 Dapl1 9.577905 8.432557 10.95892 9.816936
10571274 Gsr 8.78372 8.293302 9.226282 9.96719 10543120 Ica1 4.808833 4.379165 6.101148 5.659763
10542993 Pon3 8.473999 8.275257 9.840219 9.028057 10363070 Gp49a 6.611547 7.164611 7.764619 8.698249
10536505 Met 4.988557 4.896088 6.104732 5.75148 10563712 Mrgpra2a 5.13889 5.159265 5.877431 7.105302
10393887 Pycr1 7.5927 7.121058 8.780922 8.018259 10485622 Qser1 6.158895 6.160885 7.721083 7.337097
10363082 Lilrb4 6.263291 7.172405 7.351449 8.14273 10504757 BC005685 6.748187 6.4626 8.704298 7.288231
10454632 Camk4 5.854827 5.219637 7.05974 6.028613 10347291 Cxcr2 4.739384 4.58604 5.166677 6.857328
10547740 C1s 3.758599 3.990427 5.464801 4.224479 10487238 Hdc 7.197366 7.16186 8.034441 9.18722
10560242 C5ar1 4.96135 5.309272 5.515269 6.755356 10403066 Gm16710 8.5035 8.421247 10.68936 9.176223
10548385 Olr1 4.154801 4.312653 5.014004 5.420711 10497548 Fndc3b 7.839392 7.009982 9.561564 8.184456
10392183 Ern1 7.756928 7.190834 8.844728 8.221866 10543239 Tcfec 5.832731 6.110675 7.463833 7.326643
10495596 Frrs1 6.74356 5.809929 7.411004 7.210453 10547664 Clec4e 5.526101 5.288092 6.249053 7.398663
10391697 Itga2b 6.583876 6.423945 7.516446 7.573705 10414262 Ear2 9.2597 9.078118 8.884237 12.47751
10565994 Art2b  // Art2b 4.788126 5.126945 6.993124 4.936018 10501229 Gstm1 7.033997 7.125841 8.391186 8.745188
10407327 Emb 9.682821 8.756377 10.49698 10.15176 10415015 Gm13949 4.708076 3.535243 6.299806 4.79687
10542857 Far2 5.293806 5.11835 6.282934 6.160043 10401900 Sel1l 9.246717 8.739494 11.21195 9.850601
10367843 Utrn 7.154034 7.214114 8.730898 7.770291 10474700 Thbs1 7.638734 7.917637 8.428293 10.15216
10607952 Vamp7 7.594597 7.840863 9.098844 8.498391 10435288 Muc13 6.631204 5.442288 7.515738 7.508502
10400844 Pygl 6.875453 6.72273 7.346099 8.412729 10574276 Gpr97 6.478508 6.084798 7.755714 7.770935
10440002 Gpr128 4.97195 4.584596 5.73121 5.905748 10408928 Hspb1 8.075319 7.329114 8.845095 9.586127
10433584 Tnfrsf17 8.541339 8.018451 9.892799 8.906086 10429573 Ly6c2 11.1268 10.44939 12.5463 12.2063
10346783 Cd28 8.862856 7.407469 9.887501 8.624049 10526410 Hspb1 7.961002 7.231628 8.78004 9.478753
10383204 Rnf213 7.671423 7.88681 9.187749 8.595829 10423049 Prlr 4.422682 4.108268 6.782434 4.670915
10469255 Prkcq 8.517771 7.538423 9.932522 8.368923 10569020 Ifitm6 5.278641 6.681057 6.242225 8.76821
10387855 Alox15 6.418158 6.462885 5.723978 9.333157 10445746 Trem1 5.643428 5.676318 6.470429 7.889835
10402991 Gm16970 12.18146 11.22852 13.37507 12.44687 10429580 I830127L07Rik 8.562352 8.981112 9.926787 10.80186
10502224 Sgms2 5.725321 5.367957 6.260623 6.971786 10496872 Eltd1 5.039892 5.210004 6.911381 6.36945
10385533 Tgtp1 8.293904 8.00921 9.526764 9.043917 10451953 Lrg1 5.49291 5.675477 6.058494 8.177898
10344817 Cspp1 5.139129 6.378856 7.078473 6.600583 10523128 Ppbp 7.318691 8.105155 9.176453 9.419589
10496091 Lef1 8.898957 7.721509 10.03113 8.868871 10501020 Chi3l3 4.59649 5.60985 5.792056 7.472202
10383200 Rnf213 7.285742 7.472165 8.816395 8.18348 10538875 AY498738 9.00958 8.722036 10.68031 10.33631
10485624 Prrg4 6.770383 6.87612 8.43206 7.434144 10545180 Gm10879 11.40371 10.27454 12.77111 12.28398
10501046 Gm10673 4.518981 4.476056 5.705172 5.407722 10489463 Slpi 8.616098 8.397497 10.49968 9.821762
10427628 Il7r 8.716152 7.37142 9.900121 8.473452 10429560 Ly6i 6.304932 6.378236 8.22738 7.67772
10478633 Mmp9 6.577484 6.882494 6.761191 8.933296 10523134 Pf4 6.531179 6.362988 7.811449 8.328002
10414953 Gm16591 4.40368 3.808361 5.46169 4.87117 10419156 Ear10 8.801408 8.313081 8.437481 12.08597
10349968 Chi3l1 5.637611 5.757745 6.361109 7.234969 10598175 Ear10 8.534323 8.082186 8.239657 11.80634
10476945 Cst7 8.121135 7.433799 8.999371 8.851639 10379636 Slfn4 5.751188 6.016742 6.28997 8.821088
10596454 Alas1 6.840498 7.01092 8.043525 8.071169 10487208 Atp8b4 6.754921 6.285714 8.609427 7.831455
10523451 Anxa3 6.257323 6.595372 7.166331 7.92976 10424683 Ly6g 5.720295 5.917487 6.561203 8.462098
10383206 Rnf213 7.466496 7.758605 9.011381 8.520266 10429568 Ly6c1 10.78453 10.37706 12.65546 12.10703
10587012 Ccpg1 8.393986 7.993329 9.873787 8.857033 10367436 Cd63 5.554529 5.746743 6.450701 8.254933
10352178 Sccpdh 5.56175 4.608797 6.433246 5.949596 10473406 Prg3 6.173438 5.845471 6.37689 9.068511
10389214 Ccl9 6.305702 6.817595 7.590185 7.825161 10381096 Igfbp4 7.738251 6.642073 9.162525 8.744167
10524621 Oasl2 6.724374 6.869962 7.733228 8.163691 10410386 E430024C06Rik 4.019139 3.748498 5.604944 5.577785
10519324 Cdk6 9.027987 8.105388 9.838401 9.685663 10410388 E430024C06Rik 4.019139 3.748498 5.604944 5.577785
10362350 Themis 6.817914 5.97667 8.414124 6.682087 10473399 Prg2 9.290556 7.693725 9.421315 11.26007
10370644 Prssl1 5.426135 5.320988 6.073639 6.931323 10581605 Hp 6.376187 6.360035 7.649928 8.721138
10574023 Mt2 11.65075 9.711828 11.86205 11.99759 10419154 Ear1 9.014612 8.186208 8.582313 12.45986
10584941 Bace1 6.362609 6.375094 7.702717 7.368254 10600852 F630028O10Rik 5.486126 5.612344 6.811297 8.01732
10362511 Gstm3 5.389682 5.517532 6.653011 6.548241 10484463 Serping1 4.839833 4.817619 7.663381 5.769885
10538887 Gm5153 11.40671 10.81736 12.81975 11.95094 10499861 S100a9 6.437485 8.081434 7.949113 10.50551
10401935 BC005685 6.77597 6.441141 8.481771 7.087939 10589535 Ngp 8.74703 10.0792 10.79197 12.17001
10497646 Phc3 5.381682 5.973351 7.228276 6.445515 10445753 Trem3 5.366235 5.90491 7.087781 8.202077
10508074 Csf3r 5.971431 6.308368 6.915699 7.705809 10478048 Lbp 6.125412 5.983109 7.892826 8.259671
10365482 Timp3 5.165476 5.403523 6.770527 6.102465 10599348 Gria3 4.810802 5.087077 7.449424 6.536249
10360338 Fcer1a 4.478628 4.645157 5.229639 6.191607 10355403 Fn1 6.019461 6.779673 8.977273 8.020826
10481262 Fcnb 5.937644 6.022153 6.445356 7.882596 10442762 Prss34 6.840974 6.831545 8.682114 9.269894
10571815 Gpm6a 5.385189 5.219183 7.110599 5.834912 10589703 Ltf 6.147509 7.546659 8.118481 9.898699
10497451 Cpa3 6.50266 6.480574 8.112594 7.26506 10481627 Lcn2 6.664207 8.155189 8.720603 10.52452
10538901 BC005685 6.746758 6.487041 8.577344 7.066647 10352905 Cd34 6.056442 5.655152 8.450757 7.628768
10414728 Gm7174 5.034709 4.492245 6.286873 5.569557 10583100 Mmp8 4.34091 5.357017 5.579257 8.550432
10574259 Gpr56 9.384345 7.361527 9.480116 9.768934 10420254 Mcpt8 5.943045 5.805286 8.024098 8.276974
10403006 Gm7112 9.459102 8.890182 10.75812 10.14645 10544273 Clec5a 4.259262 4.360202 6.457104 6.802654
10466659 Gda 6.395913 5.859464 7.000996 7.674215 10452316 C3 7.817947 7.989816 10.98809 9.676615
10467216 Cpeb3 5.943641 5.153401 7.315778 6.180797 10493831 S100a8 7.308252 8.972199 9.321878 11.8728
10530516 Txk 7.479335 6.859753 8.938855 7.874419 10563597 Saa3 4.258882 4.6221 7.45257 6.252638
10358421 Rgs18 6.33867 7.480301 7.962712 8.330256 10419151 Ear1 9.000506 6.769539 8.312558 12.43943
10383192 Rnf213 7.121958 7.293264 8.442578 8.460281 10414590 Ear6 7.547207 6.06633 7.526339 11.28144
10466606 Anxa1 7.183536 7.380604 7.927135 9.14292 10365974 Dcn 5.297863 5.286076 9.277538 6.628817
10563715 Mrgpra2b 5.21449 5.174658 5.91498 6.890467 10389654 Epx 6.984108 5.110147 7.376402 10.12368
10380174 Mpo 9.121368 7.791436 11.88338 11.87076 10408693 F13a1 5.690486 6.228181 8.870432 8.605432
10364535 Elane 8.433015 7.372181 11.13115 11.56763 10466224 Ms4a3 6.057644 5.367032 8.19968 9.057676
10420261 Ctsg 7.595968 6.231912 10.48756 10.95787 10364529 Prtn3 7.478862 6.691831 9.876183 10.68878
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Appendix VI II: Genes up-regulated in Immunobody. Raw expression values are given in a log scale (OVA model) 
 
 
 
 
Probe Set IDGene SymbolOVA IM-1 OVA_IM2 OVA_PEP1 OVA_PEP3 Probe Set IDGene SymbolOVA IM-1 OVA_IM2 OVA_PEP1 OVA_PEP3
10545180 Igkv4-91 9.69314 9.805981 6.91714 6.99322 10583312 Taf1d 8.645541 8.958839 8.118399 8.040622
10563112 Snord33 8.60014 8.818928 7.375708 7.449839 10389561 Dhx40 7.417555 7.959614 7.00306 6.906667
10384968 Bod1 6.485357 6.448826 5.588012 5.293087 10577910 Fnta 6.802185 7.246727 6.260534 6.345529
10604743 Snord61 5.130029 5.877207 4.605886 4.36947 10470318 Gm11362  // Rpl7a 7.8614 8.107421 7.267119 7.289405
10351039 Mir5117 5.887665 6.16469 4.764966 5.343298 10515986 Zfp69 5.503265 5.529018 4.943538 4.737007
10420308 Gzmb 7.492692 7.599083 6.534068 6.667619 10570434 Ifitm1 6.421075 6.366988 5.710132 5.735517
10365003 Snord37 7.596515 7.936535 6.990962 6.702778 10603706 Med4 5.087574 5.736595 4.511792 4.874906
10501048 Dennd2d 7.580863 7.899948 6.903404 6.759975 10398693 Snora28 9.477392 9.738741 8.903022 8.909912
10356329 Snora75 7.435209 7.814739 6.798612 6.685408 10535894 Hmgb1 9.187836 9.311234 8.710701 8.409495
10488748 Cdk5rap1 7.006035 7.166324 6.34201 6.116799 10465244 Malat1 10.97988 11.25908 10.40462 10.43884
10380135 Mir142 8.442287 8.589273 7.59488 7.737499 10400350 Cfl2 7.893459 8.103149 7.420601 7.220647
10567171 Snord14a 8.940478 9.430416 8.35562 8.290436 10419288 Gch1 6.651633 7.067834 6.13947 6.213923
10456717 Snord58b 4.430719 5.224023 4.03425 3.910317 10547469 Wnk1 8.422059 8.558064 7.780632 7.865306
10523901 Rpl5  // Gm14217 6.409052 6.745096 5.691262 5.808454 10493626 1700094D03Rik 6.850286 6.860258 6.147926 6.261266
10464642 Carns1 8.628381 8.712394 7.835826 7.885286 10366407 Gm10752 6.893124 7.264099 6.423843 6.398476
10454828 Pnet-ps 7.895741 8.241735 7.241679 7.261731 10576216 Snord68 6.596814 7.368963 6.168699 6.40834
10414659 Snord58b 4.41347 5.200002 4.038794 3.900672 10470316 Gm11362  // Rpl7a 4.699151 5.611107 4.428719 4.488603
10501046 Gm10673 7.642265 8.178261 7.010998 7.166273 10452556 Rab12 7.319747 7.608991 6.861599 6.754037
10470320 Gm11362  // Rpl7a 6.363622 6.950526 5.656157 6.020112 10368486 Rnf146 6.092801 6.170103 5.514164 5.475348
10469720 Acbd5 6.151396 6.955054 5.709156 5.735511 10485633 Gm10796 6.868388 6.831445 6.239313 6.199461
10518145 Prdm2 6.914974 6.923786 6.291751 6.024115 10494369 Sf3b4 5.695186 5.719399 5.297318 4.859215
10344803 Cspp1 5.747438 6.07411 5.115907 5.16254 10511113 Cdk11b 8.409454 8.556264 7.858694 7.820117
10351043 Snord47 7.611231 8.150832 7.147291 7.034295 10488029 Zfand1 7.282542 7.256142 6.73473 6.552051
10427253 Map3k12 6.206707 6.71437 5.674802 5.678596 10409709 Mir7-1 8.531556 8.775112 7.995221 8.011959
10558454 Glrx3 5.746104 5.616892 4.496005 5.427341 10554895 Crebzf 7.848598 8.121634 7.221683 7.453065
10412211 Gzma 5.583329 5.724157 4.952904 4.914941 10564573 Chd2 8.295896 8.495142 7.772614 7.737996
10403073 Ighg 5.81477 6.847641 5.673496 5.436073 10586168 Snord16a 10.417 10.47286 9.823563 9.795281
10476104 Nop56 6.121158 6.746631 5.679972 5.705353 10491438 Ttc14 7.353605 7.640796 6.769305 6.940662
10439980 Pcnp 6.508757 6.442314 5.81006 5.761304 10522606 Exoc1 7.381692 7.503676 6.883982 6.76347
10389882 Luc7l3 8.402536 8.72374 7.799734 7.880173 10520388 Rbm33 7.720439 8.357555 7.256856 7.506729
10453555 2610044O15Rik 5.970062 6.579965 5.30556 5.769284 10442206 Zfp51 6.936976 7.504477 6.657868 6.487235
10440953 Donson 7.701056 7.71559 7.27808 6.958601 10482167 Zbtb6 6.373755 6.512095 5.873817 5.789457
10475912 Tmem87b 7.290926 7.563529 6.889805 6.755482 10363903 Hbs1l 9.807161 9.913036 9.246777 9.248672
10443459 Srsf3 7.033446 7.417471 6.561611 6.665708 10406614 Mtx3 6.137709 6.329241 5.623382 5.63205
10497300 Zfand1 7.523465 7.5157 6.933628 6.940027 10402564 Setd3 7.732155 8.054579 7.088573 7.45635
10410099 Cdc14b 8.015813 8.115256 7.49514 7.455571 10375735 Hnrnph1 9.984821 10.14665 9.426685 9.482327
10475350 Serf2 8.24432 8.342276 7.731792 7.673965
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Appendix IX: Genes down-regulated in Immunobody. Raw expression values are given in a log scale (OVA model) 
 
Probe Set IDGene SymbolOVA IM-1 OVA_IM2 OVA_PEP1 OVA_PEP3 Probe Set IDGene SymbolOVA IM-1 OVA_IM2 OVA_PEP1 OVA_PEP3
10509002 Rhd 4.915914 4.825545 5.572963 5.445599 10494386 Hist2h2ab 10.58032 10.6065 11.28061 11.22537
10456005 Cd74 9.415863 9.652457 10.14615 10.12623 10592816 Hmbs 7.285876 7.366234 8.041426 7.943898
10461798 Olfr1463 7.060061 7.260168 7.699183 7.846801 10399710 Rsad2 5.646624 5.706326 6.279614 6.420312
10521678 Cd38 6.692955 6.750337 7.449569 7.249082 10566626 Olfr715 6.872515 6.915068 7.503333 7.629521
10553299 Ifitm2 7.979477 7.740631 8.509089 8.500862 10487340 Ncaph 5.965194 6.151942 6.805748 6.648603
10502791 Ifi44 6.420697 6.665099 7.251917 7.068855 10494395 Hist2h2aa1 10.45082 10.51281 11.17758 11.11378
10408081 Hist1h1b 7.188938 7.218439 7.795668 7.874993 10408197 Hist1h2bh 8.502542 8.206079 9.029217 9.075888
10500324 Hist2h2ac 11.05011 11.01361 11.67572 11.64247 10598507 Slc38a5 5.857539 5.527244 6.465425 6.347484
10462623 Ifit1 6.924688 7.215146 7.692296 7.680799 10478572 Ube2c 6.271914 6.289079 7.017772 6.928547
10404069 Hist1h1a 6.912033 6.823286 7.501864 7.527173 10594774 Ccnb2 7.482479 7.488847 8.14045 8.228992
10503098 Lyn 6.442467 6.593576 7.285135 7.015993 10440160 Olfr192 5.097438 4.960466 5.631385 5.868066
10403957 Hist1h4m 11.00908 11.06604 11.61906 11.70539 10541307 Usp18 8.071953 7.975669 8.749675 8.723195
10408092 Hist1h4m 11.00908 11.06604 11.61906 11.70539 10458278 2010001M09Rik 6.581431 6.654547 7.265029 7.382614
10474875 Casc5 4.941171 5.205425 5.691702 5.720735 10379727 Gm11428 5.428035 5.239229 6.053626 6.083939
10409220 Hist2h2aa1 11.19541 11.17953 11.84357 11.80031 10462796 Kif11 5.769148 5.622241 6.384153 6.477353
10402268 Lgmn 5.190751 5.305191 6.104516 5.683601 10366180 Gm4340 6.509685 6.038043 6.939265 7.1251
10564177 Snord116 9.782273 9.221884 10.03219 10.33153 10551347 Blvrb 7.403169 7.307667 8.057964 8.114697
10434778 Rtp4 7.693832 7.984877 8.508713 8.426792 10403938 Hist1h2ao  // Hist1h2ai  // Hist1h2ab  // Hist1h2ap  // Hist1h2an  // Hist1h2ah  // Hist1h2ag  // Hist1h2ae  // Hist1h2ad  // Hist1h2ac 11.21598 11.18911 11.91754 11.9188
10578413 Gm5346 5.349745 5.434859 6.164013 5.928683 10381187 Atp6v0a1 5.506072 5.306466 6.299344 6.016981
10566678 Olfr485 7.772089 7.618953 8.443921 8.285086 10408118 Hist1h2ag 11.03688 11.03162 11.77089 11.75583
10564163 Snord116 9.798928 9.248939 10.06616 10.36345 10462618 Ifit3 7.504037 7.585826 8.283919 8.2768
10564167 Snord116 9.798928 9.248939 10.06616 10.36345 10383756 Ifitm2 7.814249 7.855592 8.607857 8.544074
10564171 Snord116 9.798928 9.248939 10.06616 10.36345 10404045 Hist1h2ao  // Hist1h2ai  // Hist1h2ab  // Hist1h2ap  // Hist1h2an  // Hist1h2ah  // Hist1h2ag  // Hist1h2ae  // Hist1h2ad  // Hist1h2ac 11.14157 11.14158 11.88349 11.87006
10564173 Snord116 9.798928 9.248939 10.06616 10.36345 10598175 Ear10 6.321431 6.164641 7.082469 6.927879
10564175 Snord116 9.798928 9.248939 10.06616 10.36345 10408077 Hist1h2ak 9.870657 9.884653 10.67732 10.55715
10564179 Snord116 9.798928 9.248939 10.06616 10.36345 10372648 Lyz2 5.765269 5.550415 6.416943 6.43749
10564181 Snord116 9.798928 9.248939 10.06616 10.36345 10408072 Hist1h2ai 11.38985 11.34416 12.11364 12.10259
10564185 Snord116 9.798928 9.248939 10.06616 10.36345 10408111 Hist1h2ah 11.33518 11.27975 12.05106 12.05029
10564187 Snord116 9.798928 9.248939 10.06616 10.36345 10481304 Gfi1b 7.243656 6.982396 7.901143 7.872323
10564189 Snord116 9.798928 9.248939 10.06616 10.36345 10451670 Tspo2 5.104416 5.004099 5.941382 5.705724
10564191 Snord116 9.798928 9.248939 10.06616 10.36345 10404026 Hist1h2af 11.39225 11.35926 12.13057 12.11629
10564193 Snord116 9.798928 9.248939 10.06616 10.36345 10403955 Hist1h2ao 11.32148 11.28478 12.05946 12.05155
10564195 Snord116 9.798928 9.248939 10.06616 10.36345 10408085 Hist1h2an 11.05695 11.04336 11.81519 11.80632
10564197 Snord116 9.798928 9.248939 10.06616 10.36345 10408094 Hist1h2ao  // Hist1h2ai  // Hist1h2ab  // Hist1h2ap  // Hist1h2an  // Hist1h2ah  // Hist1h2ag  // Hist1h2ae  // Hist1h2ad  // Hist1h2ac 11.14209 11.11843 11.89371 11.89045
10564199 Snord116 9.798928 9.248939 10.06616 10.36345 10602372 Alas2 5.782949 5.831751 6.607224 6.554678
10564201 Snord116 9.798928 9.248939 10.06616 10.36345 10403941 Hist1h3h 11.35816 11.43147 12.16844 12.14394
10564205 Snord116 9.798928 9.248939 10.06616 10.36345 10408246 Hist1h3a  // Hist1h3i  // Hist1h3h  // Hist1h3g 11.32796 11.37794 12.13447 12.12346
10564207 Snord116 9.798928 9.248939 10.06616 10.36345 10593198 Fam55b 5.432575 5.578039 6.315976 6.278376
10390707 Top2a 6.313098 6.405108 6.917174 7.114111 10374727 Bcl11a 6.882184 7.034981 7.751101 7.744086
10603551 Cybb 6.514248 6.567877 7.2821 7.129576 10574259 Gpr56 6.226099 6.421151 7.137237 7.09022
10414590 Ear6 5.50648 5.453753 6.329952 5.988084 10404028 Hist1h3g 11.34708 11.37873 12.16583 12.13317
10445192 Rhag 5.005081 4.943321 6.297024 6.153286 10394978 Rrm2 6.481926 6.763412 7.461812 7.35609
10429564 Ly6a 9.74416 9.87386 11.07964 11.01913 10404049 Hist1h3d 11.38842 11.43767 12.20783 12.20364
10531126 Igj 9.144139 9.28445 10.45521 10.59454 10404065 Hist1h3b 11.39621 11.44188 12.22151 12.21968
10403009 Ighg 5.955611 6.043149 7.261371 7.407386 10574027 Mt1 6.750691 6.684824 7.549112 7.540235
10545242 Igkv6-20 7.415425 7.362882 8.76242 8.699686 10408202 Hist1h3e 11.30255 11.35221 12.13292 12.13219
10487011 Gatm 5.975191 6.362548 7.527967 7.568853 10408239 Hist1h3c 11.37181 11.40495 12.19534 12.19687
10364535 Elane 6.22934 6.088137 7.642186 7.628078 10408083 Hist1h3i 11.34135 11.37262 12.16301 12.17356
10545194 Igkv4-59  // Igkv4-59  // Igkv4-59 8.37042 8.32493 9.852571 9.868026 10406928 Cd180 6.49757 6.760734 7.394032 7.48318
10481627 Lcn2 5.110229 4.552481 6.525882 6.361879 10473399 Prg2 5.698457 5.687837 6.406479 6.65654
10362896 Cd24a 7.189897 7.220691 8.805318 8.760952 10494402 Hist2h3c1 10.90512 10.95603 11.75216 11.74663
10490923 Car2 6.623505 6.70909 8.236732 8.330407 10511258 Fam132a 6.515189 6.508718 7.16104 7.534299
10403060 Ighv1-72 9.271645 9.111667 10.89878 10.88278 10494405 Hist2h3b 11.33089 11.31137 12.14532 12.16168
10574023 Mt2 8.606429 8.832493 10.4396 10.38246 10473367 Slc43a1 6.129727 6.107075 6.98951 6.947611
10545175 Igkv10-96  // Igkv10-96 10.253 10.2876 11.99741 12.01908 10474201 Lmo2 6.708872 6.807498 7.741296 7.470375
10569017 Ifitm3 6.195415 6.515269 7.981906 8.222151 10404063 Hist1h2ab 4.046447 4.067121 4.84863 5.010705
10545173 Igkv10-96 9.506121 9.578478 11.3659 11.29345 10403959 Hist1h2br  // Hist1h2bq  // Hist1h2bn  // Hist1h2bl  // Hist1h2bj  // Hist1h2bf 9.928025 9.961787 10.80614 10.81833
10589535 Ngp 5.084825 4.744139 6.813802 6.682652 10408087 Hist1h2br  // Hist1h2bq  // Hist1h2bn  // Hist1h2bl  // Hist1h2bj  // Hist1h2bf 9.928025 9.961787 10.80614 10.81833
10419151 Ear1 4.505959 4.571469 6.396954 6.52073 10573054 Gypa 4.262294 4.35241 5.293264 5.086112
10403069 Ighm 7.093417 7.406801 9.221152 9.157598 10397346 Fos 8.197109 8.396738 9.173129 9.153563
10545217 Igkv5-43 5.853404 5.937531 8.208887 7.58828 10559261 Cd81 7.72242 7.660189 8.513938 8.654209
10391649 Slc4a1 6.307032 6.244219 8.433184 8.182203 10403018 Ighg3 10.93873 10.99162 11.8639 11.81752
10403031 V165-D-J-C mu 7.211883 7.720778 9.491369 9.640642 10534389 Cldn13 5.042794 4.894657 5.959202 5.807876
10545215 Igk-V28 8.361155 8.754202 10.7611 10.69134 10489463 Slpi 6.399591 6.269768 7.352597 7.145491
10402991 Igh-VX24 8.759705 8.820551 11.06357 11.08999 10402347 Ifi27l2a 7.140572 7.291275 8.004104 8.210841
10545247 Igkv6-14 9.651943 9.838027 12.10501 11.94946 10419156 Ear10 6.476151 6.305223 7.383574 7.244441
10375058 Hba-a2 9.126966 9.141016 11.59062 11.72808 10413710 Nt5dc2 6.373025 6.49045 7.311954 7.367415
10380174 Mpo 5.663897 5.405417 8.215822 7.973115 10574572 Ces2g 5.951755 5.828533 6.821517 6.823285
10375051 Hba-a1 9.120332 9.13518 11.61618 11.75747 10404061 Hist1h2bb 6.751467 6.659152 7.523697 7.758821
10566254 Hbb-b1 8.313478 8.505347 11.22721 11.38285 10515848 Ermap 6.719698 6.216194 7.400573 7.483231
10566258 Hbb-b1 8.199006 8.223135 11.2548 11.40889 10420261 Ctsg 4.831854 4.552722 5.68084 5.637224
10482030 Stom 4.995683 5.158698 6.13506 6.128513 10364093 Derl3 6.739131 6.890574 7.788571 7.700519
10473384 Slc43a3 6.830793 6.898653 7.937542 7.909772 10403948 Hist1h2bn 10.28543 10.30475 11.22633 11.22825
10568714 Mki67 6.503299 6.912265 7.793732 7.719363 10408210 Hist1h2bf 10.2796 10.30092 11.2146 11.24415
10377405 Aurkb 6.029736 6.203056 7.153509 7.216507 10403943 Hist1h2bm 8.184858 8.036425 9.073481 9.100347
10538871 Igkv1-133 10.73658 10.83158 11.93002 11.7627 10438415 Iglv1 9.216059 9.370726 10.26516 10.23235
10419154 Ear1 6.870685 6.795013 7.995491 7.843473 10403980 Hist1h2bj 10.60824 10.65145 11.60415 11.62265
10543067 Asns 5.919641 6.253086 7.129128 7.174603 10408070 Hist1h2bl 10.60506 10.6571 11.60753 11.63696
10560481 Fosb 8.434941 8.607538 9.545672 9.638711 10545196 Igkv4-68 10.85706 10.92595 11.89001 11.9018
10493382 Pklr 5.977372 5.996243 7.200623 6.968264 10538459 Aqp1 6.119696 5.881849 6.982844 7.153708
10524621 Oasl2 7.161689 7.40784 8.427088 8.351056 10403978 Hist1h2bk 10.42978 10.4946 11.47072 11.52333
